UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30,~~March 31, ~~2022~~2023


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-34680

Primerica, Inc.

(Exact name of registrant as specified in its charter)


Delaware		27-1204330
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
1 Primerica Parkway Duluth, Georgia		30099
(Address of principal executive offices)		(ZIP Code)

(770) 381-1000

(Registrant’s telephone number, including area code)

Not applicable.

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	PRI	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒No

As of ~~October 31, 2022,~~April 30, 2023, the registrant had ~~36,898,170~~36,226,210 shares of common stock, $0.01 par value per share, outstanding.

TABLE OF CONTENTS



		Page
PART I – FINANCIAL INFORMATION		2
Item 1. Financial Statements (unaudited).		2
Condensed Consolidated Balance Sheets as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022		2
Condensed Consolidated Statements of Income for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 202~~1		3
Condensed Consolidated Statements of Comprehensive Income (Loss) for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~		4
Condensed Consolidated Statements of Stockholders’ Equity for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~		5
Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~		6
Notes to Condensed Consolidated Financial Statements		7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.		2933
Item 3. Quantitative and Qualitative Disclosures About Market Risk.		5352
Item 4. Controls and Procedures.		5352
PART II – OTHER INFORMATION		5352
Item 1. Legal Proceedings.		5352
Item 1A. Risk Factors.		5452
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.		5553
Item 5. Other Information		53
Item 6. Exhibits.		5553
Signatures		5755

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

PRIMERICA, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets – Unaudited


	(Unaudited)
	September 30, 2022			December 31, 2021		March 31, 2023			December 31, 2022
	(In thousands)					(In thousands)
Assets:
Investments:
Fixed-maturity securities available-for-sale, at fair value (amortized cost: $2,779,015 in 2022 and $2,621,388 in 2021)	$	2,457,989		$	2,702,567
Fixed-maturity security held-to-maturity, at amortized cost (fair value: $1,320,222 in 2022 and $1,551,113 in 2021)		1,433,760			1,379,100
Short-term investments available-for-sale, at fair value (amortized cost: $0 in 2022 and $85,246 in 2021)		-			85,243
Equity securities, at fair value (historical cost: $29,424 in 2022 and $34,255 in 2021)		33,079			42,551
Trading securities, at fair value (cost: $4,335 in 2022 and $24,769 in 2021)		3,718			24,355
Fixed-maturity securities available-for-sale, at fair value (amortized cost: $2,822,996 in 2023 and $2,801,415 in 2022)						$	2,558,626		$	2,495,456
Fixed-maturity security held-to-maturity, at amortized cost (fair value: $1,388,411 in 2023 and $1,340,265 in 2022)							1,460,000			1,444,920
Short-term investments available-for-sale, at fair value (amortized cost: $70,185 in 2023 and $69,393 in 2022)							70,187			69,406
Equity securities, at fair value (historical cost: $29,475 in 2023 and $29,430 in 2022)							33,984			35,404
Trading securities, at fair value (cost: $19,033 in 2023 and $4,229 in 2022)							18,497			3,698
Policy loans and other invested assets		48,787			30,612		50,003			48,713
Total investments		3,977,333			4,264,428		4,191,297			4,097,597
Cash and cash equivalents		438,025			392,501		515,090			489,240
Accrued investment income		19,949			18,702		22,153			20,885
Reinsurance recoverables		4,033,897			4,268,419		3,179,074			3,176,397
Deferred policy acquisition costs, net		3,049,102			2,943,782		3,256,845			3,194,029
Renewal commissions receivable		198,027			231,751		194,409			200,043
Agent balances, due premiums and other receivables		266,831			257,675		259,759			254,276
Goodwill		127,707			179,154		127,707			127,707
Intangible assets		188,150			195,825
Intangible assets, net (accumulated amortization: $18,375 in 2023 and $15,750 in 2022)							182,900			185,525
Income taxes		90,719			81,799		106,310			97,972
Operating lease right-of-use assets		42,343			47,942		38,575			40,500
Other assets		403,452			441,253		391,605			428,259
Separate account assets		2,206,608			2,799,992		2,329,968			2,305,717
Total assets	$	15,042,143		$	16,123,223	$	14,795,692		$	14,618,147

Liabilities and Stockholders’ Equity:
Liabilities:
Future policy benefits	$	7,314,688		$	7,138,649	$	6,561,624		$	6,297,906
Unearned and advance premiums		16,153			16,437		16,703			15,422
Policy claims and other benefits payable		496,563			585,382		498,483			538,250
Other policyholders’ funds		492,479			501,823		481,561			483,769
Note payable - Short term		-			15,000
Note payable - Long term		592,705			592,102
Note payable							593,106			592,905
Surplus note		1,433,293			1,378,585		1,459,565			1,444,469
Income taxes		129,347			241,311		199,394			202,462
Operating lease liabilities		47,935			53,920		43,955			45,995
Other liabilities		611,646			615,710		615,780			580,780
Payable under securities lending		80,754			94,529		74,452			100,938
Separate account liabilities		2,206,608			2,799,992		2,329,968			2,305,717
Commitments and contingent liabilities (see Commitments and Contingent Liabilities note)
Total liabilities		13,422,171			14,033,440		12,874,591			12,608,613

Temporary Stockholders’ Equity
Redeemable noncontrolling interests in consolidated entities		-			7,271		-			-
Permanent Stockholders’ Equity
Equity attributable to Primerica, Inc.:
Common stock ($0.01 par value; authorized 500,000 shares in 2022 and 2021; issued and outstanding 37,027 shares in 2022 and 39,368 shares in 2021)		370			394
Common stock ($0.01 par value; authorized 500,000 shares in 2023 and 2022; issued and outstanding 36,407 shares in 2023 and 36,824 shares in 2022)							364			368
Paid-in capital		-			5,224		-			-
Retained earnings		1,887,952			2,004,506		2,151,771			2,130,935
Accumulated other comprehensive income (loss), net of income tax:
Effect of change in discount rate assumptions on the liability for future policy benefits							(11,679	)		131,295
Unrealized foreign currency translation gains (losses)		(15,437	)		8,611		(11,198	)		(12,196	)
Net unrealized investment gains (losses) on available-for-sale securities		(252,913	)		63,777		(208,157	)		(240,868	)
Total permanent stockholders’ equity		1,619,972			2,082,512		1,921,101			2,009,534
Total liabilities and temporary and permanent stockholders’ equity	$	15,042,143		$	16,123,223	$	14,795,692		$	14,618,147

Prior year amounts related to long-duration insurance contracts have been adjusted for the adoption of accounting guidance on January 1, 2023.

See accompanying notes to condensed consolidated financial statements.

PRIMERICA, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Income – Unaudited


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
	2022			2021			2022			2021			2023			2022
	(In thousands, except per-share amounts)												(In thousands, except per-share amounts)
Revenues:
Direct premiums	$	810,079		$	785,277		$	2,417,639		$	2,327,804		$	817,872		$	798,666
Ceded premiums		(404,870	)		(401,295	)		(1,223,804	)		(1,211,117	)		(405,347	)		(399,885	)
Net premiums		405,209			383,982			1,193,835			1,116,687			412,525			398,781
Commissions and fees		225,468			269,796			717,956			754,529			231,547			251,800
Investment income net of investment expenses		40,629			35,741			112,148			106,970			47,500			34,420
Interest expense on surplus note		(16,283	)		(15,741	)		(47,613	)		(46,382	)		(16,435	)		(15,515	)
Net investment income		24,346			20,000			64,535			60,588			31,065			18,905
Realized investment gains (losses)		292			1,730			924			3,762			(985	)		577
Other investment gains (losses)		(2,991	)		(320	)		(4,765	)		114			(3,623	)		174
Investment gains (losses)		(2,699	)		1,410			(3,841	)		3,876			(4,608	)		751
Other, net		20,965			18,051			60,709			49,958			19,507			20,989
Total revenues		673,289			693,239			2,033,194			1,985,638			690,036			691,226

Benefits and expenses:
Benefits and claims		171,293			183,425			511,619			535,561			168,702			168,288
Future policy benefits remeasurement (gain) loss														(508	)		(1,272	)
Amortization of deferred policy acquisition costs		90,925			62,214			262,367			182,604			67,358			63,223
Sales commissions		105,915			129,268			359,602			382,465			110,874			133,924
Insurance expenses		57,552			51,901			176,521			149,246			61,125			59,509
Insurance commissions		7,666			8,412			22,982			25,990			8,138			7,721
Contract acquisition costs		13,446			23,524			53,479			23,524			14,984			20,649
Interest expense		6,802			7,529			20,469			21,814			6,690			6,853
Goodwill impairment loss		60,000			-			60,000			-
Other operating expenses		73,791			79,864			239,952			219,559			89,536			86,435
Total benefits and expenses		587,390			546,137			1,706,991			1,540,763			526,899			545,330
Income before income taxes		85,899			147,102			326,203			444,875			163,137			145,896
Income taxes		34,092			35,663			90,069			107,403			38,031			33,512
Net income		51,807			111,439			236,134			337,472			125,106			112,384
Net income (loss) attributable to noncontrolling interests		-			(1,017	)		(5,038	)		(1,017	)		-			(2,655	)
Net income attributable to Primerica, Inc.	$	51,807		$	112,456		$	241,172		$	338,489		$	125,106		$	115,039

Earnings per share attributable to common stockholders:
Basic earnings per share	$	1.38		$	2.83		$	6.26		$	8.53		$	3.39		$	2.92
Diluted earnings per share	$	1.37		$	2.82		$	6.24		$	8.50		$	3.38		$	2.91

Weighted-average shares used in computing earnings per share:
Basic		37,438			39,561			38,342			39,516			36,710			39,221
Diluted		37,541			39,679			38,452			39,637			36,804			39,332

Prior year amounts related to long-duration insurance contracts have been adjusted for the adoption of accounting guidance on January 1, 2023.

See accompanying notes to condensed consolidated financial statements.

PRIMERICA, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Loss) – Unaudited


	Three months ended September 30,						Nine months ended September 30,							Three months ended March 31,
	2022			2021			2022			2021				2023			2022
	(In thousands)												(In thousands)
Net income	$	51,807		$	111,439		$	236,134		$	337,472			$	125,106		$	112,384
Other comprehensive income (loss) before income taxes:
Unrealized investment gains (losses) on available-for-sale securities:
Change in unrealized holding gains (losses) on available-for-sale securities		(97,516	)		(13,796	)		(401,335	)		(52,669	)			38,549			(164,937	)
Reclassification adjustment for investment (gains) losses included in net income		(154	)		(1,879	)		(867	)		(3,052	)			3,137			(658	)
Effect of change in discount rate assumptions on the liability for future policy benefits															(182,045	)		821,904
Foreign currency translation adjustments:
Change in unrealized foreign currency translation gains (losses)		(18,086	)		(5,892	)		(24,048	)		6,490				998			3,289
Total other comprehensive income (loss) before income taxes		(115,756	)		(21,567	)		(426,250	)		(49,231	)			(139,361	)		659,598
Income tax expense (benefit) related to items of other comprehensive income (loss)		(20,504	)		(3,386	)		(85,512	)		(12,294	)			(30,096	)		140,384
Other comprehensive income (loss), net of income taxes		(95,252	)		(18,181	)		(340,738	)		(36,937	)			(109,265	)		519,214
Total comprehensive income (loss)		(43,445	)		93,258			(104,604	)		300,535				15,841			631,598
Net income (loss) attributable to noncontrolling interests		-			(1,017	)		(5,038	)		(1,017	)			-			(2,655	)
Comprehensive income (loss) attributable to Primerica, Inc.	$	(43,445	)	$	94,275		$	(99,566	)	$	301,552			$	15,841		$	634,253

Prior year amounts related to long-duration insurance contracts have been adjusted for the adoption of accounting guidance on January 1, 2023.

See accompanying notes to condensed consolidated financial statements.

PRIMERICA, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity– Unaudited


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
	2022			2021			2022			2021			2023			2022
	(In thousands)												(In thousands)
Equity attributable to Primerica, Inc./Permanent stockholders’ equity
Common stock:
Balance, beginning of period	$	378		$	394		$	394		$	393		$	368		$	394
Repurchases of common stock		(8	)		-			(26	)		-			(6	)		(7	)
Net issuance of common stock		-			1			2			2			2			1
Balance, end of period		370			395			370			395			364			388

Paid-in capital:
Balance, beginning of period		-			12,880			5,224			-			-			5,224
Share-based compensation		3,747			4,662			27,528			24,449			16,622			14,820
Net issuance of common stock		-			(1	)		(2	)		(2	)		(2	)		(1	)
Repurchases of common stock		(5,980	)		(87	)		(34,983	)		(6,993	)		(16,620	)		(20,043	)
Redemption of noncontrolling interest in consolidated entities		2,233			-			2,233			-
Balance, end of period		-			17,454			-			17,454			-			-

Retained earnings:
Balance, beginning of period		1,948,244			1,894,539			2,004,506			1,705,786
Adjusted balance, beginning of period														2,130,935			2,074,111
Net income attributable to Primerica, Inc.		51,807			112,456			241,172			338,489			125,106			115,039
Dividends		(20,571	)		(18,671	)		(63,394	)		(55,951	)		(23,910	)		(21,645	)
Repurchases of common stock		(91,528	)		-			(294,332	)		-			(80,360	)		(83,813	)
Balance, end of period		1,887,952			1,988,324			1,887,952			1,988,324			2,151,771			2,083,692

Accumulated other comprehensive income:
Balance, beginning of period		(173,098	)		110,950			72,388			129,706
Change in foreign currency translation adjustment, net of income taxes		(18,086	)		(5,892	)		(24,048	)		6,490
Change in net unrealized investment gains (losses) during the period, net of income taxes		(77,166	)		(12,289	)		(316,690	)		(43,427	)
Accumulated other comprehensive income (loss), net of income tax:
Adjusted balance, beginning of period														(121,769	)		(1,168,399	)
Effect of change in discount rate assumptions on the liability for future policy benefits														(142,974	)		646,141
Change in foreign currency translation adjustment														998			3,289
Change in net unrealized investment gains (losses) during the period														32,711			(130,216	)
Balance, end of period		(268,350	)		92,769			(268,350	)		92,769			(231,034	)		(649,185	)

Total permanent stockholders’ equity	$	1,619,972		$	2,098,942		$	1,619,972		$	2,098,942		$	1,921,101		$	1,434,895

Redeemable noncontrolling interests in consolidated entities/Temporary stockholders’ equity
Balance, beginning of period	$	2,233		$	-		$	7,271		$	-		$	-		$	7,271
Acquisition of noncontrolling interest		-			8,437			-			8,437
Net income (loss) attributable to noncontrolling interests		-			(1,017	)		(5,038	)		(1,017	)		-			(2,655	)
Change in noncontrolling interests in consolidated entities, net		-			211			-			211
Redemption of noncontrolling interest in consolidated entities		(2,233	)		-			(2,233	)		-
Balance, end of period	$	-		$	7,631		$	-		$	7,631		$	-		$	4,616

Dividends declared per share	$	0.55		$	0.47		$	1.65		$	1.41		$	0.65		$	0.55

Prior year amounts related to long-duration insurance contracts have been adjusted for the adoption of accounting guidance on January 1, 2023.

See accompanying notes to condensed consolidated financial statements.

PRIMERICA, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows – Unaudited


	Nine months ended September 30,						Three months ended March 31,
	2022			2021			2023			2022
	(In thousands)						(In thousands)
Cash flows from operating activities:
Net income	$	236,134		$	337,472		$	125,106		$	112,384
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Change in future policy benefits and other policy liabilities		125,302			334,566			(9,799	)		(161,385	)
Deferral of policy acquisition costs		(383,955	)		(422,194	)		(126,640	)		(130,881	)
Amortization of deferred policy acquisition costs		262,367			182,604			67,358			63,223
Change in income taxes		(39,270	)		(17,267	)		18,713			14,171
Investment (gains) losses		3,841			(3,876	)		4,608			(751	)
Accretion and amortization of investments		2,972			3,798			(309	)		1,356
Depreciation and amortization		25,631			19,691			8,547			8,688
Change in reinsurance recoverables		209,984			(2,426	)		47,766			248,511
Change in agent balances, due premiums and other receivables		(13,120	)		(10,957	)		(5,486	)		2,245
Change in renewal commissions receivable		21,861			(14,532	)		5,634			18,576
Trading securities sold, matured, or called (acquired), net		19,862			(10,528	)		(14,808	)		11,273
Share-based compensation		19,652			14,834			12,129			12,437
Goodwill impairment loss		60,000			-
Change in other operating assets and liabilities, net		17			23,936			43,127			14,452
Net cash provided by (used in) operating activities		551,278			435,121			175,946			214,299

Cash flows from investing activities:
Available-for-sale investments sold, matured or called:
Fixed-maturity securities — sold		23,140			99,401			5,179			1,227
Fixed-maturity securities — matured or called		283,292			340,074			80,251			96,336
Short-term investments — sold		28,251			10,089
Short-term investments — matured or called		85,302			-			-			41,550
Equity securities — sold		12			716			5			-
Equity securities — matured or called		3,000			-			-			3,000
Available-for-sale investments acquired:
Fixed-maturity securities		(471,323	)		(603,146	)		(108,713	)		(250,932	)
Short-term investments		(28,241	)		(50,902	)
Equity securities — acquired		(141	)		(2,898	)		(47	)		(44	)
Purchases of property and equipment and other investing activities, net		(23,950	)		(21,432	)		(7,861	)		(7,676	)
Cash collateral received (returned) on loaned securities, net		(13,775	)		33,110			(26,486	)		(1,358	)
Sales (purchases) of short-term investments using securities lending collateral, net		13,775			(33,110	)		26,486			1,358
Purchase of business, net of cash acquired		3,867			(494,459	)		-			3,867
Net cash provided by (used in) investing activities		(96,791	)		(722,557	)		(31,186	)		(112,672	)

Cash flows from financing activities:
Dividends paid		(63,394	)		(55,951	)		(23,910	)		(21,645	)
Common stock repurchased		(324,354	)		-			(85,275	)		(99,010	)
Proceeds from revolving credit facility		-			125,000
Payment on note issued to seller of business		(12,364	)		-			-			(9,000	)
Tax withholdings on share-based compensation		(4,989	)		(6,573	)		(9,739	)		(4,852	)
Finance leases		(195	)		(201	)		(68	)		(64	)
Net cash provided by (used in) financing activities		(405,296	)		62,275			(118,992	)		(134,571	)
Effect of foreign exchange rate changes on cash		(3,667	)		3,170			82			222
Change in cash and cash equivalents		45,524			(221,991	)		25,850			(32,722	)
Cash and cash equivalents, beginning of period		392,501			547,569			489,240			392,501
Cash and cash equivalents, end of period	$	438,025		$	325,578		$	515,090		$	359,779

Supplemental disclosures:
Non-cash financing activity:
Increase in note issued to seller of business	$	-		$	15,000

Prior year amounts related to long-duration insurance contracts have been adjusted for the adoption of accounting guidance on January 1, 2023.

See accompanying notes to condensed consolidated financial statements.

PRIMERICA, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements — Unaudited

(1) Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies

Description of Business. Primerica, Inc. (the “Parent Company”), together with its subsidiaries (collectively, “we”, “us” or the “Company”), is a leading provider of financial products to middle-income households in the United States and Canada through a network of independent contractor sales representatives (“independent sales representatives” or “independent sales force”). We assist our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. We acquired 80% of e-TeleQuote Insurance, Inc. and subsidiaries (collectively, “e-TeleQuote”) through our subsidiary, Primerica Health, Inc. (“Primerica Health”) on July 1, 2021 and ~~acquired~~ the remaining 20% of e-TeleQuote on July 1, 2022. e-TeleQuote markets Medicare-related insurance products underwritten by third-party health insurance carriers to eligible Medicare participants through its licensed health insurance agents. ~~Refer to Note 14 (Acquisition) for more information regarding the acquisition of e-TeleQuote.~~ Our other primary subsidiaries include the following entities: Primerica Financial Services, LLC, ~~(“PFS”),~~ a general agency and marketing company; Primerica Life Insurance Company (“Primerica Life”), our principal life insurance company; Primerica Financial Services (Canada) Ltd., a holding company for our Canadian operations, which includes Primerica Life Insurance Company of Canada (“Primerica Life Canada”) and PFSL Investments Canada Ltd. ~~(“PFSL Investments Canada”)~~; and PFS Investments Inc. ~~(“PFS Investments”)~~, an investment products company and broker-dealer. Primerica Life, domiciled in Tennessee, owns National Benefit Life Insurance Company, ~~(“NBLIC”),~~ a New York insurance company. Peach Re, Inc. (“Peach Re”) and Vidalia Re, Inc. (“Vidalia Re”) are special purpose financial captive insurance companies and wholly owned subsidiaries of Primerica Life. Peach Re and Vidalia Re have each entered into separate coinsurance agreements with Primerica Life whereby Primerica Life has ceded certain level-premium term life insurance policies to Peach Re and Vidalia Re (respectively, the “Peach Re Coinsurance Agreement” and the “Vidalia Re Coinsurance Agreement”).

Basis of Presentation. We prepare our financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). These principles are established primarily by the Financial Accounting Standards Board (“FASB”).

The accompanying unaudited condensed consolidated financial statements contain all adjustments, generally consisting of normal recurring accruals, which are necessary to fairly present the balance sheets as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, the statements of income, comprehensive income, and stockholders’ equity for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ and cash flows for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 and ~~2021.~~2022. Results of operations for interim periods are not necessarily indicative of results for the entire year or of the results to be expected in future periods.

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange ~~Commission (“SEC”).~~Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are sufficient to make the information not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 (“~~2021~~2022 Annual Report”).

Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect financial statement balances, revenues and expenses and cash flows, as well as the disclosure of contingent assets and liabilities. Management considers available facts and knowledge of existing circumstances when establishing the estimates included in our financial statements. The most significant items that involve a greater degree of accounting estimates and actuarial determinations subject to change in the future are the valuation of investments, deferred policy acquisition costs (“DAC”), future policy benefit reserves and corresponding amounts recoverable from reinsurers, renewal commissions receivable, income taxes, and valuation of intangible assets and goodwill. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.

Consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and those entities required to be consolidated under U.S. GAAP. All material intercompany profits, transactions, and balances among the consolidated entities have been eliminated.

Reclassifications. Certain reclassifications have been made to prior-period amounts to conform to current-period reporting classifications. These reclassifications had no impact on net income or total stockholders’ equity.

~~Changes to~~New Accounting ~~Policies~~. ~~All significant accounting policies remain unchanged from the 2021 Annual Report unless otherwise described.~~

~~Future Application of Accounting Standards.~~Principles. In August 2018, the FASB issued Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944) — Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12” or “LDTI”). The amendments in this update change accounting guidance for insurance companies that issue long-duration

contracts, such as ~~including~~ term life insurance. and segregated funds products. ASU 2018-12 requires companies that issue long-duration insurance contracts to update assumptions used in measuring the liability for future policy benefits (“LFPB”) and DAC, including mortality, disability, and persistency, at least annually instead of locking those assumptions at contract inception and reflecting differences in assumptions and actual performance as the experience occurs. ASU 2018-12 also changes how insurance companies that issue long-duration contracts

amortize DAC and determine and update the discount rate assumptions used in measuring ~~future policy benefits~~both the LFPB and ceded reserves that are part of reinsurance recoverables while increasing the level of financial statement disclosures required.

The ~~guidance in~~Company adopted ASU 2018-12 ~~will be applied~~on January 1, 2023 through the modified retrospective method, which applies the provisions of the standard by pivoting off the historical December 31, 2020 liability for future policy benefits (“Pre-transition Reserve”) and DAC balances just prior to January 1, 2021 (the “Transition Date”). Upon adoption, the ~~earliest period presented~~Company recorded the following adjustments to its consolidated balance sheet as of the Transition Date.

•

LDTI requires entities to use market observable rates, based on an upper-medium grade fixed income instrument yield, to measure future policy benefits reserves each period. The difference between the LFPB calculated using market observable rates and the Pre-transition Reserve was recognized as part of accumulated other comprehensive income (“AOCI”) at the Transition Date. Given how low market observable rates were at the Transition Date, we recorded a reduction to AOCI of approximately $1.5 billion, net of income tax, as of January 1, 2021. Market observable rates have increased since the Transition Date, which resulted in a cumulative decrease to AOCI of $11.7 million as of March 31, 2023.

•

Under LDTI, policies are grouped into cohorts and the net premium ratio for each policy cohort is used to calculate the LFPB. At the Transition Date, the “Net Premium Ratio” is defined as the present value of future benefits, which includes claim settlement expenses less the Pre-transition Reserve divided by the present value of the gross premiums. Expected future benefits and gross premiums use best estimate cash flow assumptions and the locked-in discount rate at the Transition Date is used in the calculation. Under LDTI, a cohort’s Net Premium Ratio is capped at 100%. The adjustment necessary at the Transition Date to cap the Net Premium Ratio for cohorts at 100% was approximately $23 million, which was recognized as a reduction to retained earnings as of January 1, 2021. The identified impact from capping the Net Premium Ratio at 100% was solely attributable to a limited amount of older policy year cohorts.

All prior period financial information included in the accompanying condensed consolidated financial statements ~~beginning on the effective date of January 1, 2023. The adoption of ASU 2018-12 will have an impact on our consolidated financial statements and related disclosures and will require changes~~has been restated to certain of our processes, systems, and controls. We are continuing to evaluate the impact the adoption will have on our consolidated financial statements. We are working on model refinement and model governance, finalizing actuarial assumptions and documenting our control process.

~~Below is a list of topics relevant to~~reflect the adoption of ASU ~~2018-12 and the expected impact on the Company.~~2018-12.

The Company's restated permanent and temporary stockholders' equity from the date of adoption through December 31, 2022 is as follows:


~~Topic~~	~~Description~~	~~Planned Approach~~
~~Transition Approach~~	~~LDTI guidance can be applied using either:~~ • ~~the retrospective method, which applies the provisions of the standard from the original policy inception; or~~ • the modified retrospective method, which applies the provisions of the standard by pivoting off the historical December 31, 2020 future policy benefits reserve (“Pre-transition Reserve”) and deferred acquisition costs (“DAC”) balances just prior to January 1, 2021 (the “Transition Date”).	The Company will elect to adopt the standard using the modified retrospective method for both future policy benefits reserves and amortization of DAC. The Company will adopt the standard effective January 1, 2023.
~~Cohort Definition~~	~~Cohorts refer to the level of policy grouping used in the calculation of the future policy benefits reserve (“FPBR”) and amortization of DAC.~~ ~~Under LDTI, cohorts must vary by policy issue year and may be set more granularly to reflect additional policy characteristics.~~ The net premium ratio for each policy cohort is used to calculate FPBR. At the Transition Date, the Net Premium Ratio is defined as the present value of future benefits and claim settlement expenses less the Pre-transition Reserve divided by the present value of the gross premiums. The present value of both the future benefits and gross premiums use best estimate cash flow assumptions at the locked-in discount rate (discount rate at the Transition Date). Under LDTI, a cohort’s Net Premium Ratio is capped at ~~100%. This concept replaces the need for loss recognition analysis under current GAAP. Any adjustments necessary at the Transition Date to cap the Net Premium Ratio for a cohort at~~ ~~100% are recognized in retained earnings. After the Transition Date, the Net Premium Ratio will be updated each quarter as projected benefits and premiums are replaced with actual amounts.~~	~~The Company will define its Term Life Insurance segment cohorts based on the legal entity that issued the policy and the year the policy was issued.~~ ~~The Company expects the impact as of the Transition Date of capping the Net Premium Ratio at~~ ~~100% to be less than~~ 3~~% of total retained earnings. The identified impact from capping the Net Premium Ratio at~~ ~~100% is primarily attributable to a limited amount of older policy year cohorts.~~

~~Discount Rates~~

~~LDTI requires entities to use market observable rates, based on an upper-medium grade fixed income instrument yield, to measure future policy benefits reserves each period.~~

The difference between the FPBR calculated using market observable rates and the Pre-transition Reserve is recognized as part of accumulated other comprehensive income (“AOCI”) at the Transition Date. After the Transition Date, the impact of changes in market observable rates each quarter will be recorded to AOCI and may add volatility to our reported equity.

The Company will use discount rates applied by geography to align with local currency cash flows. Discount rates will consist of yield curves that will be developed using Bloomberg’s Evaluated Pricing Product (BVAL) based on senior unsecured fixed rate bonds ratings of A+, A or A-.

~~Given how low market observable rates were at the Transition Date, we expect that the amount recorded in AOCI as of the Transition Date will reduce our AOCI and equity balances by approximately $1.2~~ ~~to $1.5~~ ~~billion, net of income tax.~~

As of September 30, 2022, market observable rates have increased relative to the Transition Date, which will significantly reduce the AOCI impact in equity on our current balance sheet. If we were to apply market observable rates as of September 30, 2022 to the FPBR as of the Transition Date, the impact on AOCI would be between a $~~150~~ ~~million increase and a $150~~ ~~million decrease on an after-tax basis.~~

~~Cash Flow Assumptions~~

LDTI requires entities to use their best estimates for cash flow assumptions with no provision for adverse deviation. Cash flow assumptions are to be reviewed at least annually at the same time each year, or more frequently if experience suggests.

~~Forecasted cash flow assumptions must be replaced with actual cash flows in FPBR at least annually.~~

~~The Company expects to formally review cash flow assumptions during the third quarter each year and update these assumptions as necessary.~~

~~The Company will replace forecasted cash flow assumptions with actual cash flows in FPBR each quarter.~~

The impact of assumption changes and experience variances will be partly reflected in the current period and partly spread to future periods, based on the remaining duration of the impacted cohort(s), by unlocking the Net Premium Ratio in FPBR.

~~DAC Amortization~~

LDTI requires DAC to be amortized on a constant-level basis over the expected term of the contracts using an appropriate unit of measure. Companies can amortize DAC either at an individual contract level on a straight-line basis or at a cohort level that approximates a straight-line basis.

Under current GAAP, DAC is amortized using amortization models linked to revenue or profit. Also, interest is accrued on unamortized DAC under current GAAP while LDTI disallows the accrual of interest.

The Company anticipates it will use current face amount as a unit of measure to amortize DAC for its term life insurance products and policy count as a unit of measure to amortize DAC for its Canadian segregated funds products. In addition, the Company expects to group contracts by cohort to amortize DAC.

~~For term life insurance products, we expect DAC to be amortized more slowly under LDTI as compared with current GAAP.~~

For Canadian segregated funds, we expect DAC amortization to be less volatile than under current GAAP as it will no longer be based on the present value of gross profits, which are subject to changes in the market value of assets under management.


	Year ended December 31,
	2022			2021
	(Unaudited)			(Unaudited)
	(In thousands)
Equity attributable to Primerica, Inc./Permanent stockholders’ equity
Common stock:
Balance, beginning of period	$	394		$	393
Repurchases of common stock		(28	)		(1	)
Net issuance of common stock		2			2
Balance, end of period		368			394

Paid-in capital:
Balance, beginning of period		5,224			-
Share-based compensation		33,624			31,043
Net issuance of common stock		(2	)		(2	)
Repurchases of common stock		(41,079	)		(25,817	)
Redemption of noncontrolling interest in consolidated entities		2,233			-
Balance, end of period		-			5,224

Retained earnings:
Balance, beginning of period		2,074,111			1,705,786
Cumulative effect of adoption of new accounting standards - ASU 2018-12, net of income tax		-			(22,847	)
Adjusted balance		2,074,111			1,682,939
Net income		460,939			465,808
Dividends		(83,783	)		(74,636	)
Repurchases of common stock		(320,332	)		-
Balance, end of period		2,130,935			2,074,111

Accumulated other comprehensive income (loss), net of income tax:
Balance, beginning of period		(1,168,399	)		129,706
Cumulative effect of adoption of new accounting standards - ASU 2018-12		-			(1,510,618	)
Adjusted balance		(1,168,399	)		(1,380,912	)
Effect of change in discount rate assumptions on the liability for future policy benefits		1,372,022			269,895
Change in foreign currency translation adjustment		(20,747	)		6,973
Change in net unrealized investment gains (losses) during the period:		(304,645	)		(64,355	)
Balance, end of period		(121,769	)		(1,168,399	)
Total permanent stockholders’ equity	$	2,009,534		$	911,330

Redeemable noncontrolling interests in consolidated entities/Temporary stockholders’ equity
Balance, beginning of period	$	7,271		$	-
Acquisition of noncontrolling interest		-			8,438
Net income (loss) attributable to noncontrolling interests		(5,038	)		(1,377	)
Changes in noncontrolling interests in consolidated entities, net		-			210
Redemption of noncontrolling interest in consolidated entities		(2,233	)
Balance, end of period	$	-		$	7,271

~~Market Risk Benefits (“MRBs”)~~

The impact on the Company's previously reported consolidated balance sheet as of December 31, 2022 is as follows:


Consolidated Balance Sheet
December 31, 2022

	As Previously Reported			Adoption Impacts (Unaudited)			As Adjusted (Unaudited)
	(In thousands)
Assets:
Investments:
Fixed-maturity securities available-for-sale, at fair value (amortized cost: $2,801,415)	$	2,495,456		$	-		$	2,495,456
Fixed-maturity security held-to-maturity, at amortized cost (fair value: $1,340,265)		1,444,920			-			1,444,920
Short-term investments available-for-sale, at fair value (amortized cost: $69,393)		69,406			-			69,406
Equity securities, at fair value (historical cost: $29,430)		35,404			-			35,404
Trading securities, at fair value (cost: $4,229)		3,698			-			3,698
Policy loans and other invested assets		48,713			-			48,713
Total investments		4,097,597			-			4,097,597
Cash and cash equivalents		489,240			-			489,240
Accrued investment income		20,885			-			20,885
Reinsurance recoverables		4,015,909			(839,512	)		3,176,397
Deferred policy acquisition costs, net		3,081,886			112,143			3,194,029
Renewal commissions receivable		200,043			-			200,043
Agent balances, due premiums and other receivables		254,276			-			254,276
Goodwill		127,707			-			127,707
Intangible assets		185,525			-			185,525
Deferred income taxes		101,333			(3,361	)		97,972
Operating lease right-of-use assets		40,500			-			40,500
Other assets		428,259			-			428,259
Separate account assets		2,305,717			-			2,305,717
Total assets	$	15,348,877		$	(730,730	)	$	14,618,147

Liabilities and Stockholders’ Equity:
Liabilities:
Future policy benefits	$	7,390,800		$	(1,092,894	)	$	6,297,906
Unearned and advance premiums		15,422			-			15,422
Policy claims and other benefits payable		538,250			-			538,250
Other policyholders’ funds		483,769			-			483,769
Note payable		592,905			-			592,905
Surplus note		1,444,469			-			1,444,469
Income tax payable		36,876			-			36,876
Deferred income taxes		91,457			74,129			165,586
Operating lease liabilities		45,995			-			45,995
Other liabilities		580,780			-			580,780
Payable under securities lending		100,938			-			100,938
Separate account liabilities		2,305,717			-			2,305,717
Commitments and contingent liabilities (see Commitments and Contingent Liabilities note)
Total liabilities		13,627,378			(1,018,765	)		12,608,613

Temporary Stockholders’ Equity
Redeemable noncontrolling interests in consolidated entities		-			-			-
Permanent Stockholders’ Equity
Equity attributable to Primerica, Inc.:
Common stock ($0.01 par value; authorized 500,000 shares; issued and outstanding 36,824)		368			-			368
Paid-in capital		-			-			-
Retained earnings		1,973,403			157,532			2,130,935
Accumulated other comprehensive income (loss), net of income tax:
Effect of change in discount rate assumptions on the liability for future policy benefits		-			131,295			131,295
Unrealized foreign currency translation gains (losses)		(11,404	)		(792	)		(12,196	)
Net unrealized investment gains (losses) on available-for-sale securities		(240,868	)		-			(240,868	)
Total permanent stockholders’ equity		1,721,499			288,035			2,009,534
Total liabilities and temporary and permanent stockholders’ equity	$	15,348,877		$	(730,730	)	$	14,618,147

The impact on the Company's previously reported condensed consolidated statement of income for the three months ended March 31, 2022 is as follows:


Condensed Consolidated Statement of Income
Three months ended March 31, 2022

	As Previously Reported (Unaudited)			Adoption Impacts (Unaudited)			As Adjusted (Unaudited)
	(In thousands)
Revenues:
Direct premiums	$	798,666		$	-		$	798,666
Ceded premiums		(399,885	)		-			(399,885	)
Net premiums		398,781			-			398,781
Commissions and fees		251,800			-			251,800
Investment income net of investment expenses		34,420			-			34,420
Interest expense on surplus note		(15,515	)		-			(15,515	)
Net investment income		18,905			-			18,905
Realized investment gains (losses)		577			-			577
Other investment gains (losses)		174			-			174
Investment gains (losses)		751			-			751
Other, net		20,989			-			20,989
Total revenues		691,226			-			691,226

Benefits and expenses:
Benefits and claims		187,069			(18,781	)		168,288
Future policy benefits remeasurement (gain) loss		-			(1,272	)		(1,272	)
Amortization of deferred policy acquisition costs		86,063			(22,840	)		63,223
Sales commissions		133,924			-			133,924
Insurance expenses		59,509			-			59,509
Insurance commissions		7,721			-			7,721
Contract acquisition costs		20,649			-			20,649
Interest expense		6,853			-			6,853
Other operating expenses		86,435			-			86,435
Total benefits and expenses		588,223			(42,893	)		545,330
Income before income taxes		103,003			42,893			145,896
Income taxes		24,239			9,273			33,512
Net income		78,764			33,620			112,384
Net income (loss) attributable to noncontrolling interests		(2,655	)		-			(2,655	)
Net income attributable to Primerica, Inc.	$	81,419		$	33,620		$	115,039

Earnings per share attributable to common stockholders:
Basic earnings per share	$	2.07		$	0.85		$	2.92
Diluted earnings per share	$	2.06		$	0.85		$	2.91

Weighted-average shares used in computing earnings per share:
Basic		39,221			-			39,221
Diluted		39,332			-			39,332

Transition Impact on the Liability for Future Policy Benefits.

The Company adopted ASU 2018-12 using the modified retrospective transition method. As part of the transition disclosures ASU 2018-12 requires a reconciliation of the adoption impacts to the Company’s LFPB, separated between the changes in the present value of expected net premiums and the present value of expected future policy benefits as of the Transition Date. Theses balances are presented before reinsurance and income taxes for the Term Life Insurance segment, which makes up the substantial portion of the Company's long-duration insurance contract liabilities.


	Transition Impact at January 1, 2021
	(In thousands)
Present Value of Expected Premiums	Term Life
Balance at December 31, 2020	$	10,867,358
Impact to retained earnings from capping Transition Date net premium ratio		(137,112	)
Balance at original discount rate		10,730,246
Effect of changes in discount rate assumptions		2,774,082
Balance at January 1, 2021	$	13,504,328

Present Value of Expected Future Policy Benefits
Balance at December 31, 2020	$	17,445,700
Effect of changes in discount rate assumptions		5,624,494
Balance at January 1, 2021	$	23,070,194

~~MRBs are benefits that protect policyholders from capital market risk. Under LDTI, MRBs are measured at fair value.~~

~~The Company has MRBs from limited guaranteed benefits provided as part of our Canadian segregated funds products.~~

We are still undergoing the process of evaluating MRBs associated with our Canadian segregated funds products but we currently anticipate that the fair value of MRBs associated with this product will be immaterial when LDTI is adopted.

Recently-issued accounting guidance not discussed above is not applicable, is not material to our unaudited condensed consolidated financial statements, or did not or is not expected to have a material impact on our business.

Changes to Accounting Policies. All significant accounting policies remain unchanged from the 2022 Annual Report except for the following:

DAC. We defer incremental direct costs of successful contract acquisitions that result from and are essential to the contract transaction(s) and that would not have been incurred had the contract transaction(s) not occurred. These deferred policy acquisition costs mainly include commissions, underwriting costs and certain other policy issuance expenses associated with successful contract acquisitions. All other acquisition-related costs, including unsuccessful acquisition and renewal efforts, are charged to expense as incurred. Also, administrative costs, rent, depreciation, occupancy, equipment, and all other general overhead costs are considered indirect costs and are charged to expense as incurred.

DAC for term life insurance policies is amortized on a constant-level basis over the expected term of the contracts using face amount as the unit of measure. Contracts are grouped by cohorts consistent with the grouping used in estimating the LFPB. The cohorts are defined by the legal entity that issued the policy and the year the policy was issued. Assumptions of face amounts used to amortize DAC for term life insurance policies, including persistency and mortality, are consistent with the assumptions used in estimating the LFPB.

DAC for Canadian segregated funds is amortized on a constant-level basis over the expected term of the contracts using policy count as the unit of measure. Contracts are grouped by cohorts based on the issue year of the policy.

Interest is not accrued on unamortized DAC balances and DAC is not subject to impairment testing.

Separate Accounts. The separate accounts are primarily comprised of contracts issued by the Company through its subsidiary, Primerica Life Canada, pursuant to the Insurance Companies Act (Canada). The Insurance Companies Act authorizes Primerica Life Canada to establish the separate accounts.

The separate accounts are represented by individual variable insurance contracts. Purchasers of variable insurance contracts issued by Primerica Life Canada have a direct claim to the benefits of the contract that entitles the holder to units in one or more investment funds (the “Funds”) maintained by Primerica Life Canada. The Funds invest in assets that are held for the benefit of the owners of the contracts. The Funds’ assets are administered by Primerica Life Canada and are held separate and apart from the general assets of the Company. The liabilities reflect the variable insurance contract holders’ interests in the Funds’ net assets based upon actual investment performance of the respective Funds.

These Funds primarily consist of a series of branded investment funds known as the Asset Builder Funds, a registered retirement fund known as the Strategic Retirement Income Fund (“SRIF”), and a money market fund known as the Cash Management Fund. The principal investment objective of the Asset Builder Funds is to achieve long-term growth while preserving capital. The principal objective of the SRIF is to provide a stream of investment income during retirement plus the opportunity for modest capital appreciation. The Asset Builder Funds and the SRIF use diversified portfolios of publicly-traded Canadian stocks, investment-grade corporate bonds, Government of Canada bonds, and foreign equity investments to achieve their objectives. The Cash Management Fund invests in government guaranteed short-term bonds and short-term commercial and bank papers, with the principal investment objective being the provision of interest income while maintaining liquidity and preserving capital.

Under these contract offerings, benefit payments to contract holders or their designated beneficiaries are only due upon death of the annuitant or upon reaching a specific maturity date. Benefit payments are based on the value of the contract holder’s units in the portfolio at the payment date, but are guaranteed to be no less than 75% of the contract holder’s contribution, adjusted for withdrawals. Account values are not guaranteed for withdrawn units if contract holders make withdrawals prior to the maturity dates.

Maturity dates for contracts investing in the Asset Builder Funds and Cash Management Fund vary by contract and range from 10 years from the contract issuance date to December 31, 2070. Contracts investing in the SRIF mature when the policyholder reaches age 100, which is a minimum of 20 years after issue. The SRIF is designed to provide periodic retirement income payments and as such, regular withdrawals, subject to legislated minimums, are anticipated. The cumulative effects of the periodic withdrawals are expected to substantially reduce both account and minimum guaranteed values prior to maturity.

Both the asset and the liability for the separate accounts reflect the net value of the underlying assets in the portfolio as of the reporting date. Primerica Life Canada’s exposure to losses under the guarantee at the time of account maturity is limited to contract holder accounts that have declined in value more than 25%, adjusted for withdrawals since the contribution date, prior to maturity. As maturity dates are of a long-term nature, the likelihood that guarantee payments will be required at any given point is very small. Additionally, the portfolios consist of a very large number of individual contracts, further spreading the risk related to the guarantee. The length of the contract terms provides significant opportunity for the underlying portfolios to recover any short-term losses prior to maturity or the death of the contract holder. The Company has estimated the fair value associated with the market risk benefits provided by these limited guarantees to be immaterial. Furthermore, the Funds investment allocations are aligned with the maturity risks of the related contracts and include investments in Government Strip Bonds and floating-rate notes.

Future Policy Benefits. The LFPB on traditional life insurance products is established for future policy benefits, which includes death benefits, waiver of premium benefits and claim settlement expenses. The LFPB is calculated as the present value of expected future benefits less the present value of expected future net premiums receivable under the contracts. Net premiums are defined as the portion of the gross premiums received from policyholders that are needed to pay for all benefits.

The assumptions underlying the LFPB include mortality, persistency, disability rates, and other assumptions that reflect our best estimate based on our historical experience and modified, as necessary, to reflect non-recurring and/or anticipated trends.

The LFPB is estimated by grouping insurance policies into cohorts. Policy cohorts for the Term Life Insurance segment are based on the legal entity that issued the policy and the year the policy was issued.

The cash flows and assumptions underlying the LFPB are unlocked each quarter to reflect differences between actual and expected experience. In general, assumption changes, to the extent necessary, are expected to only occur during the third quarter when we update our experience studies. However, they may occur at any time based on emerging experience.

The impact of unlocking will be partly reflected in the current period and partly spread to future periods based on the remaining duration of the impacted cohort(s). The catch-up is retroactive back to the later of the Transition Date or issue date, after reinsurance recoverables and is recognized as a remeasurement gain or loss as a separate component of benefits and claims expense in the consolidated statements of income.

The ceded reserve balances included in reinsurance recoverables are calculated in the same manner as the LFPB by cohort and apply best estimate assumptions and quarterly unlocking.

The Company uses discount rates applied by country to align with local currency cash flows. Discount rates consist of yield curves that are developed using Bloomberg’s Evaluated Pricing Product (BVAL) based on senior unsecured fixed rate bonds ratings of A+, A or A-. The discount rate assumption is updated quarterly and the impact of remeasuring the net LFPB, after reinsurance recoverables from changes in the locked-in discount rate assumption is reflected in other comprehensive income in the consolidated statements of comprehensive income.

The LFPB we establish are necessarily based on estimates, assumptions and our analysis of historical experience. Our results depend upon the extent to which our actual experience is consistent with the assumptions we use in determining the LFPB. The assumptions and estimates underlying the LFPB require significant judgment and, therefore, are inherently uncertain.

(2) Segment and Geographical Information

Segments. We have three primary operating segments — Term Life Insurance, Investment and Savings Products, and ~~(as of July 1, 2021)~~ Senior Health. We also have a Corporate and Other Distributed Products segment.

Notable information included in profit or loss by segment was as follows:


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
	2022			2021			2022			2021			2023			2022
	(In thousands)												(In thousands)
Revenues:
Term life insurance segment	$	427,830		$	401,451		$	1,256,967		$	1,167,016		$	421,069		$	406,983
Investment and savings products segment		201,697			233,337			665,152			694,770			210,202			241,039
Senior health segment		17,184			22,936			34,828			22,936			18,710			5,831
Corporate and other distributed products segment		26,578			35,515			76,247			100,916			40,055			37,373
Total revenues	$	673,289		$	693,239		$	2,033,194		$	1,985,638		$	690,036		$	691,226

Net investment income:
Term life insurance segment	$	13,241		$	9,320		$	36,973		$	26,324		$	-		$	-
Investment and savings products segment		-			-			-			-			-			-
Senior health segment		-			-			-			-			-			-
Corporate and other distributed products segment		11,105			10,680			27,562			34,264			31,065			18,905
Total net investment income	$	24,346		$	20,000		$	64,535		$	60,588		$	31,065		$	18,905

Amortization of DAC:
Term life insurance segment	$	88,275		$	59,287		$	249,826		$	174,106		$	65,503		$	61,369
Investment and savings products segment		2,222			2,580			11,610			7,641			1,493			1,446
Senior health segment		-			-			-			-			-			-
Corporate and other distributed products segment		428			347			931			857			362			408
Total amortization of DAC	$	90,925		$	62,214		$	262,367		$	182,604		$	67,358		$	63,223

Non-cash share-based compensation expense:
Term life insurance segment	$	645		$	570		$	3,388		$	3,303		$	1,850		$	2,125
Investment and savings products segment		672			665			2,559			2,532			993			1,204
Senior health segment		67			-			67			-			160			-
Corporate and other distributed products segment		(324	)		(594	)		13,638			8,999			9,071			9,108
Total non-cash share-based compensation expense	$	1,060		$	641		$	19,652		$	14,834		$	12,074		$	12,437

Income (loss) before income taxes:
Term life insurance segment	$	111,764		$	107,589		$	323,220		$	312,603		$	126,736		$	118,576
Investment and savings products segment		58,377			69,368			181,913			203,885			56,106			67,039
Senior health segment		(63,723	)		(8,490	)		(102,959	)		(8,490	)		(3,762	)		(23,085	)
Corporate and other distributed products segment		(20,519	)		(21,365	)		(75,971	)		(63,123	)		(15,943	)		(16,634	)
Total income (loss) before income taxes	$	85,899		$	147,102		$	326,203		$	444,875		$	163,137		$	145,896

Total assets by segment were as follows:


	September 30, 2022		December 31, 2021		March 31, 2023		December 31, 2022
	(In thousands)				(In thousands)
Assets:
Term life insurance segment	$	7,164,005	$	7,274,820	$	6,506,068	$	6,433,880
Investment and savings products segment (1)		2,324,810		2,920,271		2,454,810		2,424,256
Senior health segment		428,317		528,974		429,884		431,993
Corporate and other distributed products segment		5,125,011		5,399,158		5,404,930		5,328,018
Total assets	$	15,042,143	$	16,123,223	$	14,795,692	$	14,618,147

(1) The Investment and Savings Products segment includes assets held in separate accounts. Excluding separate accounts, the Investment and Savings Products segment assets were $~~118.2~~124.9 million and $~~120.3~~118.5 million as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively.

Geographical Information. Results of operations by country and long-lived assets, primarily tangible assets reported in other assets in our unaudited condensed consolidated balance sheets and condensed consolidated statements of income, were as follows:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021		2023		2022
	(In thousands)								(In thousands)
Revenues by country:
United States	$	588,954	$	594,406	$	1,750,621	$	1,687,868	$	603,850	$	586,153
Canada		84,335		98,833		282,573		297,770		86,186		105,073
Total revenues	$	673,289	$	693,239	$	2,033,194	$	1,985,638	$	690,036	$	691,226


	September 30, 2022		December 31, 2021		March 31, 2023		December 31, 2022
	(In thousands)				(In thousands)
Long-lived assets by country:
United States	$	51,147	$	62,921	$	48,835	$	49,637
Canada		3,111		3,871		2,689		2,803
Other		233		230		215		217
Total long-lived assets	$	54,491	$	67,022	$	51,739	$	52,657

(3) Investments

Available-for-sale Securities. The period-end amortized cost, gross unrealized gains and losses, and fair value of available-for-sale securities were as follows:


	September 30, 2022									March 31, 2023
	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value		Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value
	(In thousands)									(In thousands)
Securities available-for-sale, carried at fair value:
Fixed-maturity securities:
U.S. government and agencies	$	32,698	$	20	$	(980	)	$	31,738	$	9,976	$	26	$	(571	)	$	9,431
Foreign government		150,507		474		(11,037	)		139,944		157,424		1,234		(9,053	)		149,605
States and political subdivisions		142,852		59		(21,789	)		121,122		138,835		239		(15,799	)		123,275
Corporates		1,668,098		1,985		(194,251	)		1,475,832		1,701,254		5,056		(148,291	)		1,558,019
Residential mortgage-backed securities		477,103		251		(65,328	)		412,026		476,070		456		(67,980	)		408,546
Commercial mortgage-backed securities		139,940		3		(14,204	)		125,739		142,789		43		(15,114	)		127,718
Other asset-backed securities		167,817		-		(16,229	)		151,588		196,648		410		(15,026	)		182,032
Total fixed-maturity securities		2,779,015		2,792		(323,818	)		2,457,989		2,822,996		7,464		(271,834	)		2,558,626
Short-term investments											70,185		7		(5	)		70,187
Total fixed-maturity and short-term investments										$	2,893,181	$	7,471	$	(271,839	)	$	2,628,813


	December 31, 2021									December 31, 2022
	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value		Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value
	(In thousands)									(In thousands)
Securities available-for-sale, carried at fair value:
Fixed-maturity securities:
U.S. government and agencies	$	32,292	$	187	$	(79	)	$	32,400	$	31,217	$	18	$	(767	)	$	30,468
Foreign government		147,288		6,283		(595	)		152,976		163,725		780		(11,590	)		152,915
States and political subdivisions		147,455		6,326		(254	)		153,527		142,189		112		(20,056	)		122,245
Corporates		1,649,334		72,418		(8,068	)		1,713,684		1,665,962		2,439		(171,552	)		1,496,849
Residential mortgage-backed securities		373,753		5,108		(3,230	)		375,631		473,309		370		(71,949	)		401,730
Commercial mortgage-backed securities		142,631		3,314		(420	)		145,525		139,306		3		(16,342	)		122,967
Other asset-backed securities		128,635		1,409		(1,220	)		128,824		185,707		108		(17,533	)		168,282
Total fixed-maturity securities		2,621,388		95,045		(13,866	)		2,702,567		2,801,415		3,830		(309,789	)		2,495,456
Short-term investments		85,246		1		(4	)		85,243		69,393		20		(7	)		69,406
Total fixed-maturity and short-term investments	$	2,706,634	$	95,046	$	(13,870	)	$	2,787,810	$	2,870,808	$	3,850	$	(309,796	)	$	2,564,862

All of our available-for-sale mortgage- and asset-backed securities represent variable interests in variable interest entities (“VIEs”). We are not the primary beneficiary of these VIEs because we do not have the power to direct the activities that most significantly impact the entities’ economic performance. The maximum exposure to loss as a result of our involvement in these VIEs equals the carrying value of the securities.

The scheduled maturity distribution of the available-for-sale (“AFS”) fixed-maturity portfolio as of ~~September 30, 2022~~March 31, 2023 was as follows:

Amortized cost

Fair value

(In thousands)

Due in one year or less

$
185,346

$
184,509

Due after one year through five years

768,889

724,190

Due after five years through 10 years

747,297

627,289

Due after 10 years

292,623

232,648

1,994,155

1,768,636

Mortgage- and asset-backed securities

784,860

689,353

Total AFS fixed-maturity securities

$
2,779,015

$
2,457,989


	Amortized cost		Fair value
	(In thousands)
Due in one year or less	$	154,148	$	152,676
Due after one year through five years		770,897		733,708
Due after five years through 10 years		783,681		697,131
Due after 10 years		298,763		256,815
		2,007,489		1,840,330
Mortgage- and asset-backed securities		815,507		718,296
Total AFS fixed-maturity securities	$	2,822,996	$	2,558,626

Expected maturities may differ from scheduled contractual maturities because issuers of securities may have the right to call or prepay obligations with or without call or prepayment penalties.

Trading Securities. The cost and fair value of the securities classified as trading securities were as follows:

September 30, 2022

December 31, 2021

Cost

Fair value

Cost

Fair value

(In thousands)

Fixed-maturity securities

$
4,335

$
3,718

$
24,769

$
24,355


	March 31, 2023				December 31, 2022
	Cost		Fair value		Cost		Fair value
	(In thousands)
Fixed-maturity securities	$	19,033	$	18,497	$	4,229	$	3,698

Held-to-maturity Security. Concurrent with the execution of the Vidalia Re Coinsurance Agreement, Vidalia Re entered into a Surplus Note Purchase Agreement (the “Surplus Note Purchase Agreement”) with Hannover Life Reassurance Company of America and certain of its affiliates (collectively, “Hannover Re”) and a newly formed limited liability company (the “LLC”) owned by a third- party service provider. Under the Surplus Note Purchase Agreement, Vidalia Re issued a surplus note (the “Surplus Note”) to the LLC in exchange for a credit enhanced note from the LLC with an equal principal amount (the “LLC Note”). The principal amount of both the LLC Note and the Surplus Note will fluctuate over time to coincide with the amount of reserves contractually supported under the Vidalia Re Coinsurance Agreement. Both the LLC Note and the Surplus Note mature on December 31, 2030 and bear interest at an annual interest rate of 4.50%. The LLC Note is guaranteed by Hannover Re through a credit enhancement feature in exchange for a fee, which is reflected in interest expense on our unaudited condensed consolidated statements of income.

The LLC is a VIE as its owner does not have an equity investment at risk that is sufficient to permit the LLC to finance its activities without Vidalia Re or Hannover Re. The Parent Company, Primerica Life, and Vidalia Re share the power to direct the activities of the LLC with Hannover Re, but do not have the obligation to absorb losses or the right to receive any residual returns related to the LLC’s primary risks or sources of variability. Through the credit enhancement feature, Hannover Re is the ultimate risk taker in this transaction and bears the obligation to absorb the LLC’s losses in the event of a Surplus Note default in exchange for the fee. Accordingly, the Company is not the primary beneficiary of the LLC and does not consolidate the LLC within its unaudited condensed consolidated financial statements. See Note 5 (Reinsurance) for Hannover Re’s financial strength rating.

The LLC Note is classified as a fixed-maturity held-to-maturity security in the Company’s invested asset portfolio as we have the positive intent and ability to hold the security until maturity. As of ~~September 30, 2022,~~March 31, 2023, the LLC Note had an estimated unrealized holding loss of $~~113.5~~71.6 million based on its amortized cost and estimated fair value. The estimated fair value of the LLC Note is

expected to be at least equal to the estimated fair value of the offsetting Surplus Note. See Note 1215 (Debt) for more information on the Surplus Note.

As of ~~September 30, 2022,~~March 31, 2023, no credit losses have been recognized on the LLC Note.

Investments on Deposit with Governmental Authorities. As required by law, we have investments on deposit with governmental authorities and banks for the protection of policyholders. The fair values of investments on deposit were $7.1 million and $~~7.6~~7.1 million as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively.

Securities Lending Transactions. We participate in securities lending transactions with broker-dealers and other financial institutions to increase investment income with minimal risk. We require minimum collateral on securities loaned equal to 102% of the fair value of the loaned securities. We accept collateral in the form of securities, which we are not able to sell or encumber, and to the extent the collateral declines in value below 100%, we require additional collateral from the borrower. Any securities collateral received is not reflected on our unaudited condensed consolidated balance sheets. We also accept collateral in the form of cash, all of which we reinvest. For loans involving unrestricted cash collateral, the collateral is reported as an asset with a corresponding liability representing our obligation to return the collateral. We continue to carry the loaned securities as invested assets on our unaudited condensed consolidated balance sheets during the terms of the loans, and we do not report them as sales. Cash collateral received and reinvested was $~~80.8~~74.5 million and $~~94.5~~100.9 million as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively.

Investment Income. The components of net investment income were as follows:


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
	2022			2021			2022			2021			2023			2022
	(In thousands)												(In thousands)
Fixed-maturity securities (available-for-sale)	$	23,067		$	19,860		$	66,370		$	60,035		$	25,806		$	20,889
Fixed-maturity security (held-to-maturity)		16,283			15,741			47,613			46,382			16,435			15,515
Equity securities		373			413			1,131			1,216			380			387
Policy loans and other invested assets		436			289			596			618			(71	)		102
Cash and cash equivalents		1,714			96			2,338			371			5,128			125
Total return on deposit asset underlying 10% coinsurance agreement(1)		489			346			(1,790	)		1,989			2,049			(1,510	)
Gross investment income		42,362			36,745			116,258			110,611			49,727			35,508
Investment expenses		(1,733	)		(1,004	)		(4,110	)		(3,641	)		(2,227	)		(1,088	)
Investment income net of investment expenses		40,629			35,741			112,148			106,970			47,500			34,420
Interest expense on surplus note		(16,283	)		(15,741	)		(47,613	)		(46,382	)		(16,435	)		(15,515	)
Net investment income	$	24,346		$	20,000		$	64,535		$	60,588		$	31,065		$	18,905

(1)

~~For the three months ended September 30, 2022, includes less than~~Includes ($~~0.1~~0.3) million and $(2.1) million of net ~~losses~~gains (losses) recognized for the change in fair value of the deposit asset underlying the 10% coinsurance ~~agreement. For~~agreement for the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and 2022, ~~includes $(3.4) million of net losses recognized for the change in fair value of the deposit asset underlying the~~ 10~~% coinsurance agreement. For the three and nine months ended September 30, 2021, includes $(0.6) million and $(1.6) million, respectively, of net losses recognized for the change in fair value of the deposit asset underlying the~~ 10~~% coinsurance agreement.~~respectively.

The components of investment gains (losses), as well as details on gross realized investment gains (losses) and other investment gains (losses) were as follows:


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
	2022			2021			2022			2021			2023			2022
	(In thousands)												(In thousands)
Realized investment gains (losses):
Gross gains from sales of available-for-sale securities fixed maturity securities	$	491		$	1,801		$	1,512		$	5,780		$	49		$	602
Gross losses from sales of available-for-sale fixed maturity securities		(199	)		(71	)		(588	)		(2,018	)		(1,034	)		(25	)
Net realized investment gains (losses):		292			1,730			924			3,762			(985	)		577
Other investment gains (losses):
Credit losses impairment of available-for-sale securities		(138	)		149			(57	)		(710	)		(2,160	)		81
Market gains (losses) recognized in net income during the period on equity securities		(2,858	)		(418	)		(4,692	)		1,117			(1,475	)		115
Gains (losses) from bifurcated options		-			1			-			(48	)		8			-
Gains (losses) on trading securities		5			(52	)		(16	)		(245	)		4			(22	)
Other investment gains (losses):		(2,991	)		(320	)		(4,765	)		114			(3,623	)		174
Investment gains (losses)	$	(2,699	)	$	1,410		$	(3,841	)	$	3,876		$	(4,608	)	$	751

The proceeds from sales or other redemptions of available-for-sale securities were as follows:

Three months ended September 30,

Nine months ended September 30,

2022

2021

2022

2021

(In thousands)

Proceeds from sales or other redemptions

$
117,909

$
135,393

$
419,985

$
449,564


	Three months ended March 31,
	2023		2022
	(In thousands)
Proceeds from sales or other redemptions	$	85,430	$	139,113

Accrued Interest. Accrued interest is recorded in accordance with the original interest schedule of the underlying security. In the event of default, the Company’s policy is to no longer accrue interest on these securities and any remaining accrued interest will be written off. As a result, the Company has made the policy election to not record an allowance for credit losses on accrued interest.

Credit Losses for Available-for-sale Securities. The following table summarizes all available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of ~~September 30, 2022,~~March 31, 2023, aggregated by major security type and length of time such securities have continuously been in an unrealized loss position:


	September 30, 2022										March 31, 2023
	Less than 12 months					12 months or longer					Less than 12 months					12 months or longer
	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
	(Dollars in thousands)										(Dollars in thousands)
Fixed-maturity securities:
U.S. government and agencies	$	27,735	$	(744	)	$	2,170	$	(236	)	$	3,920	$	(99	)	$	5,173	$	(472	)
Foreign government		114,843		(7,332	)		17,132		(3,705	)		30,377		(399	)		91,887		(8,654	)
States and political subdivisions		105,750		(18,900	)		11,798		(2,889	)		10,178		(277	)		102,623		(15,522	)
Corporates		1,202,033		(127,943	)		239,948		(66,308	)		457,448		(12,678	)		926,057		(135,613	)
Residential mortgage-backed securities		301,304		(41,127	)		103,895		(24,201	)		40,398		(3,342	)		348,490		(64,638	)
Commercial mortgage-backed securities		96,986		(10,949	)		28,352		(3,255	)		27,240		(884	)		95,244		(14,230	)
Other asset-backed securities		102,080		(8,368	)		49,508		(7,861	)		29,901		(1,243	)		117,076		(13,783	)
Total fixed-maturity securities		1,950,731		(215,363	)		452,803		(108,455	)		599,462		(18,922	)		1,686,550		(252,912	)
Short-term investments:
U.S. government and agencies												15,835		(4	)		-		-
Foreign government												1,756		(1	)		-		-
Total short-term investments												17,591		(5	)		-		-
Total fixed-maturity securities and short-term investments											$	617,053	$	(18,927	)	$	1,686,550	$	(252,912	)

December 31, 2021

Less than 12 months

12 months or longer

Fair value

Unrealized losses

Fair value

Unrealized losses

(Dollars in thousands)

Fixed-maturity securities:

U.S. government and agencies

$
24,928

$
(45
)

$
1,557

$
(34
)
Foreign government

18,894

(384
)

3,335

(211
)
States and political subdivisions

15,909

(254
)

-

-

Corporates

341,963

(5,035
)

59,414

(3,033
)
Residential mortgage-backed securities

234,911

(3,131
)

2,707

(99
)
Commercial mortgage-backed securities

47,220

(419
)

117

(1
)
Other asset-backed securities

80,509

(1,037
)

3,779

(183
)
Total fixed-maturity securities

764,334

(10,305
)

70,909

(3,561
)
Short-term investments:

U.S. government and agencies

34,967

*

-

-

Foreign government

4,995

*

-

-

States and political subdivisions

11,394

(1
)

-

-

Corporates

23,891

(3
)

-

-

Total short-term investments

75,247

(4
)

-

-

Total fixed-maturity securities and short-term investments

$
839,581

$
(10,309
)

$
70,909

$
(3,561
)

* Less than $

118

~~thousand.~~


	December 31, 2022
	Less than 12 months					12 months or longer
	Fair value		Unrealized losses			Fair value		Unrealized losses
	(Dollars in thousands)
Fixed-maturity securities:
U.S. government and agencies	$	4,927	$	(204	)	$	25,209	$	(563	)
Foreign government		97,094		(4,430	)		38,085		(7,160	)
States and political subdivisions		71,131		(10,666	)		44,324		(9,390	)
Corporates		974,931		(69,726	)		452,541		(101,826	)
Residential mortgage-backed securities		187,158		(22,171	)		201,595		(49,778	)
Commercial mortgage-backed securities		65,165		(5,069	)		56,799		(11,273	)
Other asset-backed securities		81,907		(5,807	)		72,977		(11,726	)
Total fixed-maturity securities		1,482,313		(118,073	)		891,530		(191,716	)
Short-term investments:
U.S. government and agencies		28,379		(5	)		-		-
Foreign government		1,744		(2	)		-		-
Total short-term investments		30,123		(7	)		-		-
Total fixed-maturity securities and short-term investments	$	1,512,436	$	(118,080	)	$	891,530	$	(191,716	)

The amortized cost of available-for-sale fixed-maturity securities with a cost basis in excess of their fair values were $~~2.7~~2,575.4 ~~billion~~million and $~~924.4~~2,713.8 million as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively.

As of ~~September 30, 2022,~~March 31, 2023, we did not recognize credit losses in the unaudited condensed consolidated statements of income on available-for-sale securities with unrealized losses that were due to interest rate sensitivity and changes in credit spreads. We believe that fluctuations caused by movement in interest rates and credit spreads generally have little bearing on the recoverability of our investments. We recognized credit losses in the unaudited condensed consolidated statements of income on available-for-sale securities that are in an unrealized loss position that we have the intent to sell. For those that remain in an unrealized loss position we have the ability to hold these investments until maturity or a market price recovery, and we have no present intention to dispose them. The sharp increase in interest rates ~~during~~over the ~~three and nine~~last 12 months ~~ended September 30, 2022~~ was the primary driver of the increase in unrealized losses on available-for-sale securities.

For the three months ended ~~September 30,~~March 31, 2023 and 2022, we recognized $~~0.1~~2.2 million ofand $(0.1) million, respectively, for credit (gains) losses on available-for-sale securities in the unaudited condensed consolidated statements of ~~income on available-for-sale securities. For the nine months ended September 30, 2022, we recorded less than $0.1~~ million for credit (gains) losses in the unaudited condensed consolidated statements of income on available-for-sale securities. For the three and nine months ended September 30, 2021, we recorded a total of $(~~0.1) million and $0.7~~ ~~million, respectively, for credit (gains) losses in the unaudited condensed consolidated statements of income on available-for-sale securities.~~income. We recognized credit losses on securities due to: (i) our intent to sell them; (ii) adverse credit events indicating that we will not receive the security’s contractual cash flows when contractually due, such as news of an impending filing for bankruptcy; (iii) analyses of the issuer’s most recent financial statements or other information indicating that significant liquidity deficiencies, significant losses and large declines in capitalization exist; and (iv) analyses of rating agency information for issuances with severe ratings downgrades indicating a significant increase in the possibility of default.

The rollforward of the allowance for credit losses on available-for-sale securities ~~were~~was as follows:


	Three months ended September 30,					Nine months ended September 30,					Three months ended March 31,
	2022		2021			2022			2021		2023		2022
	(In thousands)										(In thousands)
Allowance for credit losses, beginning of period	$	-	$	858		$	816		$	-	$	-	$	816
Additions to the allowance for credit losses on securities for which credit losses were not previously recorded		-		6			-			160		-		-
Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period		-		(154	)		(81	)		550		-		(81	)
Write-offs charged against the allowance, if any		-		-			(735	)		-		-		-
Allowance for credit losses, end of period	$	-	$	710		$	-		$	710	$	-	$	735

Derivatives. We carry a deferred loss related to closed forward contracts, which were settled several years ago, that were used to mitigate our exposure to foreign currency exchange rates that resulted from the net investment in our Canadian operations. The amount of deferred loss included in accumulated other comprehensive income was $26.4 million as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021.~~2022. These deferred losses will not be recognized until such time as we sell or substantially liquidate our Canadian operations. We have no such intention.

(4) Fair Value of Financial Instruments

Fair value is the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Invested assets recorded at fair value are measured and classified in accordance with a

three-tier fair value hierarchy based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. We classify and disclose all invested assets carried at fair value in one of the following three levels:

•

Level 1. Quoted prices for identical instruments in active markets. Level 1 consists of financial instruments whose value is based on quoted market prices in active markets, such as cash, cash equivalents in money market funds, exchange-traded common stocks and actively traded mutual fund investments;

•

Level 2. Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 2 includes those financial instruments that are valued using industry-standard pricing methodologies, models or other valuation methodologies. Various inputs are considered in deriving the fair value of the underlying financial instrument, including interest rate and yield curves, credit spread, and foreign exchange rates. All significant inputs are observable, or derived from observable information in the marketplace or are supported by observable levels at which transactions are executed in the marketplace. Financial instruments in this category primarily include: cash equivalents and short-term investments in U.S. treasury securities, certain public and private corporate fixed-maturity and equity securities; government or agency securities; and certain mortgage- and asset-backed securities; and

•

Level 3. Valuations derived from valuation techniques in which one or more significant inputs are unobservable. Level 3 consists of financial instruments whose fair value is estimated based on industry-standard pricing methodologies and models using significant inputs not based on, nor corroborated by, readily available market information. Valuations for this category primarily consist of non-binding broker quotes. Financial instruments in this category primarily include less liquid mortgage- and asset-backed securities and equity securities.

As of each reporting period, all assets and liabilities recorded at fair value are classified in their entirety based on the lowest level of input (Level 3 being the lowest in the hierarchy) that is significant to the fair value measurement. Significant levels of estimation and judgment are required to determine the fair value of certain of our investments. The factors influencing these estimations and judgments are subject to change in subsequent reporting periods.

The estimated fair value and hierarchy classifications for assets and liabilities that are measured at fair value on a recurring basis were as follows:


	September 30, 2022								March 31, 2023
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	(In thousands)								(In thousands)
Fair value assets:
Available-for-sale fixed-maturity securities:
U.S. government and agencies	$	-	$	31,738	$	-	$	31,738	$	-	$	9,431	$	-	$	9,431
Foreign government		-		139,944		-		139,944		-		149,605		-		149,605
States and political subdivisions		-		121,122		-		121,122		-		123,275		-		123,275
Corporates		3,811		1,472,021		-		1,475,832		3,960		1,554,059		-		1,558,019
Mortgage- and asset-backed securities:
Residential mortgage-backed securities		-		408,228		3,798		412,026		-		408,546		-		408,546
Commercial mortgage-backed securities		-		124,741		998		125,739		-		127,718		-		127,718
Other asset-backed securities		-		150,214		1,374		151,588		-		179,716		2,316		182,032
Total available-for-sale fixed-maturity securities		3,811		2,448,008		6,170		2,457,989		3,960		2,552,350		2,316		2,558,626
Short-term investments		-		-		-		-		-		70,187		-		70,187
Total available-for-sale securities		3,811		2,448,008		6,170		2,457,989		3,960		2,622,537		2,316		2,628,813
Equity securities		30,577		988		1,514		33,079		31,305		986		1,693		33,984
Trading securities		-		3,718		-		3,718		-		18,497		-		18,497
Cash and cash equivalents		438,025		-		-		438,025		494,093		20,997		-		515,090
Separate accounts		-		2,206,608		-		2,206,608		-		2,329,968		-		2,329,968
Total fair value assets	$	472,413	$	4,659,322	$	7,684	$	5,139,419	$	529,358	$	4,992,985	$	4,009	$	5,526,352
Fair value liabilities:
Separate accounts	$	-	$	2,206,608	$	-	$	2,206,608	$	-	$	2,329,968	$	-	$	2,329,968
Total fair value liabilities	$	-	$	2,206,608	$	-	$	2,206,608	$	-	$	2,329,968	$	-	$	2,329,968

December 31, 2021

Level 1

Level 2

Level 3

Total

(In thousands)

Fair value assets:

Available-for-sale fixed-maturity securities:

U.S. government and agencies

$
-

$
32,400

$
-

$
32,400

Foreign government

-

152,976

-

152,976

States and political subdivisions

-

153,527

-

153,527

Corporates

5,898

1,707,786

-

1,713,684

Mortgage-and asset-backed securities:

Residential mortgage-backed securities

-

375,604

27

375,631

Commercial mortgage-backed securities

-

145,525

-

145,525

Other asset-backed securities

-

128,824

-

128,824

Total available-for-sale fixed-maturity securities

5,898

2,696,642

27

2,702,567

Short-term investments

-

85,243

-

85,243

Total available-for-sale securities

5,898

2,781,885

27

2,787,810

Equity securities

37,912

1,070

3,569

42,551

Trading securities

-

24,355

-

24,355

Cash and cash equivalents

351,508

40,993

-

392,501

Separate accounts

-

2,799,992

-

2,799,992

Total fair value assets

$
395,318

$
5,648,295

$
3,596

$
6,047,209

Fair value liabilities:

Separate accounts

$
-

$
2,799,992

$
-

$
2,799,992

Total fair value liabilities

$
-

$
2,799,992

$
-

$
2,799,992


	December 31, 2022
	Level 1		Level 2		Level 3		Total
	(In thousands)
Fair value assets:
Available-for-sale fixed-maturity securities:
U.S. government and agencies	$	-	$	30,468	$	-	$	30,468
Foreign government		-		152,915		-		152,915
States and political subdivisions		-		122,245		-		122,245
Corporates		3,586		1,493,263		-		1,496,849
Mortgage-and asset-backed securities:
Residential mortgage-backed securities		-		401,730		-		401,730
Commercial mortgage-backed securities		-		122,967		-		122,967
Other asset-backed securities		-		168,282		-		168,282
Total available-for-sale fixed-maturity securities		3,586		2,491,870		-		2,495,456
Short-term investments		-		69,406		-		69,406
Total available-for-sale securities		3,586		2,561,276		-		2,564,862
Equity securities		32,727		967		1,710		35,404
Trading securities		-		3,698		-		3,698
Cash and cash equivalents		489,240		-		-		489,240
Separate accounts		-		2,305,717		-		2,305,717
Total fair value assets	$	525,553	$	4,871,658	$	1,710	$	5,398,921
Fair value liabilities:
Separate accounts	$	-	$	2,305,717	$	-	$	2,305,717
Total fair value liabilities	$	-	$	2,305,717	$	-	$	2,305,717

In estimating fair value of our investments, we use a third-party pricing service for approximately 99%all of our securities that are measured at fair value on a recurring basis. The remaining securities are primarily thinly-traded securities, such as private placements, and are valued using models based on observable inputs on public corporate spreads having similar characteristics (e.g., sector, average life and quality rating), liquidity and yield based on quality rating, average life and U.S. Treasury yields. All observable data inputs are corroborated by independent third-party data. We also corroborate pricing information provided by our third-party pricing service by performing a review of selected securities. Our review activities include: obtaining detailed information about the assumptions, inputs and methodologies used in pricing the security; documenting this information; and corroborating it by comparison to independently obtained prices and/or independently developed pricing methodologies.

Furthermore, we perform internal reasonableness assessments on fair value determinations within our portfolio throughout the year and as of year-end, including pricing variance analyses and comparisons to alternative pricing sources and benchmark returns. If a fair

value appears unusual relative to these assessments, we will re-examine the inputs and may challenge a fair value assessment made by the pricing service. If there is a known pricing error, we will request a reassessment by the pricing service. If the pricing service is unable to perform the reassessment on a timely basis, we will determine the appropriate price by requesting a reassessment from an alternative pricing service or other qualified source as necessary. We do not adjust quotes or prices except in a rare circumstance to resolve a known error.

Because many fixed-maturity securities do not trade on a daily basis, third-party pricing services generally determine fair value using industry-standard methodologies, which vary by asset class. For corporates, governments, and agency securities, these methodologies include developing prices by incorporating available market information such as U.S. Treasury curves, benchmarking of similar securities including new issues, sector groupings, quotes from market participants and matrix pricing. Observable information is compiled and integrates relevant credit information, perceived market movements and sector news. Additionally, security prices are periodically back-tested to validate and/or refine models as conditions warrant. Market indicators and industry and economic events are also monitored as triggers to obtain additional data. For certain structured securities (such as mortgage- and asset-backed securities) with limited trading activity, third-party pricing services generally use industry-standard pricing methodologies that incorporate market information, such as index prices or discounting expected future cash flows based on underlying collateral, and quotes from market participants, to estimate fair value. If one or more of these input measures are not deemed observable for a particular security, the security will be classified as Level 3 in the fair value hierarchy.

Where specific market information is unavailable for certain securities, pricing models produce estimates of fair value primarily using Level 2 inputs along with certain Level 3 inputs. These models include matrix pricing. The pricing matrix uses current U.S. Treasury rates and credit spreads received from third-party sources to estimate fair value. The credit spreads incorporate the issuer’s industry- or issuer-specific credit characteristics and the security’s time to maturity, if warranted. Remaining unpriced securities are valued using an estimate of fair value based on indicative market prices that include significant unobservable inputs not based on, nor corroborated by, market information, including the utilization of non-binding broker quotes.

The roll-forward of the Level 3 assets measured at fair value on a recurring basis was as follows:

Three months ended September 30,

Nine months ended September 30, (1)

2022

2021

2022

2021

(In thousands)

Level 3 assets, beginning of period

$
1,634

$
3,336

$
3,596

$
2,047

Net unrealized gains (losses) included in other comprehensive income

(8
)

1

99

1

Realized gains (losses) and accretion (amortization) recognized in earnings

(127
)

(125
)

(328
)

(359
)
Purchases

6,170

2,068

13,661

3,067

Sales

-

-

-

-

Settlements

15

(1
)

(1,385
)

(2,191
)
Transfers into Level 3

-

-

1,399

2,714

Transfers out of Level 3

-

(1,501
)

(9,358
)

(1,501
)
Level 3 assets, end of period

$
7,684

$
3,778

$
7,684

$
3,778

~~(1)~~

~~Activities for investments that enter and exit Level 3 in different quarters within the same fiscal year are not eliminated until the full year amounts are presented.~~


	Three months ended March 31,
	2023			2022
	(In thousands)
Level 3 assets, beginning of period	$	1,710		$	3,596
Net unrealized gains (losses) included in other comprehensive income		-			(2	)
Realized gains (losses) and accretion (amortization) recognized in earnings		(17	)		(207	)
Purchases		2,316			5,903
Sales		-			-
Settlements		-			-
Transfers into Level 3		-			1,399
Transfers out of Level 3		-			-
Level 3 assets, end of period	$	4,009		$	10,689

We obtain independent pricing quotes based on observable inputs as of the end of the reporting period for all securities in Level 2. Those inputs include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, market bids/offers, quoted prices for similar instruments in markets that are not active, and other relevant data. We monitor these inputs for market indicators, industry and economic events. There were no material transfers between Level 1 and Level 3 during the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023 and ~~2021.~~2022.

The carrying values and estimated fair values of our financial instruments were as follows:


	September 30, 2022				December 31, 2021				March 31, 2023				December 31, 2022
	Carrying value		Estimated fair value		Carrying value		Estimated fair value		Carrying value		Estimated fair value		Carrying value		Estimated fair value
	(In thousands)								(In thousands)
Assets:
Fixed-maturity securities (available-for-sale)	$	2,457,989	$	2,457,989	$	2,702,567	$	2,702,567	$	2,558,626	$	2,558,626	$	2,495,456	$	2,495,456
Fixed-maturity security (held-to-maturity) (3)		1,433,760		1,320,222		1,379,100		1,551,113		1,460,000		1,388,411		1,444,920		1,340,265
Short-term investments (available-for-sale)		-		-		85,243		85,243		70,187		70,187		69,406		69,406
Equity securities		33,079		33,079		42,551		42,551		33,984		33,984		35,404		35,404
Trading securities		3,718		3,718		24,355		24,355		18,497		18,497		3,698		3,698
Policy loans (3)		48,787		48,787		30,612		30,612		37,554		37,554		35,940		35,940
Deposit asset underlying 10% coinsurance agreement (3)		226,902		226,902		231,368		231,368		215,871		215,871		224,371		224,371
Separate accounts		2,206,608		2,206,608		2,799,992		2,799,992		2,329,968		2,329,968		2,305,717		2,305,717
Liabilities:
Notes payable - Long term (1) (2)	$	592,705	$	471,511	$	592,102	$	605,667
Notes payable (1) (2)									$	593,106	$	496,098	$	592,905	$	491,753
Surplus note (1) (3)		1,433,293		1,316,919		1,378,585		1,545,854		1,459,565		1,380,029		1,444,469		1,333,047
Separate accounts		2,206,608		2,206,608		2,799,992		2,799,992		2,329,968		2,329,968		2,305,717		2,305,717

(1)

Carrying value amounts shown are net of issuance costs.

(2)

Classified as a Level 2 fair value measurement.

(3)

Classified as a Level 3 fair value measurement.

The fair values of financial instruments presented above are estimates of the fair values at a specific point in time using various sources and methods, including market quotations and a complex matrix system that takes into account issuer sector, quality, and spreads in the current marketplace.

Financial Instruments Recognized at Fair Value in the Balance ~~Sheet.~~Sheets. Estimated fair values of investments in AFS securities are principally a function of current spreads and interest rates that are corroborated by independent third-party data. Therefore, the fair values presented are indicative of amounts we could realize or settle at the respective balance sheet date. We do not necessarily intend to dispose of or liquidate such instruments prior to maturity. Trading securities and equity securities, including common and nonredeemable preferred stocks, are carried at fair value. Segregated funds in separate accounts are carried at the underlying value of the variable insurance contracts, which is fair value.

The carrying amounts for cash and cash equivalents, trade receivables, accrued investment income, accounts payable, notes payable – short term, cash collateral and payables for security transactions approximate their fair values due to the short-term nature of these instruments. Consequently, such financial instruments are not included in the above table.

(5) Reinsurance

We use reinsurance extensively, which has a significant effect on our results of operations. Reinsurance arrangements do not relieve us of our primary obligation to the policyholder.

Details on in-force life insurance were as follows:

September 30, 2022

December 31, 2021

(Dollars in thousands)

Direct life insurance in-force

$
915,091,729

$
905,819,671

Amounts ceded to other companies

(782,367,621
)

(777,826,233
)
Net life insurance in-force

$
132,724,108

$
127,993,438

Percentage of reinsured life insurance in-force

85
%

86
%


	March 31, 2023			December 31, 2022
	(Dollars in thousands)
Direct life insurance in-force	$	925,084,773		$	919,081,738
Amounts ceded to other companies		(792,325,968	)		(787,907,229	)
Net life insurance in-force	$	132,758,805		$	131,174,509
Percentage of reinsured life insurance in-force		86	%		86	%

Benefits and claims ceded to reinsurers during the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 were $~~375.8~~338.9 million and $~~1,218.8~~288.4 million, ~~respectively, compared to $486.7~~ ~~million and $1,474.6~~ ~~million, respectively, for the three and nine months ended September 30, 2021.~~respectively.

Reinsurance recoverables as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022 include ceded reserve balances, ceded claim liabilities, and ceded claims paid. Reinsurance recoverables and financial strength ratings by reinsurer were as follows:


	September 30, 2022				December 31, 2021				March 31, 2023				December 31, 2022
	Reinsurance recoverables			A.M. Best rating	Reinsurance recoverables			A.M. Best rating	Reinsurance recoverables			A.M. Best rating	Reinsurance recoverables			A.M. Best rating
	(In thousands)								(In thousands)
Swiss Re Life & Health America Inc. (Novated from Pecan Re, Inc.) (1) (2)	$	2,474,068		A+	$	-		-
Pecan Re Inc. (1)(2)	-			-		2,567,602		NR
Swiss Re Life and Health America, Inc. (Novated from Pecan Re Inc.) (1)									$	2,432,148		A+	$	2,403,180		A+
Munich Re of Malta (1) (2)										249,328		NR	$	245,521		NR
American Health and Life Insurance Company (1)										150,874		B++	$	148,573		B++
SCOR Global Life Reinsurance Companies (3)		385,653		A+		426,634		A+		126,485		A+		121,408		A+
Munich Re of Malta (2) (5)		249,942		NR		278,591		NR
Swiss Re Life & Health America Inc. (4)		238,280		A+		259,239		A+		44,624		A+		57,439		A+
American Health and Life Insurance Company (2)		150,364		B++		157,837		B++
RGA Reinsurance Company										41,213		A+		47,110		A+
Korean Reinsurance Company										35,602		A		42,169		A
Munich American Reassurance Company		134,059		A+		142,705		A+		34,942		A+		41,450		A+
RGA Reinsurance		127,750		A+		140,953		A+
Korean Reinsurance Company		119,526		A		134,048		A
Hannover Life Reassurance Company		47,263		A+		49,749		A+		20,297		A+		18,504		A+
TOA Reinsurance Company		36,590		A		38,909		A		16,938		A		18,043		A
All other reinsurers		73,444		-		75,094		-		30,186		-		35,936		-
Allowance for credit losses		(3,042	)			(2,942	)			(3,563	)			(2,936	)
Reinsurance recoverables	$	4,033,897			$	4,268,419			$	3,179,074			$	3,176,397

NR – not rated

(1)

~~Effective April 1, 2022, the coinsurance agreement with Pecan Re Inc. was novated and replaced by an agreement with Swiss Re Life and Health America, Inc.~~

~~(2)~~

Reinsurance recoverables includes balances ceded under coinsurance transactions of term life insurance policies that were in-force as of December 31, 2009. Amounts shown are net of their share of the reinsurance recoverables from other reinsurers. Arrangements with these reinsurers include collateral trust agreements held in support of reinsurance recoverables.

(2)

Entity is rated AA- by S&P.

(3)

Includes amounts ceded to Transamerica Reinsurance Companies and fully retroceded to SCOR Global Life Reinsurance Companies.

(4)

Includes amounts ceded to Lincoln National Life Insurance and fully retroceded to Swiss Re Life & Health America Inc.

~~(5)~~

~~Entity is rated AA- by S&P.~~

We estimate and recognize lifetime expected credit losses for reinsurance recoverables. In estimating the allowance for expected credit losses for reinsurance recoverables, we factor in the underlying collateral for reinsurance agreements where available. Specifically, for reinsurers with underlying trust assets, we compare the reinsurance recoverables balance to the underlying trust assets that mitigate the potential exposure to credit losses. We also analyze the financial condition of the reinsurers, as determined by third-party rating agencies, to determine the probability of default for the reinsurers. We then utilize a third-party credit default study to calculate an expected credit loss given default rate or recovery rate. The probability of default and loss given default rates are then applied to the reinsurers’ recoverable balance, while also factoring in any third-party letters of credit that support the reinsurance agreement, in order to calculate our current expected credit loss allowance.

The rollforward of the allowance for credit losses on reinsurance recoverables were as follows:


	Three months ended September 30,					Nine months ended September 30,						Three months ended March 31,
	2022		2021			2022			2021			2023		2022
	(In thousands)											(In thousands)
Balance, beginning of period	$	2,964	$	7,654		$	2,942		$	7,144		$	2,936	$	2,942
Current period provision for expected credit losses		78		-			270			510			627		141
Less: Collections from expected credit losses previously recorded		-		(53	)		(170	)		(53	)
Balance, at the end of period	$	3,042	$	7,601		$	3,042		$	7,601		$	3,563	$	3,083

(6) Deferred Policy Acquisition Costs

The balances and activity in DAC were as follows:


	Three months ended						Year ended
	March 31, 2023						December 31, 2022
	(In thousands)
	Term Life			Segregated Funds (Canada)			Term Life			Segregated Funds (Canada)
Balance, beginning of period	$	3,111,675		$	62,341		$	2,872,816		$	65,411
Capitalization		127,293			1,834			507,834			7,003
Amortization		(65,503	)		(1,493	)		(252,352	)		(5,581	)
Foreign exchange translation and other		830			181			(16,623	)		(4,492	)
Balance, at the end of period	$	3,174,295		$	62,863		$	3,111,675		$	62,341

Reconciliation of DAC by product was as follows:


	March 31, 2023		December 31, 2022
	(In thousands)
Term Life	$	3,174,295	$	3,111,675
Segregated Funds (Canada)		62,863		62,341
Other		19,687		20,013
Total DAC, net	$	3,256,845	$	3,194,029

There were no changes to the judgments, assumptions and methods used to amortize DAC during the three months ended March 31, 2023 and 2022.

(7) Separate Accounts

The following table represents the fair value of assets supporting separate accounts assets by major investment category:


	March 31, 2023			December 31, 2022
	(In thousands)
Fixed-income securities	$	850,880		$	796,384
Equity securities		1,358,331			1,340,541
Cash and cash equivalents		130,713			181,162
Due to/from funds		(9,983	)		(12,399	)
Other		27			29
Total separate accounts assets	$	2,329,968		$	2,305,717

The following table represents the balances of and changes in separate account liabilities:


	Three months ended			Year ended
	March 31, 2023			December 31, 2022
	(In thousands)
Separate account liabilities balance, beginning of period	$	2,305,717		$	2,799,992
Premiums and deposits		77,897			253,982
Surrenders and withdrawals		(108,494	)		(293,278	)
Investment performance		67,262			(202,997	)
Management fees and other charges		(15,140	)		(62,281	)
Foreign exchange translation		2,726			(189,701	)
Separate accounts liabilities balance, end of period	$	2,329,968		$	2,305,717
Cash surrender value	$	2,293,074		$	2,268,436

The cash surrender value represents the amount of the contract holders account balance distributable at the balance sheet date less the Company’s estimate of the deferred sales charges that would be assessed if the policyholders redeemed their contracts at the balance sheet date. This estimate requires the Company to make certain assumptions regarding the underlying account balances by contribution year and application of the contractually defined deferred sales charges that would be applicable to each contribution year.

(8) Policy Claims and Other Benefits Payable

Changes in policy claims incurred and other benefits payable were as follows:

1924


	Nine months ended September 30,						Three months ended March 31,
	2022			2021			2023			2022
	(In thousands)						(In thousands)
Policy claims and other benefits payable, beginning of period	$	585,382		$	519,711		$	538,250		$	585,382
Less reinsured policy claims and other benefits payable		638,007			545,857			542,613			638,007
Net balance, beginning of period		(52,625	)		(26,146	)		(4,363	)		(52,625	)
Incurred related to current year		189,739			207,542			65,820			77,232
Incurred related to prior years (1)		(3,383	)		(121	)		(2,732	)		(4,547	)
Total incurred		186,356			207,421			63,088			72,685
Claims paid related to current year, net of reinsured policy claims received		(236,246	)		(276,730	)		(141,557	)		(161,818	)
Reinsured policy claims received related to prior years, net of claims paid		66,047			36,439			8,422			64,532
Total paid		(170,199	)		(240,291	)		(133,135	)		(97,286	)
Foreign currency translation		(659	)		44			38			(12	)
Net balance, end of period		(37,127	)		(58,972	)		(74,372	)		(77,238	)
Add reinsured policy claims and other benefits payable		533,690			616,097			572,855			652,088
Balance, end of period	$	496,563		$	557,125		$	498,483		$	574,850

(1)

Includes the difference between our estimate of claims incurred but not yet reported as of period-end and the actual incurred claims reported after period-end.

The liability for policy claims and other benefits payable on traditional life insurance products includes estimated unpaid claims that have been reported to us and claims incurred but not yet reported. We estimate claims incurred but not yet reported based on our historical claims activity, adjusted for any current new trends and conditions, and reported lag time experience.

~~(7)~~(9) Future Policy Benefits

The following tables summarize balances and changes in the present value of expected net premiums and the present value of expected future policy benefits underlying the LFPB:


	Three months ended			Year ended
	March 31, 2023			December 31, 2022
	(In thousands)
Present Value of Expected Net Premiums	Term Life
Balance at current discount rate, beginning of period	$	13,053,386		$	14,988,852
Balance at original discount rate, beginning of period		13,521,221			12,800,441
Effect of changes in cash flow assumptions		-			26,090
Effect of actual variances from expected experience		(66,059	)		8,653
Adjusted balance, beginning of period		13,455,162			12,835,184
Issuances		465,861			1,892,716
Interest accrual at original discount rate		130,130			486,436
Net premiums collected		(414,681	)		(1,623,000	)
Foreign currency translation		1,326			(70,115	)
Expected net premiums at original discount rate, end of period		13,637,798			13,521,221
Effect of changes in discount rate assumptions		(117,304	)		(467,835	)
Expected net premiums at current discount rate, end of period	$	13,520,494		$	13,053,386

Present Value of Expected Future Policy Benefits
Balance at current discount rate, beginning of period	$	19,143,253		$	23,309,576
Balance at original discount rate, beginning of period		19,706,818			18,991,175
Effect of changes in cash flow assumptions		-			29,915
Effect of actual variances from expected experience		(58,593	)		21,101
Adjusted balance, beginning of period		19,648,225			19,042,191
Issuances		465,885			1,892,730
Interest Accrual at original discount rate		206,814			796,017
Benefit payments		(467,008	)		(1,915,518	)
Foreign currency translation		2,016			(108,602	)
Expected future policy benefits at original discount rate, end of period		19,855,932			19,706,818
Effect of changes in discount rate assumptions		13,498			(563,565	)
Expected future policy benefits at current discount rate, end of period	$	19,869,430		$	19,143,253

LFPB	$	6,348,936		$	6,089,867
Less: reinsurance recoverables		3,154,789			3,153,121
Net LFPB, after reinsurance recoverables	$	3,194,147		$	2,936,746

Weighted-average duration of net LFPB		7.8			7.8

During the three months ended March 31, 2023 and 2022, experience variances resulted in remeasurement gains of $0.5 million and $1.3 million, respectively. The impact of experience variances in persistency and mortality during each period was largely offset by reinsurance. There were no changes to the inputs, judgments, assumptions, and methods used in measuring the LFPB during the three months ended March 31, 2023 and 2022.

For the full year 2022, the remeasurement gain recognized by the Company was $0.5 million. During 2022, a small assumption change was made relating to moving mortality improvement forward one calendar year when the Company reviewed assumptions during the third quarter. The impact of this change in assumption, together with experience variances during 2022, were largely offset by reinsurance.

Losses recognized as a result of capping the net premium ratio at 100% were immaterial during the three months ended March 31, 2023 and 2022.

The following table reconciles the LFPB to the condensed consolidated balance sheets:


	March 31, 2023		December 31, 2022
	(In thousands)
Term Life	$	6,348,936	$	6,089,867
Other		212,688		208,039
Total	$	6,561,624	$	6,297,906

The following table reconciles the reinsurance recoverables to the condensed consolidated balance sheets:


	March 31, 2023		December 31, 2022
	(In thousands)
Term Life	$	3,154,789	$	3,153,121
Other		24,285		23,276
Total	$	3,179,074	$	3,176,397

The amount of discounted (using the original discount rate) and undiscounted expected gross premiums and expected future benefit payments were as follows:


	March 31, 2023				December 31, 2022
	(In thousands)
Term Life
	Undiscounted		Discounted		Undiscounted		Discounted
Expected future benefit payments	$	32,216,059	$	19,869,430	$	31,904,059	$	19,143,253
Expected future gross premiums	$	37,480,296	$	25,902,466	$	37,135,605	$	25,070,802

The amount of revenue and interest recognized in our unaudited condensed consolidated statements of income were as follows:


	Three months ended March 31,
	2023			2022
	(In thousands)
Term Life
Gross premiums	$	812,880		$	793,254
Interest accretion (expense)	$	(76,684	)	$	(76,496	)

The weighted-average rates were as follows:


	March 31, 2023			December 31, 2022
	(In thousands)
Term Life
Original discount rate		4.95	%		5.00	%
Current discount rate		4.91	%		5.28	%

There were no changes to the methods used to determine the discount rates during the three months ended March 31, 2023 and the twelve months ended December 31, 2022.

(10) Stockholders’ Equity

A reconciliation of the number of shares of our outstanding common stock follows:


	Nine months ended September 30,						Three months ended March 31,
	2022			2021			2023			2022
	(In thousands)						(In thousands)
Common stock, beginning of period	$	39,368		$	39,306		$	36,824		$	39,368
Shares issued for stock options exercised		-			10			43			-
Shares of common stock issued upon lapse of sales restrictions on restricted stock units (“RSUs”)		201			204			129			132
Common stock retired		(2,542	)		(49	)		(589	)		(748	)
Common stock, end of period	$	37,027		$	39,471		$	36,407		$	38,752

The above reconciliation excludes RSUs and performance-based stock units (“PSUs”), which do not have voting rights. As sales restrictions on RSUs lapse and PSUs are earned, we issue common shares with voting rights. As of ~~September 30, 2022,~~March 31, 2023, we had a total of ~~294,829~~266,601 RSUs and ~~74,054~~65,459 PSUs outstanding. The PSU outstanding balance is based on the number of PSUs granted pursuant to the award ~~agreements;~~agreement; however, the actual number of common shares ~~issued~~earned could be higher or lower based on actual versus targeted performance. See Note 912 (Share-Based Transactions) for discussion of the PSU award structure.

On November 17, ~~2021~~2022, our Board of Directors authorized a share repurchase program for up to $~~275.0~~375.0 million of our outstanding common stock for purchases from January 1, 2023 through December 31, ~~2022~~2023 (the “Share Repurchase Program”). ~~On February 14, 2022, our Board of Directors authorized an increase of $50.0~~ ~~million to the Share Repurchase Program. On August 11, 2022, our Board of Directors authorized an additional increase of $50.0~~ ~~million to the Share Repurchase Program bringing the authorized share repurchases to $375.0~~ ~~million of our outstanding common stock through December 31, 2022.~~ Under the Share Repurchase Program, we repurchased ~~2,628,425~~530,723 shares of our common stock in the open market for an aggregate purchase price of $~~343.1~~85.3 million through ~~September 30, 2022.~~March 31, 2023. Approximately $~~31.9~~289.7 million remains available for repurchases of our outstanding common stock under the Share Repurchase Program as of ~~September 30, 2022.~~March 31, 2023.

~~(8)~~(11) Earnings Per Share

The Company has outstanding common stock and equity awards that consist of RSUs, PSUs and stock options. The RSUs maintain non-forfeitable dividend rights that result in dividend payment obligations on a one-to-one ratio with common shares for any future dividend declarations.

Unvested RSUs are deemed participating securities for purposes of calculating earnings per share (“EPS”) as they maintain dividend rights. We calculate EPS using the two-class method. Under the two-class method, we allocate earnings to common shares and vested RSUs outstanding for the period. Earnings attributable to unvested participating securities, along with the corresponding share counts, are excluded from EPS as reflected in our unaudited condensed consolidated statements of income.

In calculating basic EPS, we deduct from net income any dividends and undistributed earnings allocated to unvested RSUs and then divide the result by the weighted-average number of common shares and vested RSUs outstanding for the period.

We determine the potential dilutive effect of PSUs and stock options outstanding (“contingently-issuable shares”) on EPS using the treasury-stock method. Under this method, we determine the proceeds that would be received from the issuance of the contingently-issuable shares if the end of the reporting period were the end of the contingency period. The proceeds from the contingently-issuable shares include the remaining unrecognized compensation expense of the awards and the cash received for the exercise price on stock options. We then use the average market price of our common shares during the period the contingently-issuable shares were outstanding to determine how many shares we could repurchase with the proceeds raised from the issuance of the contingently-issuable shares. The net incremental share count issued represents the potential dilutive securities. We then reallocate earnings to common shares and vested RSUs by incorporating the increased fully-diluted share count to determine diluted EPS.

The calculation of basic and diluted EPS was as follows:


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
	2022			2021			2022			2021			2023			2022
	(In thousands, except per-share amounts)												(In thousands, except per-share amounts)
Basic EPS:
Numerator:
Net income attributable to Primerica, Inc.	$	51,807		$	112,456		$	241,172		$	338,489		$	125,106		$	115,039
Income attributable to unvested participating securities		(244	)		(458	)		(1,067	)		(1,403	)		(565	)		(476	)
Net income used in calculating basic EPS	$	51,563		$	111,998		$	240,105		$	337,086		$	124,541		$	114,563
Denominator:
Weighted-average vested shares		37,438			39,561			38,342			39,516			36,710			39,221
Basic EPS	$	1.38		$	2.83		$	6.26		$	8.53		$	3.39		$	2.92

Diluted EPS:
Numerator:
Net income attributable to Primerica, Inc.	$	51,807		$	112,456		$	241,172		$	338,489		$	125,106		$	115,039
Income attributable to unvested participating securities		(244	)		(457	)		(1,065	)		(1,399	)		(564	)		(475	)
Net income used in calculating diluted EPS	$	51,563		$	111,999		$	240,107		$	337,090		$	124,542		$	114,564
Denominator:
Weighted-average vested shares		37,438			39,561			38,342			39,516			36,710			39,221
Dilutive effect of incremental shares to be issued for contingently-issuable shares		103			118			110			121			94			111
Weighted-average shares used in calculating diluted EPS		37,541			39,679			38,452			39,637			36,804			39,332
Diluted EPS	$	1.37		$	2.82		$	6.24		$	8.50		$	3.38		$	2.91

~~(9)~~(12) Share-Based Transactions

The Company has outstanding equity awards under the Primerica, Inc. Second Amended and Restated 2010 Omnibus Incentive Plan (“2010 OIP”), which expired in 2020 in accordance with its terms and under which no future awards will be made, and the Primerica, Inc. 2020 Omnibus Incentive Plan (the “2020 OIP”, and together with the 2010 OIP, the “OIP”), which was approved by the Company’s stockholders on May 13, 2020. The OIP provides for the issuance of equity awards, including stock options, stock appreciation rights, restricted stock, deferred stock, RSUs, PSUs, and stock payment awards, as well as cash-based awards. In addition to time-based vesting requirements, awards granted under the OIP may also be subject to specified performance criteria. Under the OIP, the Company issues equity awards to our management (officers and other key employees), non-employees who serve on our Board of Directors, and sales force leaders. For more information on equity awards granted under the OIP, see Note 14 (Share-Based Transactions) to our consolidated financial statements within our ~~2021~~2022 Annual Report.

In connection with our granting of equity awards to management and members of the Board of Directors, we recognize expense over the requisite service period of the equity award. We defer and amortize the fair value of equity awards granted to the sales force in the same manner as other deferred policy acquisition costs for those awards that are an incremental direct cost of successful acquisitions of life insurance policies that result directly from and are essential to the policy acquisition(s) and would not have been incurred had the policy acquisition(s) not occurred. All equity awards granted to the sales force that are not directly related to the successful acquisition of life insurance policies are recognized as expense as incurred, which is in the quarter granted and earned.

The impact of equity awards granted under the OIP are as follows:

Three months ended September 30,

Nine months ended September 30,

2022

2021

2022

2021

(In thousands)

Equity awards expense recognized

$
1,060

$
2,369

$
16,068

$
16,561

Equity awards expense deferred

2,691

2,048

7,878

7,227


	Three months ended March 31,
	2023		2022
	(In thousands)
Equity awards expense recognized	$	12,125	$	12,181
Equity awards expense deferred		2,523		2,377

On February ~~24, 2022,~~28, 2023, the Compensation Committee of our Board of Directors granted the following equity awards to employees as part of the annual approval of management incentive compensation:

•

~~85,844~~55,137 RSUs awarded to management with a measurement-date fair value of $~~130.3~~185.240 per unit that have time-based vesting requirements with equal and annual graded vesting over approximately three years subsequent to the grant date.

•

~~26,475~~17,139 PSUs awarded to our four top executives with a measurement-date fair value of $~~130.3~~185.240 per unit. The PSUs will be earned on March 1, ~~2025~~2026 contingent upon the Company achieving a targeted annual average three-year return on adjusted equity (“ROAE”) and average EPS growth for the period from January 1, ~~2022~~2023 through December 31, ~~2024.~~2025. The actual number of common shares that will be ~~issued~~earned will vary based on the actual ROAE and average EPS growth relative to the targeted ROAE and average EPS growth and can range from zero to ~~39,713~~25,708 shares.

All awards granted to employees on February ~~24, 2022~~28, 2023 vest upon voluntary termination of employment by any employee who is “retirement eligible” as of his or her termination date. In order to be retirement eligible, an employee must be at least 55 years old and his or her age plus years of service with the Company must equal at least 75. The number of PSUs that will ultimately be ~~issued~~earned for a retirement eligible employee is equal to the amount calculated using the Company’s actual cumulative three-year ROAE and average EPS growth for the performance period ending on December 31, ~~2024,~~2025, even if that employee retires prior to the completion of the three-year performance period.

~~During the three months ended September 30, 2022,~~ ~~10,711~~ ~~RSUs were awarded to certain members of management of e-TeleQuote with an average measurement-date fair value of $125.65~~ ~~per unit that have time-based vesting requirements with equal and annual graded vesting over approximately~~ ~~three years~~ ~~subsequent to the grant date.~~

~~(10)~~(13) Commitments and Contingent Liabilities

Letter of Credit (“LOC”). Peach Re maintains a credit facility agreement with Deutsche Bank (the “Credit Facility Agreement”) to support certain obligations for a portion of the Regulation XXX reserves related to the Peach Re Coinsurance Agreement. Under the Credit Facility Agreement, Deutsche Bank issued a letter of credit for the benefit of Primerica Life with a term expiring on December 31, 2025. As of ~~September 30, 2022,~~March 31, 2023, the amount of the LOC outstanding was $~~102.8~~80.4 million. This amount will decline over the remaining term of the LOC to correspond with declines in the Regulation XXX reserves. As of ~~September 30, 2022,~~March 31, 2023, the Company was in compliance with all financial covenants under the Credit Facility Agreement.

Further discussion on the Company’s ~~letter of credit~~LOC is included in Note 16 (Commitments and Contingent Liabilities) to our consolidated financial statements within our ~~2021~~2022 Annual Report.

Contingent Liabilities. The Company is involved from time to time in legal disputes, regulatory inquiries and arbitration proceedings in the normal course of business. These disputes are subject to uncertainties, including the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation. As such, the Company is unable to estimate the possible loss or range of loss that may result from these matters unless otherwise indicated.

~~(11)~~(14) Other Comprehensive Income

The components of other comprehensive income (“OCI”), including the income tax expense or benefit allocated to each component, were as follows:


	Three months ended September 30,						Nine months ended September 30,						Three months ended March 31,
	2022			2021			2022			2021			2023			2022
	(In thousands)												(In thousands)
Foreign currency translation adjustments:
Change in unrealized foreign currency translation gains (losses) before income taxes	$	(18,086	)	$	(5,892	)	$	(24,048	)	$	6,490		$	998		$	3,289
Income tax expense (benefit) on unrealized foreign currency translation gains (losses)		-			-			-			-			-			-
Change in unrealized foreign currency translation gains (losses), net of income taxes	$	(18,086	)	$	(5,892	)	$	(24,048	)	$	6,490		$	998		$	3,289
Unrealized gain (losses) on available-for-sale securities:
Change in unrealized holding gains (losses) arising during period before income taxes	$	(97,516	)	$	(13,796	)	$	(401,335	)	$	(52,669	)	$	38,549		$	(164,937	)
Income tax expense (benefit) on unrealized holding gains (losses) arising during period		(20,471	)		(2,991	)		(85,330	)		(11,653	)		8,316			(35,241	)
Change in unrealized holding gains (losses) on available-for-sale securities arising during period, net of income taxes		(77,045	)		(10,805	)		(316,005	)		(41,016	)		30,233			(129,696	)
							…
Reclassification from accumulated OCI to net income for (gains) losses realized on available-for-sale securities		(154	)		(1,879	)		(867	)		(3,052	)		3,137			(658	)
Income tax (expense) benefit on (gains) losses reclassified from accumulated OCI to net income		(33	)		(395	)		(182	)		(641	)		659			(138	)
Reclassification from accumulated OCI to net income for (gains) losses realized on available-for-sale securities, net of income taxes		(121	)		(1,484	)		(685	)		(2,411	)		2,478			(520	)
Change in unrealized gains (losses) on available-for-sale securities, net of income taxes and reclassification adjustment	$	(77,166	)	$	(12,289	)	$	(316,690	)	$	(43,427	)	$	32,711		$	(130,216	)
Effect of change in discount rate assumptions on the LFPB:
Change in effect in discount rate assumptions on the LFPB before income taxes													$	(182,045	)	$	821,904
Income tax (expense) benefit on the effect of change in discount rate assumptions on the LFPB from accumulated OCI to net income														(39,071	)		175,763
Change in effect in discount rate assumptions on the LFPB, net of income taxes													$	(142,974	)	$	646,141

~~(12)~~(15) Debt

Notes ~~Payable – Long Term.~~Payable. As of ~~September 30, 2022,~~March 31, 2023, the Company had outstanding $600.0 million of publicly-traded, senior unsecured notes (the “Senior Notes”), with an annual interest rate of 2.80% that are scheduled to mature on November 19, 2031. As of ~~September 30, 2022,~~March 31, 2023, we

were in compliance with the covenants of the Senior Notes. No events of default occurred on the Senior Notes during the three ~~and nine~~ months ended ~~September 30, 2022.~~March 31, 2023.

Further discussion on the Company’s Senior Notes is included in Note 10 (Debt) to our consolidated financial statements within our ~~2021~~2022 Annual Report.

~~Notes Payable – Short Term.On July 1, 2021, as part of the acquisition of e-TeleQuote, Primerica Health issued a $15.0~~ million unsecured, subordinated note, guaranteed by the Parent Company, to Etelequote Limited’s (“Etelequote Bermuda”) majority shareholder (the “Majority Shareholder Note”). This note was retired during the nine months ended September 30, 2022.

Surplus Note. As of ~~September 30, 2022,~~March 31, 2023, the principal amount outstanding on the Surplus Note issued by Vidalia Re was $~~1.4~~1.46 billion, which is equal to the principal amount of the LLC Note. The principal amount of both the Surplus Note and the LLC Note will fluctuate over time to coincide with the amount of policy reserves being contractually supported under the Vidalia Re Coinsurance Agreement. Both the LLC Note and the Surplus Note mature on December 31, 2030 and bear interest at an annual interest rate of 4.50%. Based on the estimated reserves for policies issued in 2011 through 2017 that have been ceded under the Vidalia Re Coinsurance Agreement, the principal amounts of the Surplus Note and the LLC Note are expected to reach $1.5 billion each. This financing arrangement is non-recourse to the Parent Company and Primerica Life, meaning that neither of these companies has guaranteed the Surplus Note or is otherwise liable for reimbursement for any payments triggered by the LLC Note’s credit enhancement feature. The Parent Company has agreed to support Vidalia Re’s obligation to pay the credit enhancement fee incurred on the LLC Note.

Further discussion on the Company’s LLC Note is included in Note 3 (Investments).

Revolving Credit Facility. We maintain an unsecured $200.0 million revolving credit facility (“Revolving Credit Facility”) with a syndicate of commercial banks. The Revolving Credit Facility has a scheduled termination date of June 22, 2026. Amounts outstanding under the Revolving Credit Facility are borrowed, at our discretion, on the basis of either a ~~LIBOR~~Secured Overnight Financing Rate (“SOFR”) rate loan, or a base rate loan. ~~LIBOR~~SOFR rate loans bear interest at a periodic rate equal to one-, three-, ~~six-,~~ or ~~12-month LIBOR,~~six-month Adjusted Term SOFR, plus an applicable margin. Base rate loans bear interest at the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) one-month ~~LIBOR~~Adjusted Term SOFR plus 1.00%, plus an applicable margin. ~~The Revolving Credit Facility contains language providing for a benchmark replacement in the event that LIBOR is no longer available.~~ The Revolving Credit Facility also permits the issuance of letters of credit. The applicable margins are based on our debt rating with such margins for ~~LIBOR~~SOFR rate loans and letters of credit ranging from 1.00% to 1.625% per annum and for base rate loans ranging from 0.00% to 0.625% per annum. Under the Revolving Credit Facility, we incur a

commitment fee that is payable quarterly in arrears and is determined by our debt rating. This commitment fee ranges from 0.10% to 0.225% per annum of the aggregate amount of the $200.0 million commitment of the lenders under the Revolving Credit Facility that remains undrawn. During the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, no amounts ~~have been drawn~~were outstanding under the Revolving Credit Facility and we were in compliance with ~~the~~its covenants. Furthermore, no events of default occurred under the Revolving Credit Facility during the three ~~and nine~~ months ended ~~September 30, 2022.~~March 31, 2023.

~~(13)~~(16) Revenue from Contracts with Customers

Our revenues from contracts with customers primarily include:

•

Commissions and fees earned for the marketing and distribution of investment and savings products underwritten by mutual fund companies and annuity providers. For purposes of revenue recognition, mutual fund companies and annuity providers are considered the customers in marketing and distribution arrangements;

•

Fees earned for investment advisory and administrative services within our managed investments program and shareholder services fees earned in Canada for mutual funds for which we serve as principal distributor;

•

Account-based fees for transfer agent recordkeeping functions and non-bank custodial services;

•

Commissions and fees earned from the distribution of Medicare-related insurance products on behalf of health insurance carriers, including tail revenue adjustments;

•

Marketing development revenues earned for selling Medicare-related insurance products on behalf of health insurance carriers, which is recorded in Other, net revenue;

•

Fees associated with mortgage distribution and the distribution of other third-party financial products; and

•

Other revenue from the sale of miscellaneous products and services including monthly subscription fees from the sales representatives for access to Primerica Online, ~~(“POL”),~~ our primary sales force support tool.

Premiums from insurance contracts we underwrite, fees received from segregated funds insurance contracts, and income earned on our invested assets are excluded from the definition of revenues from contracts with customers in accordance with U.S. GAAP.

Further discussion on the Company’s revenues from contracts with customers and revenue recognition policies are included in Note 18 (Revenue from Contracts with Customers) to our consolidated financial statements within our ~~2021~~2022 Annual Report.

2430

The disaggregation of our revenues from contracts with customers were as follows:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021		2023		2022
	(In thousands)								(In thousands)
Term Life Insurance segment revenues:
Other, net	$	13,419	$	12,476	$	37,969	$	36,601	$	12,233	$	12,175
Total segment revenues from contracts with customers		13,419		12,476		37,969		36,601		12,233		12,175
Revenues from sources other than contracts with customers		414,411		388,975		1,218,998		1,130,415		408,836		394,808
Total Term Life Insurance segment revenues	$	427,830	$	401,451	$	1,256,967	$	1,167,016	$	421,069	$	406,983

Investment and Savings Products segment revenues:
Commissions and fees
Sales-based revenues	$	67,962	$	95,229	$	259,905	$	298,057	$	72,388	$	103,242
Asset-based revenues		93,068		97,184		283,841		275,084		98,104		97,355
Account-based revenues		22,910		21,456		67,043		64,424		22,790		21,541
Other, net		3,342		3,094		9,508		9,001		3,120		3,144
Total segment revenues from contracts with customers		187,282		216,963		620,297		646,566		196,402		225,282
Revenues from sources other than contracts with customers (segregated funds)		14,415		16,374		44,855		48,204		13,800		15,757
Total Investment and Savings Products segment revenues	$	201,697	$	233,337	$	665,152	$	694,770	$	210,202	$	241,039

Senior Health segment revenues:
Commissions and fees	$	14,601	$	21,558	$	25,222	$	21,558	$	15,755	$	1,278
Other, net		2,583		1,378		9,606		1,378		2,955		4,553
Total Senior Health segment revenues	$	17,184	$	22,936	$	34,828	$	22,936	$	18,710	$	5,831

Corporate and Other Distributed Products segment revenues:
Commissions and fees	$	12,512	$	17,995	$	37,090	$	47,202	$	8,710	$	12,627
Other, net		1,621		1,103		3,626		2,978		1,199		1,117
Total segment revenues from contracts with customers		14,133		19,098		40,716		50,180		9,909		13,744
Revenues from sources other than contracts with customers		12,445		16,417		35,531		50,736		30,146		23,629
Total Corporate and Other Distributed Products segment revenues	$	26,578	$	35,515	$	76,247	$	100,916	$	40,055	$	37,373

Renewal Commissions Receivable. For revenue associated with ongoing renewal commissions in the Senior Health and Corporate and Other Distributed Products segments, we record a renewal commission receivable asset for the amount of ongoing renewal commissions we anticipate collecting in reporting periods subsequent to the satisfaction of the performance obligation, less amounts that are constrained in the accompanying unaudited condensed consolidated balance sheets. We update our estimate of variable consideration each period and new facts or circumstances that were not available at the time of the initial estimate will indicate that the expected renewal commissions are higher or lower than our renewal commissions receivable. As such, the expected renewal commissions receivable will be written down or up to its revised expected value by adjustments to revenue, which we refer to as tail revenue adjustments. During the three months ended ~~September 30, 2022, we recognized a positive~~March 31, 2023, no tail revenue ~~adjustment due to renewal rate escalations communicated by health insurance carriers during the quarter. During the nine months ended September 30, 2022, we~~adjustments were recognized a net negative tail revenue adjustment to reduce the balance of the renewal commissions receivable in the Senior Health business as retention for policies scheduled to renew during the period was lower than expectations.based on our current estimates.

Activity in the Renewal commissions receivable account was as follows:


	Three months ended March 31,
	2023			2022
	(In thousands)
Senior Health segment:
Balance, beginning of period	$	139,399		$	172,308
Commissions revenue		9,062			12,849
Less: collections		(14,262	)		(12,314	)
Tail revenue adjustments from change in estimate		-			(19,060	)
Balance, at the end of period	$	134,199		$	153,783

Corporate and Other Distributed Products segments:
Balance, beginning of period	$	60,644		$	59,443
Commissions revenue		5,370			5,643
Less: collections		(5,804	)		(5,694	)
Balance, at the end of period	$	60,210		$	59,392

Three months ended September 30,

Nine months ended September 30,

2022

2021

2022

2021

(In thousands)

Senior Health segment:

Balance, beginning of period

$
134,212

$
-

$
172,308

$
-

Contract balances acquired as part of business combination

-

199,575

-

199,575

Measurement period adjustment (1)

-

-

(11,863
)

-

Commissions revenue

9,600

16,526

32,011

16,526

Less: collections

(8,808
)

(6,842
)

(33,032
)

(6,842
)
Tail revenue adjustments from change in estimate

1,700

-

(22,720
)

-

Balance, at the end of period

$
136,704

$
209,259

$
136,704

$
209,259

Corporate and Other Distributed Products segments:

Balance, beginning of period

$
59,449

$
56,683

$
59,443

$
54,845

Commissions revenue

7,908

8,810

19,833

21,969

Less: collections

(6,034
)

(5,800
)

(17,953
)

(17,121
)
Balance, at the end of period

$
61,323

$
59,693

$
61,323

$
59,693

~~(1)~~

The measurement period adjustment was recorded during the nine months ended September 30, 2022 in order to finalize the purchase price allocation for the acquisition of e-TeleQuote. Refer to Note 14 (Acquisition) for further details.

Incremental costs to obtain or fulfill contracts, most notably sales commissions to the sales representatives, are not incurred prior to the recognition of the related revenue. Therefore, we have no assets recognized for incremental costs to obtain or fulfill contracts.

~~(14) Acquisition~~

On ~~July 1, 2021~~ ~~(the "Acquisition Date"), the Company acquired an~~ 80% interest, as described in the next paragraph, in the operating subsidiaries of Etelequote Bermuda, including e-TeleQuote, a Florida corporation that is a senior health insurance distributor of Medicare-related insurance policies in all 50 states and Puerto Rico (the “Acquisition”).

~~The Company’s subsidiary, Primerica Health, purchased from the shareholders of Etelequote Bermuda (the “selling shareholders”)~~ ~~100% of the issued and outstanding capital stock of e-TeleQuote and its subsidiaries for consideration of (i) approximately $350~~ ~~million in cash, (ii) replacement of e-TeleQuote’s debt as of the closing date of $146~~ ~~million with intercompany funding provided by the Parent Company, (iii) a $~~15 ~~million Majority Shareholder Note and (iv) common shares of Primerica Health constituting~~ 20% of the total issued and outstanding shares of capital stock of Primerica Health that were issued to Etelequote Bermuda’s minority shareholders, most of which included or were beneficially owned by e-TeleQuote’s management (“Noncontrolling Equity Holders”). The cash consideration provided was subsequently reduced by $~~3.9~~ ~~million as a result of the final purchase price agreed upon with the sellers following finalization of the closing statement.~~

In connection with the Company’s acquisition of e-TeleQuote, the Company entered into a shareholders’ agreement with the noncontrolling equity holders of Primerica Health (the “Shareholders’ Agreement”) which, among other matters, sets forth certain call and put rights beginning in 2022. Under the terms of the Shareholders’ Agreement, the Company agreed to purchase, and the noncontrolling equity holders agreed to sell, the remaining 20% stake over a period of up to four years through a series of call and put rights. The Shareholders’ Agreement provides for the purchase of the noncontrolling equity holders’ equity interests in Primerica Health at a contractually defined formulaic purchase price (the “Formulaic Price”), which is based on a discounted calculation of selected peer company equity value multiples times the trailing twelve months of adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) reduced by the balance of intercompany debt owed by e-TeleQuote to the Parent Company. Effective ~~July 1, 2022, the Company executed its call option to acquire the remaining~~ 20~~% of Primerica Health. The Formulaic Price calculation resulted in a purchase price of~~ ~~zero~~. As such, no further consideration was required to obtain the outstanding 20% stake in Primerica Health and the noncontrolling interest in the Company's consolidated financial statements was redeemed.

The following table presents the preliminary purchase price allocation recorded in the Company’s consolidated balance sheet as of the Acquisition Date, adjustments made during the measurement period that ended June 30, 2022, and the final purchase price allocation:

Preliminary Purchase Price Adjustment

2021 Measurement Period Adjustments

2022 Measurement Period Adjustments

Final Acquisition Date Purchase Price Allocation

(In thousands)

Assets:

Cash and cash equivalent

1,080

-

-

1,080

Accounts receivables

692

(389
)

-

303

Renewal commissions receivable

199,575

(46,128
)

(11,863
)

141,584

Other assets

15,705

-

-

15,705

Intangible assets

162,000

(6,000
)

-

156,000

Goodwill

224,180

30,973

8,553

263,706

Total assets

603,232

(21,544
)

(3,310
)

578,378

Liabilities:

Accounts payable and accrued expenses

8,785

(4,195
)
(1)

-

4,590

Deferred tax liability

65,425

(13,482
)

(3,310
)

48,633

Other liabilities

10,046

-

-

10,046

Total liabilities

84,256

(17,677
)

(3,310
)

63,269

Net assets acquired

518,976

(3,867
)

-

515,109

Temporary Stockholders' Equity:

Redeemable noncontrolling interests

8,437

-

-

8,437

Total temporary stockholders' equity

8,437

8,437

~~(1)~~

~~The Company also recognized an adjustment during the measurement period to reclassify certain amounts from a payable to a reduction in the renewal commissions receivable.~~

~~Renewal commissions receivable from the acquired business was recognized in accordance with Accounting Standards Codification Topic 606,~~ ~~Revenue from Contracts with Customers (“ASC 606”) as the Company adopted Accounting Standards Update No. 2021-08,~~ ~~Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers~~ ~~(“ASU 2021-08”). ASU 2021-08 requires contract assets arising from revenue contracts with customers to be accounted for in~~

~~accordance with ASC 606 instead of at fair value.~~

During the measurement period, the Company made two adjustments to renewal commissions receivable as of the Acquisition Date. The adjustments, which were booked in 2021 and 2022 resulted from the Company’s reassessment of the estimates made by e-TeleQuote for the variable consideration expected for approved policies as of the Acquisition Date. The reassessment of estimates involved the implementation of an enhanced algorithmic model for processing historical lapse data and forecasting future policy duration curves. In addition, the Company revised the estimate for renewal commission rate escalation assumptions in accordance with its accounting policy for determining constraints of variable consideration. As a result, the Company recognized a purchase price allocation adjustment to decrease renewal commissions receivable and deferred tax liability with a corresponding increase to goodwill.

Intangible assets identified in the acquisition of the business are capitalized separately from goodwill if the fair value can be measured reliably on initial recognition (transaction date). The primary intangible assets identified were customer relationships with health insurance carriers of $~~153.0~~ ~~million with an estimated useful life of~~ 15 years. The Company will amortize the intangible assets acquired on a straight-line basis over their estimated useful lives. During the measurement period, the Company revised long-term growth rates used in the cash flow projections that support the intangibles valuation. As a result, the Company recognized a purchase price allocation adjustment to decrease intangible assets and deferred tax liability with a corresponding increase to goodwill.

Goodwill is calculated as the difference between the acquisition date fair value of the total consideration transferred and the aggregate values assigned to the assets acquired and liabilities assumed. The amount of goodwill calculated as of the Acquisition Date determined by the final purchase price allocation was $~~263.7~~ ~~million. The goodwill created in the acquisition is not deductible for tax purposes. Refer to Note 15 (Goodwill) for more information regarding the valuation of goodwill.~~

~~(15)~~(17) Goodwill

Goodwill represents the excess of the purchase price over the estimated acquired values of identifiable assets and liabilities acquired in a business ~~combination at the acquisition date.~~combination. In accordance with U.S. GAAP, goodwill is not amortized. The Company tests goodwill for impairment annually on July 1 and whenever events occur or circumstances change that would indicate the carrying value of goodwill may be impaired. All of the Company’s goodwill was obtained from the ~~Acquisition and~~acquisition of the e-TeleQuote business, which has been designated as a separate operating segment called Senior Health. Therefore, goodwill has been allocated solely to the Senior Health segment and is evaluated for impairment at the Senior Health segment level, which is also defined as the reporting unit.

~~During the annual impairment test as of July 1, 2022, the Company performed a quantitative impairment analysis using the income~~approach by preparing a discounted cash flow analysis to determine the reporting unit’s fair value. The discounted cash flow analysis included key assumptions such as the weighted average cost of capital ("WACC'), long-term growth rate and projected operating results such as approved policies, lifetime value of commissions, contract acquisition costs, operating expenses, collections of renewal commissions receivable, and utilization of net operating losses for income tax purposes. We did not utilize a market approach as part of the quantitative impairment analysis as we believe management’s expectations of the cash flow generated by the reporting unit were more relevant in determining fair value given inherent limitations in the credibility of available peer company data. The measurement of the reporting unit’s fair value is classified as a Level 3 fair value measurement given the significance of the unobservable inputs such as forecasted operating results and discount rates.

After the fair value of the reporting unit was determined, the Company calculated its carrying value by taking the reporting unit’s assets minus its liabilities. The carrying value of the reporting unit was then compared to its fair value to determine the extent of any goodwill impairment. Based on this analysis, we recognized a non-cash goodwill impairment charge of $~~60.0~~ million during the three months ended September 30, 2022, which represents the excess of the Senior Health reporting unit’s carrying value over its estimated fair value at July 1, 2022. The goodwill impairment charge recognized did not impact the Company’s income tax expense as the goodwill acquired from the Acquisition does not have any tax basis. The decline in the reporting unit's fair value below its carrying value was primarily attributable to an increase in the market-based WACC used to discount the forecasted cash flows. The increase in the WACC was driven by recent increases in the equity market risk premium and higher interest rates. The determination of whether the carrying value of the reporting unit exceeds its fair value involves a high degree of estimation and can be affected by a number of industry and company-specific risk factors that are subject to change over time.

At ~~September 30, 2022,~~March 31, 2023, the Company recognized goodwill of $127.7 million in its Senior Health reporting unit after accumulated

goodwill impairment charges ~~since the Acquisition Date~~ of $136.0 million. There was no change in the goodwill balance during the three months ended March 31, 2023.

2832

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to inform the reader about matters affecting the financial condition and results of operations of Primerica, Inc. (the “Parent Company”) and its subsidiaries (collectively, “we”, “us” or the “Company”) for the period from December 31, ~~2021~~2022 to ~~September 30, 2022.~~March 31, 2023. As a result, the following discussion should be read in conjunction with MD&A and the consolidated financial statements and notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 (“~~2021~~2022 Annual Report”). This discussion contains forward-looking statements that constitute our plans, estimates and beliefs. These forward-looking statements involve numerous risks and uncertainties, including, but not limited to, those discussed under the heading “Risk Factors” in the ~~2021~~2022 Annual Report and in Item 1A of this Report. Actual results may differ materially from those contained in any forward-looking statements.

This MD&A is divided into the following sections:

•

Business Overview

•

Business Trends and Conditions

•

Factors Affecting Our Results

•

Critical Accounting Estimates

•

Results of Operations

•

Financial Condition

•

Liquidity and Capital Resources

Business Overview

We are a leading provider of financial products to middle-income households in the United States and Canada primarily through a network of independent contractor sales representatives (“independent sales representatives” or “independent sales force”). We assist our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments, Medicare-related insurance products and other financial products, which we distribute primarily on behalf of third parties. We ~~historically~~ have ~~had two~~three primary operating segments, Term Life Insurance, ~~and~~ Investment and Savings Products, and Senior Health, and a ~~third~~fourth segment, Corporate and Other Distributed Products. ~~On July~~

The Company adopted Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944) — Targeted Improvements to the Accounting for Long-Duration Contracts (“LDTI”) on January 1, 2023. The amendments in LDTI change accounting guidance for insurance companies that issue long-duration contracts, such as term life insurance and segregated funds products. All prior period financial information has been restated as of January 1, 2021 ~~we acquired 80%~~(the “Transition Date”). See Note 1 (Description of ~~e-TeleQuote Insurance, Inc.~~Business, Basis of Presentation, and ~~subsidiaries (collectively, “e-TeleQuote”) through~~Summary of Significant Accounting Policies) to our subsidiary, Primerica Health, Inc. (“Primerica Health”). e-TeleQuote markets Medicare-related insurance products underwritten by third-party health insurance carriers to eligible Medicare participants through its licensed health insurance agents. Effective July 1, 2022, we acquired the remaining 20% of Primerica Health, which owns e-TeleQuote, as described in Note 14 (Acquisition) in the condensed consolidated financial statements included elsewhere in this ~~report. Beginning July 1, 2021,~~report for more information about the ~~Company has reported the operations~~adoption of ~~e-TeleQuote as its own operating segment called Senior Health. e-TeleQuote licensed health insurance agents are employees of e-TeleQuote.~~LDTI.

Term Life Insurance. We distribute the term life insurance products that we underwrite through our three issuing life insurance company subsidiaries: Primerica Life Insurance Company (“Primerica Life”), National Benefit Life Insurance Company (“NBLIC”), and Primerica Life Insurance Company of Canada (“Primerica Life Canada”). Policies remain in-force until the expiration of the coverage period or until the policyholder ceases to make premium payments. Our in-force term life insurance policies have level premiums for the stated term period. As such, the policyholder pays the same amount each year. Initial policy term periods are between 10 and 35 years. While premiums typically remain level during the initial term period, our claim obligations generally increase as our policyholders age. In addition, we incur significant upfront costs in acquiring new insurance business. Our deferral and amortization of policy acquisition costs and reserving methodology are designed to match the recognition of premium revenues with the timing of policy lapses and the payment of expected claims obligations.

Investment and Savings Products. In the United States, we distribute mutual funds, managed investments, variable annuity, and fixed annuity products of several third-party companies. We provide investment advisory and administrative services for client assets invested in our managed investments program. We also perform distinct transfer agent recordkeeping services and non-bank custodial services for investors purchasing certain mutual funds we distribute. In Canada, we offer mutual funds of other companies and segregated funds, which are underwritten by Primerica Life Canada.

Senior Health. In the United States, we distribute Medicare-related insurance products nationwide to eligible Medicare participants and enroll them in coverage utilizing ~~e-TeleQuote’s team of~~ licensed health insurance ~~agents.~~agents through our e-TeleQuote, Inc. subsidiary ("e-TeleQuote"). The health insurance products we distribute are underwritten and administered by third-party health insurance carriers and primarily consist of Medicare Advantage enrollments. Contract acquisition costs are incurred upfront when policy applications are approved and include costs associated with generating or acquiring leads as well as fees paid to Primerica Senior Health certified independent sales representatives and compensation, licensing, and training costs incurred for e-TeleQuote’s workforce of licensed health insurance agents. e-TeleQuote's licensed health insurance agents are employees of the Company. We receive compensation from the health insurance carriers in the form of initial commissions when eligible Medicare participants are enrolled and renewal commissions, upon the anniversary of the effective date, for as long as policies remain in-force.

2933

Corporate and Other Distributed Products. The Corporate and Other Distributed Products segment consists primarily of revenues and expenses related to other distributed products, including closed blocks of various insurance products underwritten by NBLIC, prepaid legal services, mortgage originations, and other financial products. These products, except for closed blocks of various insurance products underwritten by NBLIC, are distributed pursuant to distribution arrangements with third-party companies through the independent sales force. Net investment income earned on our invested asset portfolio is recorded in the Corporate and Other Distributed Products ~~segment, with the exception of the assumed net interest accreted to the Term Life Insurance segment’s future policy benefit reserve liability less deferred acquisition costs.~~segment. Interest expense incurred by the Company is attributed solely to the Corporate and Other Distributed Products segment.

Business Trends and Conditions

The relative strength and stability of financial markets and economies in the United States and Canada affect our growth and profitability. Our business is, and we expect will continue to be, influenced by a number of industry-wide and product-specific trends and conditions. Economic conditions, including unemployment levels and consumer confidence, influence investment and ~~inflation, can impact the disposable income of~~spending decisions by middle-income consumers, who are generally our primary ~~clients, which can influence their investment and spending decisions.~~clients. These conditions and factors also impact prospective recruits’ perceptions of the business opportunity that becoming an independent sales representative offers, which can drive or dampen recruiting. ~~Similarly, these conditions also affect e-TeleQuote’s ability to recruit and retain licensed health insurance agents.~~ Consumer spending and borrowing levels affect how consumers evaluate their savings and debt management plans. In addition, interest rates and equity market returns impact consumer demand for the savings and investment products we distribute. Our customers’ perception of the strength of the capital markets may also influence their decisions to invest in the investment and savings products we distribute.

The financial and distribution results of our operations in Canada, as reported in U.S. dollars, are affected by changes in the currency exchange rate. As a result, changes in the Canadian dollar exchange rate may significantly affect the result of our business for all amounts translated and reported in U.S. dollars.

~~The COVID-19 (“COVID-19”) pandemic~~Significant volatility in capital markets in recent periods has continued to impact our ~~business~~business. Declines in ~~2022, but to a much lesser extent than in 2021, as discussed in more detail later in this section,~~ the ~~Results of Operations section, and the Financial Condition section. We are unsure as to the extent COVID-19 will continue to impact our business as described below:~~

•

We have experienced an increase in mortality expense due to premature deaths of our insureds caused by COVID-19 infections. Since March 2022, we have experienced fewer COVID-19 related claims than in prior periods. Going forward, we do not expect significant COVID-19 related death claims.

•

The COVID-19 pandemic initially led to high levels of persistency and increased policy sales as a result of strong client sentiment toward owning life insurance products. However, throughout the second half of 2021 and the first nine months of 2022, policy sales and persistency trended toward pre-COVID-19 levels. Refer to the Factors Affecting Our Results section for more information about how persistency impacts our financial results.

~~Significant volatility in~~ capital markets during 2022 continued to adversely impact revenue generated by the Investments and Savings Products segment in the first ~~nine months~~quarter of ~~2022 has also impacted our business. The~~2023. In addition, the sharp rise in market interest rates during 2022 has ~~resulted in~~driven unrealized losses in our investment portfolio. We have not recognized losses caused by interest rate volatility in the income statement as we have the ability to hold these investments until maturity or a market price recovery, and we have no present intention to dispose of them. ~~Significant declines~~Increased interest rates have also led to increases in ~~capital markets also adversely~~net investment income as we are able to earn higher returns on our new debt securities purchases and cash balances.

Inflation remained elevated from historical levels during the first quarter of 2023, which led to an increased cost of living for middle-income families. Continued elevated inflation could impact demand for our products.

Certain year-over-year comparisons are impacted ~~revenue generated~~ by the effects of the COVID-19 pandemic (“COVID-19”). Results during the first quarter of 2022 reflect the continued effects of COVID-19, namely strong policyholder persistency and elevated claims activity in our ~~Investment~~Term Life Insurance segment. Subsequent to the first quarter of 2022, persistency and ~~Savings Products segment.~~claims trends have returned to pre-COVID-19 levels.

The effects of ~~business~~these trends and conditions on our quarterly results are discussed below in the Results of Operations ~~section,~~ and ~~in the~~ Financial Condition ~~section.~~sections.

Size of the Independent Sales Force.

Our ability to increase the size of the independent sales force (“independent sales representatives” or “independent sales force”) is largely based on the success of the ~~independent~~ sales force’s recruiting efforts as well as training and motivating recruits to get licensed to sell life insurance. We believe that recruitment and licensing levels are important to independent sales force trends, and growth in recruiting and licensing is usually indicative of future growth in the overall size of the independent sales force. ~~Changes in the number of new recruits~~Recruiting changes do not always result in commensurate changes in the size of the licensed independent sales force because new recruits may obtain the requisite licenses at rates above or below historical levels.

Details on ~~new recruits~~recruiting and life-licensed independent sales representative activity were as follows:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021		2023		2022
New recruits		127,788		91,884		282,710		275,802		93,540		84,707
New life-licensed independent sales representatives		12,518		9,381		34,030		30,326		11,118		9,983
Life-licensed independent sales representatives, at period end										136,430		130,206

~~The size of the life-licensed independent sales force was as follows:~~

September 30, 2022

September 30, 2021

Life-licensed independent sales representatives

134,313

130,023

The number of new recruits increased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the same period in ~~2021. The year-over-year increase was~~2022 primarily ~~driven by~~due to strong recruiting efforts during 2023 as the Company continues to see a ~~combination~~high degree of excitement generated by our biennial convention and the offering of special recruiting incentives during July 2022. Approximately 83,000 individuals were recruited while the special incentives were in place. The number of new recruits increased during the nine months ended September 30, 2022 comparedinterest from people who are attracted to the ~~same period in 2021 due to the same reasons as described in the three-month comparison but at a lower rate due to COVID-19 related recruiting incentives that were offered during the first half~~flexibility of ~~2021.~~its business opportunity.

New life-licensed sales representatives increased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the same period in ~~2021~~2022 primarily ~~due to elevated recruiting volume as discussed above. New life-licensed sales representatives increased during the nine months ended September 30, 2022 compared to the same period in 2021~~ as the Company and field leaders remained focused on licensing rates and continued to see the benefits of improvements to the licensing process. These improvements included new licensing progress-tracking tools and additional in-person licensing ~~classes.~~classes.

The number of life-licensed independent sales representatives grew to ~~134,313~~136,430 as of ~~September 30, 2022~~March 31, 2023 and reflects recent improvements to the licensing process and ~~the elevated~~higher recruiting volume as discussed above.

Term Life Insurance Product Sales and Face Amount In-Force.

The average number of life-licensed independent sales representatives and the number of term life insurance policies issued, as well as the average monthly rate of new policies issued per life-licensed independent sales representative (historically (1)between ~~0.18~~0.20 and ~~0.22)~~0.24), were as follows:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021		2023		2022		Adjusted 2022
Average number of life-licensed independent sales representatives		132,823		130,753		131,187		131,834		135,366		129,494		129,494
Number of new policies issued(1)		71,104		75,914		219,374		248,652		84,561		71,324		83,050
Average monthly rate of new policies issued per life-licensed independent sales representative		0.18		0.19		0.19		0.21
Average monthly rate of new policies issued per life-licensed (1) independent sales representative										0.21		0.18		0.21

(1) The previously reported number of new policies issued and average monthly rate of new policies issued per life-licensed independent sales representatives has been adjusted for the three months ended March 31, 2022 for comparability purposes as a result of our new generation of life insurance products introduced in October 2022, which modified how policies are structured in relation to individual lives. Historically, two adult lives could be covered under a single policy by adding a spouse rider. To better align risk and pricing in our new life insurance products, we eliminated this rider and now sell a separate policy for each insured life. Results for the three months ended March 31, 2023 reflect additional policies issued to reflect the spouse rider with a separate policy in the new life insurance products. To make year-over year comparisons more consistent, we have provided an estimate for the three months ended March 31, 2022.

Average number of life-licensed independent sales representatives increased for the three months ended March 31, 2023 from the same period in 2022 as a result of continued improvements made to the licensing process and elevated recruiting volume discussed above.

New policies issued during the three months ended ~~September 30, 2022 decreased~~March 31, 2023 increased slightly compared to the same period in ~~2021 primarily due to softer economic conditions~~2022 as a result of continued growth in the sales force and ~~a higher cost~~the launch of ~~living,~~our new life insurance products, which ~~impacts middle-income families. New policies issued during the nine months ended September 30, 2022 normalized compared to the elevated levels experienced during the comparable period~~occurred in ~~2021. New policies issued during the nine months ended September 30, 2021 reflected elevated demand for protection products as the COVID-19 pandemic highlighted the need for protection products.~~late 2022.

Productivity ~~during~~in the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, measured by the average monthly rate of new policies issued per life-licensed independent sales representative, ~~was in line with~~remained within our historical ~~range, although lower than prior year periods primarily due to the elevated demand for protection products in 2021 as described above.~~range.

The changes in the face amount of our in-force book of term life insurance policies were as follows:


	Three months ended September 30,												Nine months ended September 30,												Three months ended March 31,
	2022			% of beginning balance			2021			% of beginning balance			2022			% of beginning balance			2021			% of beginning balance			2023			% of beginning balance			2022			% of beginning balance
	(Dollars in millions)																								(Dollars in millions)
Face amount in force, beginning of period	$	914,438					$	886,519					$	903,404					$	858,818					$	916,808					$	903,404
Net change in face amount:
Issued face amount		26,049			3	%		26,219			3	%		78,472			9	%		82,843			10	%		28,124			3	%		24,773			3	%
Terminations		(21,033	)		(2	)%		(16,241	)		(2	)%		(60,117	)		(7	)%		(48,187	)		(6	)%		(22,211	)		(2	)%		(19,787	)		(2	)%
Foreign currency		(6,669	)		(1	)%		(2,479	)	*				(8,974	)		(1	)%		544		*				124		*				1,242		*
Net change in face amount		(1,653	)	*				7,499			1	%		9,381			1	%		35,200			4	%		6,037		*				6,228			1	%
Face amount in force, end of period	$	912,785					$	894,018					$	912,785					$	894,018					$	922,845					$	909,632

* Less than 1%.

The face amount of term life policies in-force ~~decreased~~increased for the three months ended September 30, 2022 primarily driven by movements in the foreign exchange rate. The U.S. dollar strengthened in relation to the Canadian dollar, which negatively impacted the translated face amount in force as of September 30, 2022. As a percentage of the beginning face amount in-force, issued face amount, as well as terminated face amount, during the three months ended September 30, 2022 remained consistent with the comparable 2021 period. In dollar terms, issued face amount during the three months ended September 30, 2022 was in line with the

March 31,

comparable 2021 period despite a decrease in the number of policies issued due to higher average issued face amounts. Terminations were higher during the three months ended September 30, 2022 compared to the comparable 2021 period as persistency normalized to pre-pandemic levels.

~~The face amount of term life policies in-force increased 1% for the nine months ended September 30, 2022~~ 2023 as the level of face amount issued continued to exceed the face amount terminated. The increase was partially offset by movement in the foreign exchange rate as discussed in the three-month comparison above. As a percentage of the beginning face amount in-force, issued face amount, as well as terminatedIssued face amount during the ~~nine~~three months ended ~~September 30, 2022 remained consistent with the three-month comparison as discussed above.In dollar terms, issued face amount during the nine months ended September 30, 2022 decreased versus the comparable 2021 period albeit at a lower rate than the decrease~~March 31, 2023 increased due to an increase in both the number of new policies issued ~~due to~~and higher average ~~issued~~ face ~~amounts. Terminations~~amounts per policy. Policy terminations were higher during the ~~nine~~three months ended ~~September 30, 2022 compared to the same 2021 period~~March 31, 2023 as persistency ~~normalized~~returned to ~~pre-pandemic~~pre-COVID-19 pandemic levels. In addition, higher cost of living on middle income families may have contributed to higher terminations.

Investment and Savings ~~Products~~Product Sales, Asset Values and Accounts/Positions.

Investment and savings ~~products~~product sales and average client asset values were as follows:

Three months ended September 30,

Change

Nine months ended September 30,

Change

2022

2021

$

%

2022

2021

$

%

(Dollars in millions)

Product sales:

U.S. Retail mutual funds

$
932

$
1,248

$
(316
)

(25
)%

$
3,382

$
3,846

$
(464
)

(12
)%
Canada retail mutual funds - with upfront sales commissions

112

315

(203
)

(64
)%

801

1,096

(295
)

(27
)%
Annuities and other

598

721

(123
)

(17
)%

2,012

2,233

(221
)

(10
)%
Total sales-based revenue generating product sales

1,642

2,284

(642
)

(28
)%

6,195

7,175

(980
)

(14
)%
Managed investments

320

387

(67
)

(17
)%

1,225

1,099

126

11
%
Canada retail mutual funds - no upfront sales commissions

158

76

82

108
%

160

239

(79
)

(33
)%
Segregated funds

42

44

(2
)

(5
)%

338

171

167

98
%
Total product sales

$
2,162

$
2,791

$
(629
)

(23
)%

$
7,918

$
8,684

$
(766
)

(9
)%
Average client asset values:

Retail mutual funds

$
51,171

$
57,780

$
(6,609
)

(11
)%

$
54,709

$
54,954

$
(245
)

*

Annuities and other

22,965

25,778

(2,813
)

(11
)%

24,314

24,886

(572
)

(2
)%
Managed investments

6,817

6,362

455

7
%

6,951

5,857

1,094

19
%
Segregated funds

2,368

2,732

(364
)

(13
)%

2,532

2,688

(156
)

(6
)%
Total average client asset values

$
83,321

$
92,652

$
(9,331
)

(10
)%

$
88,506

$
88,385

$
121

*

* Less than 1%.


	Three months ended March 31,				Change
	2023		2022		$			%
	(Dollars in millions)
Product sales:
U.S. Retail mutual funds	$	972	$	1,298	$	(326	)		(25	)%
Canada retail mutual funds - with upfront sales commissions		150		438		(288	)		(66	)%
Annuities and other		637		726		(89	)		(12	)%
Total sales-based revenue generating product sales		1,759		2,462		(703	)		(29	)%
Managed investments		306		454		(148	)		(33	)%
Canada retail mutual funds - no upfront sales commissions		183		82		101			124	%
Segregated funds		52		68		(16	)		(24	)%
Total product sales	$	2,300	$	3,066	$	(766	)		(25	)%
Average client asset values:
Retail mutual funds	$	53,442	$	58,548	$	(5,106	)		(9	)%
Annuities and other		23,473		25,868		(2,395	)		(9	)%
Managed investments		7,338		7,077		261			4	%
Segregated funds		2,329		2,710		(381	)		(14	)%
Total average client asset values	$	86,582	$	94,203	$	(7,621	)		(8	)%

The rollforward of asset values in client accounts was as follows:


	Three months ended September 30,												Nine months ended September 30,												Three months ended March 31,
	2022			% of beginning balance			2021			% of beginning balance			2022			% of beginning balance			2021			% of beginning balance			2023			% of beginning balance			2022			% of beginning balance
	(Dollars in millions)																								(Dollars in millions)
Asset values, beginning of period	$	82,291					$	91,735					$	97,312					$	81,533					$	83,949					$	97,312
Net change in asset values:
Inflows		2,161			3	%		2,791			3	%		7,916			8	%		8,684			11	%		2,300			3	%		3,066			3	%
Redemptions		(1,447	)		(2	)%		(1,756	)		(2	)%		(5,144	)		(5	)%		(5,341	)		(7	)%		(1,658	)		(2	)%		(1,900	)		(2	)%
Net flows		714			1	%		1,035			1	%		2,772			3	%		3,343			4	%		642		*				1,166			1	%
Change in fair value, net		(3,466	)		(4	)%		(681	)		(1	)%		(20,243	)		(21	)%		6,840			8	%		3,014			4	%		(4,941	)		(5	)%
Foreign currency, net		(802	)		(1	)%		(323	)	*				(1,104	)		(1	)%		50		*				16		*				171		*
Net change in asset values		(3,554	)		(4	)%		31		*				(18,575	)		(19	)%		10,233			13	%		3,672			4	%		(3,604	)		(4	)%
Asset values, end of period	$	78,737					$	91,766					$	78,737					$	91,766					$	87,621					$	93,708

* Less than 1%.

Average number of fee-generating positions was as follows:


	Three months ended September 30,				Change					Nine months ended September 30,				Change					Three months ended March 31,				Change
	2022		2021		Positions		%			2022		2021		Positions		%			2023		2022		Positions		%
	(Positions in thousands)																		(Positions in thousands)
Average number of fee-generating positions (1):
Recordkeeping and custodial		2,295		2,192		103		5	%		2,272		2,155		117		5	%		2,316		2,243		73		3	%
Recordkeeping only		820		762		58		8	%		810		739		71		10	%		829		797		32		4	%
Total average number of fee- generating positions		3,115		2,954		161		5	%		3,082		2,894		188		7	%
Total average number of fee-generating positions																				3,145		3,040		105		3	%

(1)

We receive transfer agent recordkeeping fees by mutual fund positions. An individual client account may include multiple mutual fund positions. We may also receive fees, which are earned on a per account basis, for custodial services that we provide to clients with retirement plan accounts that hold positions in these mutual funds.

Changes in Investment and Savings ~~Products~~Product Sales, Asset Values and Accounts/Positions During the Three Months Ended ~~September 30, 2022~~March 31, 2023

Product sales. Investment and savings ~~products~~product sales decreased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the three months ended ~~September 30, 2021~~March 31, 2022 led by lower sales of ~~retail mutual funds~~investment and ~~variable annuities~~savings products as investor demand deteriorated ~~in response~~due to ~~negative~~the lingering effects of equity market ~~conditions~~volatility during 2022. By comparison, product sales during the three months ended March 31, 2022 reflected strong demand that followed positive equity market returns during 2021.

Average client asset values. Average client asset values decreased for the three months ended ~~September 30, 2022~~March 31, 2023 compared to the three months ended ~~September 30, 2021~~March 31, 2022 primarily due to negative equity market conditions ~~during 2022.~~leading into 2023, which yielded a lower average asset base. Net flows remained positive for the first quarter of 2023.

Rollforward of client asset values. Ending client asset values decreased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to ~~an increase in~~ the three months ended ~~September 30, 2021~~March 31, 2022 primarily due to negative equity market performance ~~during~~leading into 2023, which led to lower beginning asset values. During the ~~2022 period.~~three months ended March 31, 2023, equity markets performance appreciated slightly. Net flows remained positive infor the ~~three months ended September 30, 2022, albeit to a lesser extent than in the comparable 2021 period.~~first quarter of 2023.

Average number of fee-generating positions. The average number of fee-generating positions increased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the three months ended ~~September 30, 2021~~March 31, 2022 primarily due to the cumulative effect of retail mutual fund sales in recent periods that led to an increase in the number of retail mutual fund positions serviced on our transfer agent recordkeeping platform.

~~Changes in Investment and Savings Products Sales, Asset Values and Accounts/Positions During the Nine Months Ended September 30, 2022~~

~~Product sales.~~ Investment and savings products sales decreased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 led by lower sales of retail mutual funds and variable annuities as investor demand during the second and third quarters of 2022 deteriorated in response to negative market conditions.

~~Average client asset values.~~ Average client asset values increased slightly for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the impact of elevated market values of client assets at the beginning of 2022. Continued positive net flows during 2022 also contributed to the increase in average client asset values, which was partially offset by negative market performance.

~~Rollforward of client asset values.~~ Ending client asset values decreased during the nine months ended September 30, 2022 compared to an increase in the nine months ended September 30, 2021 primarily due to negative market performance during the 2022 period compared to strong market performance in the comparable 2021 period. Net flows remained positive in the nine months ended September 30, 2022, albeit to a lesser extent than in the comparable 2021 period.

~~Average number of fee-generating positions.~~ The average number of fee-generating positions increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the same factors described in the three-month comparison.

Senior Health Key Performance Indicators.

Submitted Policies and Approved Policies and Policies Sourced by Primerica Independent Sales Representatives

Submitted policies. Submitted policies ~~represents~~represent the number of completed applications that, with respect to each ~~such~~ application, the applicant has authorized e-TeleQuote to submit to the health insurance carrier. The applicant may need to take additional ~~actions,~~action, including providing subsequent information, before the application is reviewed by the health insurance carrier.

Approved policies. Approved policies represent an estimate of submitted policies approved by the health insurance carriers for the identified product during the indicated period. Not all approved policies will go in force. In general, the relationship between submitted policies and approved policies has been seasonally ~~consistent over time.~~consistent. Therefore, factors impacting the number of submitted policies generally impact the number of approved policies.

Policies sourced by Primerica Independent Sales Representatives. Primerica independent sales representatives are eligible to refer Medicare participants to e-TeleQuote licensed agents for potential enrollment in policies distributed by e-TeleQuote after completion of a brief certification course offered by Primerica.

33The number of submitted policies by e-TeleQuote sourced from Primerica independent sales representatives measures the number of Senior Health policies submitted by e-TeleQuote to its third-party health insurance carriers that originated through the Primerica independent sales force.

The number of Senior Health submitted policies and approved policies were as follows:


	Three months ended September 30,				Nine months ended September 30,				Three months ended March 31,
	2022		2021		2022		2021 (1)		2023		2022
Number of Senior Health submitted policies		16,095		20,867		61,978		20,867		19,826		26,231
Number of Senior Health approved policies		14,862		18,276		56,381		18,276		18,413		23,594
Submitted policies sourced by Primerica independent sales representatives										2,073		988

~~(1)~~

~~Only reflects three months of activity as the e-TeleQuote acquisition occurred on July 1, 2021.~~

The Senior Health segment experiences notable seasonality with the strongest demand occurring in the fourth quarter due to the Medicare Annual Election Period (“AEP”) from October 15th to December 7th. ~~The business typically experiences strong~~We also experience seasonally higher demand in the first quarter due to the Medicare Open Enrollment Period ~~(“OEP”)~~ from January 1st to March 31st, which allows individuals to switch Medicare Advantage plans. Meanwhile, the second and third quarters experience seasonally lower demand as the focus for submitted policies is limited to participants that are dual eligible (Medicare and Medicaid), qualify for a special enrollment period, recently aged into Medicare or are ~~transitioning to Medicare from~~enrolling off of an employer-sponsored plan, and other less common situations.

During the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, the volume of submitted and approved policies reflects the Company’s efforts to ~~scale back~~control growth in favor of developing more efficient lead procurement and limiting the number of agents. The nine month comparison is also impacted by the timing of the acquisition of e-TeleQuote on July 1, 2021. The 2022 period includes nine months of submitted and approved policies compared to only three months for the 2021 period.conversion. Approved policies as a percentage of submitted policies increased during the ~~2022 periods as~~three months ended March 31, 2023 due to a ~~result~~higher conversion rate of policies submitted in 2023. The increase in the ~~lead procurement efforts mentioned above.~~

~~Senior Health Policies Sourced~~conversion rate of submitted policies is largely due to a higher mix of policies submitted by ~~Primerica Independent Sales Representatives~~

Primerica independent sales representatives ~~are eligible to refer Medicare participants to e-TeleQuote licensed~~as well as having a greater concentration of more tenured agents ~~for potential enrollment~~ in policies distributed by e-TeleQuote after completion of a brief certification course offered by Primerica. At September 30, 2022, there were 83,280 Primerica independent sales representatives certified to refer participants for enrollment in Senior Health policies.e-TeleQuote's employee agent population.

The number of submitted policies by e-TeleQuote sourced from Primerica independent sales representatives measures the number of Senior Health policies submitted by e-TeleQuote to its third-party health insurance carriers that originated through the Primerica independent sales force.

Three months ended September 30,

Nine months ended September 30,

2022

2021

2022

2021 (1)

Submitted policies sourced by Primerica independent sales representatives

1,016

319

2,835

319

~~(1)~~

~~Only reflects three months of activity as the e-TeleQuote acquisition occurred on July 1, 2021.~~

For the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, the number of submitted policies sourced by Primerica Senior Health certified independent sales representatives increased compared to the same ~~periods~~period in ~~2021~~2022 primarily due to the timing of the acquisition of e-TeleQuote on July 1, 2021. The 2022 period includes nine months of submitted policies sourced by Primerica independent sales representatives compared to only three months for the 2021 period. In addition, the three months ended September 30, 2021 represents the initial launchincreasing maturity of the Primerica referral program ~~which occurred toward the end of the quarter.~~that has achieved greater participation by Primerica independent sales representatives.

Lifetime ~~value~~Value of ~~commissions~~Commissions and Contract ~~acquisition costs~~Acquisition Costs

Lifetime value of commissions (“LTV”). LTV represents the cumulative total of commissions and administrative fees estimated to be collected over the expected life of a policy for policies approved during the period. For more information on LTV, refer to Note 1318 (Revenue from Contracts with Customers) of our consolidated financial statements within our ~~2021~~2022 Annual Report and the Factors Affecting our Results – Senior Health Segment section of MD&A included elsewhere in this report.

Contract acquisition costs (“CAC”). CAC represents the total direct costs incurred to acquire approved policies. CAC are primarily comprised of the costs associated with acquiring leads, ~~from third parties and internally generated leads~~ including fees paid to Primerica Senior Health certified independent sales representatives as well as compensation, licensing, and training costs associated with our team of e-TeleQuote licensed health insurance agents. The number of e-TeleQuote licensed health insurance agents, agent tenure, attrition rate and productivity all impact

CAC. Other than costs incurred to assist beneficiaries ~~with~~who are switching plans ~~within~~with the same carrier, we incur the entire cost of approved policies prior to enrollment and prior to receiving our first commission-related payment.

Per policy metrics for ~~the~~ LTV and CAC measure our ability to profitably distribute Senior Health insurance products.

The LTV per approved policy, CAC per approved policy, and ratio of LTV to CAC per approved policy were as follows:

Three months ended September 30,

Nine months ended September 30,

2022

2021

2022

2021 (1)

LTV per approved policy during the period

$
868

1,180

$
850

1,180

CAC per approved policy during the period

$
905

1,287

$
949

1,287

LTV/CAC per approved policy

0.96

0.91

0.90

0.91

~~(1)~~

~~Only reflects three months of activity as the e-TeleQuote acquisition occurred on July 1, 2021.~~


	Three months ended March 31,
	2023		2022
LTV per approved policy during the period	$	856		862
CAC per approved policy during the period	$	814		875
LTV/CAC per approved policy		1.05		0.98

LTV per approved policy reflects current estimates for renewal rates, policy retention and chargeback activity taking into consideration the most recent experience through ~~September 30, 2022. The Company saw lower renewal retention rates~~March 31, 2023.LTV per approved policy remained relatively consistent during ~~2022~~the three months ended March 31, 2023 compared to ~~historical experience due to an increased propensity of consumers to consider changing plans and increased plan offerings by carriers. This experience led to lower LTV~~the three months ended March 31, 2022.

The reduction in CAC per approved policy during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the three months ended ~~September 30, 2021.~~March 31, 2022 was primarily driven by lower agent counts with a higher concentration of tenured agents, which resulted in lower per unit labor costs and greater lead conversion efficiency.

CAC per approved policy for the three months ended September 30, 2022 reflects selective procurement of leads and a deliberate approach in limiting agent count. This led to a decrease in CAC per approved policy for the three months ended September 30, 2022 as compared with the three months ended September 30, 2021.Regulatory Changes.

LTV and CAC per approved policy for the nine months ended September 30, 2022 compared to the same period in 2021 exhibited the same trends as the three-month comparison even though the nine-month period ended September 30, 2021 only reflects activity since the July 1, 2021 acquisition date.

~~Other business trends and conditions.~~

Worker classification standards. There has been a trend toward administrative and legislative activity around worker classification. For example, in January 2021, the Department of Labor (“DOL”) under the prior presidential administration issued a rulemaking interpreting the “economic realities” worker classification standard applicable to the Fair Labor Standards Act (“~~FSLA”~~FLSA”). In October 2022, the DOL under the current presidential administration proposed a new rule that would rescind the 2021 rule and replace it with its own interpretation of the “economic realities” standard under the ~~FSLA.~~FLSA. Other federal and state legislative and regulatory proposals regarding worker classification have also come under consideration. It is difficult to predict what the outcome of worker classification activity may be. Changes to worker classification laws could impact our business as sales representatives (other than those hired by e-TeleQuote) are independent contractors.

Restrictions on compensation models in Canada. During 2022, in response to regulatory changes in Canada, we developed a set of mutual fund products with two third-party mutual fund companies that are sold exclusively by our independent sales representatives (the “Principal Distributor funds”). The revenue we receive is primarily in the form of asset-based distribution fees from the mutual fund companies and asset-based service fees that are charged to investors. In turn, the primary compensation we offer independent sales representatives is the option of an upfront sales commission or higher asset-based commissions over time. Although we received the requisite approval, the organization of provincial and territorial securities ~~regulators~~commissions throughout Canada (collectively referred to as the “Canadian Securities Administrators” or “CSA”) published final rule amendments to prohibit upfront sales commissions by fund companies for the sale of mutual funds offered under a prospectus in Canada (“DSC Ban”). The final amendments became effective on June 1, 2022. These rules have resulted in changes in compensation arrangements with both the fund companies that offer the mutual fund products we distribute and sales representatives. In particular, we have entered into agreements with two third-party mutual fund companies to develop and offer a broad range of funds being sold exclusively by our independent sales representatives. These agreements provide for the payment to us of asset-based revenue by the mutual fund companies. We also earn revenue through an asset-based fee charged to clients. As part of our new model (the “Principal Distributor model”) we are funding an advance of compensation at the time of sale to our independent sales representatives, taken at their option, to partially replace upfront sales commission cash flow from fund companies paid under the deferred sales charge compensation model. We expect that these changes to our mutual fund model will have the impact of initially decreasing our pre-tax operating income in the short term due to the elimination of upfront commissions. Over the long term, we expect pre-tax operating income to recover through the collection of asset-based commissions over time. We began offering our new Principal Distributor model on July 6, 2022. Although we received the requisite approval to do so, the CSA has indicated that it intends to closely examine the model, including potentially through a public consultation on sales practices, and may require undertakings or consider future amendments that would require modifications to the model, including with respect to its ~~advance and chargeback~~upfront commission features. At this time, we cannot quantify the financial impact, if any, of ~~any~~future changes to our business that may be necessary ~~in order to comply~~ if our Principal Distributor funds model is required to be modified or discontinued. During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, Canadian mutual funds represented approximately 14% of our total investment and savings product sales and approximately 13% of our average client asset values.

~~In an announcement February 10, 2022, and~~

Insurance regulators in ~~line with the DSC Ban for the sale~~Canada have indicated that a cessation of ~~mutual funds, the organization of provincial and territorial insurance regulators (collectively referred to as the “Canadian Council of Insurance Regulators”) urged insurers to refrain from new~~ deferred ~~sale charge~~ sales incharges on segregated fund contracts beginning June 1, 2022, and expect a transition to a cessation of such sales by June 1, 2023. In addition, on September 8, 2022, the Canadian Council of Insurance Regulators issued a discussion paper for consultation to consider other changes to upfront compensation, including advance compensation and chargeback features suchentered into after May 31, 2023 will go into effect as ~~those used in our Principal Distributor model.~~previously announced. We currently expect that ~~changes, if any,~~deferred sales charges will continue to be allowed on subsequent deposits of existing segregated funds ~~compensation practice,~~contracts for a period of time, however, insurance regulators will ~~also~~ be ~~adopted by securities regulators which may impact our Principal Distributor model.~~further evaluating whether to allow this continued use. Currently, our Canadian segregated ~~fund~~funds products are primarily sold on a deferred sales charge basis and we pay upfront commissions to the independent ~~agents~~sales representatives for the sale of these products. At this time, without further clarity from regulators on allowable segregated funds compensation practices, we ~~are unable to assess the impact~~expect a decline in segregated funds product sales beginning in June 2023. We earn revenue from Canadian segregated funds products based on a percentage of ~~any such reforms to our operations and income.~~client assets under management. During the ~~nine~~three months

ended ~~September 30, 2022,~~March 31, 2023, Canadian segregated funds represented approximately 2% of our total investment and savings product sales and approximately 3% of our average client asset values.

Factors Affecting Our Results

~~Refer to the Business Trends and Conditions section for discussion of the potential impact on our business from the COVID-19 pandemic.~~

Term Life Insurance Segment. The Term Life Insurance segment results are primarily driven by sales volumes, how closely actual experience matches our ~~pricing~~actuarial assumptions, terms and use of reinsurance, and expenses.

Sales and policies in-force. Sales of term policies and the size and characteristics of our in-force book of policies are vital to our results over the long term. Premium revenue is recognized as it is earned over the term of the ~~policy, and eligible acquisition expenses are deferred and amortized ratably with the level premiums of the underlying policies.~~policy. However, because we incur significant cash outflows at or about the time policies are issued, including the payment of sales commissions and underwriting costs, changes in life insurance sales volume in a period will have a more immediate impact on our cash flows than on ~~revenue and expense recognition in that period.~~revenue.

Historically, we have found that while sales volume of term life insurance products between fiscal periods may vary based on a variety of factors, the productivity of sales representatives generally remains within a range (i.e., an average monthly rate of new policies issued per life-licensed independent sales representative between ~~0.18~~0.20 and ~~0.22)~~0.24). The volume of term life insurance products sales will fluctuate in the short term, but over the longer term, our sales volume generally correlates to the size of the independent sales force.

~~Pricing~~Actuarial assumptions. Our pricing methodology is intended to provide us with appropriate profit margins for the risks we assume. We determine pricing classifications based on the coverage sought, such as the size and term of the policy, and certain policyholder attributes, such as age and health. In addition, we generally utilize unisex rates for term life insurance policies. The ~~pricing~~actuarial assumptions that underlie our ~~rates~~reserves are based upon our best estimates of mortality, persistency, ~~disability,~~ and interest rates at the time of issuance, sales force commission rates, issue and underwriting expenses, operating expenses and the characteristics of the insureds, including the distribution of sex, age, underwriting class, product and amount of coverage.disability. Our results will be affected to the extent there is a variance between our ~~pricing~~actuarial assumptions and actual experience. These variances will be reflected in our financial results by unlocking assumptions and cash flows underlying the liability for future policy benefits (“LFPB”) and ceded reserves that are part of the reinsurance recoverables. See Note 9 (Future Policy Benefits) for more information on LFPB. The variances are also reflected in the projection of future face amount that is the basis for amortizing DAC.

•

Persistency. Persistency is a measure of how long our insurance policies stay in-force. As a general matter, persistency that is lower than our ~~pricing~~actuarial assumptions adversely affects our results over the long term because we lose the recurring revenue stream associated with the policies that lapse. ~~Determining the near-term effects of changes in~~In general, persistency ~~is more complicated. When actual persistency is lower than~~differences have a minimal impact on our ~~pricing assumptions, we must accelerate the amortization of~~financial results from period to period since deferred policy acquisition costs (“DAC”)~~. The resultant increase in amortization expense~~ is ~~offset by~~generally amortized on a ~~corresponding release~~straight-line basis and the unlocking of ~~reserves associated with lapsed policies, which causes a reduction in~~the LFPB adjusts both expected net premiums and expected future policy benefits and ~~claims expense. The future policy benefit reserves associated with~~spreads any ~~given policy will change~~variances over the term of such policy. As a general matter, future policy benefit reserves are lowest at the inception of a policy term and rise steadily to a peak before declining to zero at the expiration of the policy term. Accordingly, depending on when the lapse occurs in relation to the overall policy term, the reduction in benefits and claims expense may be greater or less than the increase in amortization expense, and, consequently, the effects on earnings for a given period could be positive or negative. Persistency levels will impact results to the extent actual experience deviates from the persistency assumptions that are locked-in at time of issue.remaining contract period.

•

Mortality. Our profitability will fluctuate to the extent actual mortality rates differ from ~~the assumptions that are locked-in at time of issue.~~actuarial assumptions. We mitigate a significant portion of our mortality exposure through reinsurance. Long term mortality variances that result in an assumption change may have a significant impact on our financial results.

•

Disability. Our profitability will fluctuate to the extent actual disability rates underlying our waiver benefits, including recovery rates for individuals currently disabled, differ from actuarial assumptions. The waiver benefit is secondary to the death benefit coverage provided. However, the waiver benefit is not reinsured on a yearly renewable term (“YRT”) basis and material changes in assumptions ~~that are locked-in at the time of issue or time of disability.~~compared to expectations can have a disproportionate impact on our financial results.

•

Interest Rates. We use ana locked-in assumption for future interest rates for reserves underlying our segment results. Policies issued prior to the Transition Date use an interest rate that ~~initially~~ reflects the portfolio’s current reinvestment rate ~~gradually increasing over seven years to a level consistent with our expectation~~while policies issued on or after the Transition Date use an upper-medium grade fixed income instrument yield during the period of future yield growth. Both DAC and the future policy benefit reserve liability increase with the assumed interest rate. Since DAC is higher than the future policy benefit reserve liability in the early years of a policy, a lower assumed interest rate generally will result in lower profits. In the later years, when the future policy benefit reserve liability is higher than DAC, a lower assumed interest rate generally will result in higher profits. These assumed interest rates, which like other pricing assumptions are locked-in at issue, impact the timing but not the aggregate amount of DAC and future policy benefit reserve changes. We allocate net investment income generated by the investment portfolio to the Term Life Insurance segment in an amount equal to the assumed net interest accreted to the segment’s U.S. generally accepted accounting principles (“U.S. GAAP”)-measured future policy benefit reserve liability less DAC. All remaining net investment income, and therefore the impact of actual interest rates, is attributed to the Corporate and Other Distributed Products segment.issue.

Reinsurance. We use reinsurance extensively, which has a significant effect on our results of operations. We have generally reinsured between 80% and 90% of the mortality risk on term life insurance (excluding coverage under certain riders) on a quota share ~~yearly renewable term (“YRT”)~~YRT basis. To the extent actual mortality experience is more or less favorable than the contractual rate, the

reinsurer will earn incremental profits or bear the incremental cost, as applicable. In contrast to coinsurance, which is intended to eliminate all risks (other than counterparty risk of the reinsurer) and rewards associated with a specified percentage of the block of policies subject to the reinsurance arrangement, the YRT reinsurance arrangements we enter into are intended only to reduce volatility associated with variances between estimated and actual mortality rates.

In 2010, as part of our corporate reorganization and the initial public offering of our common stock, we entered into significant coinsurance transactions (the “IPO coinsurance transactions”) with entities then affiliated with Citigroup, Inc. (collectively, the “IPO coinsurers”) and ceded between 80% and 90% of the risks and rewards of term life insurance policies that were in-force at year-end 2009. We administer all such policies subject to these coinsurance agreements. Policies reaching the end of their initial level term period are no longer ceded under the IPO coinsurance transactions.

The effect of our reinsurance arrangements on ceded premiums and benefits and expenses on our statements of income follows:

•

Ceded premiums. Ceded premiums are the premiums we pay to reinsurers. These amounts are deducted from the direct premiums we earn to calculate our net premium revenues. Similar to direct premium revenues, ceded coinsurance premiums remain level over the initial term of the insurance policy. Ceded YRT premiums increase over the period that the policy has been in-force. Accordingly, ceded YRT premiums generally constitute an increasing percentage of direct premiums over the policy term.

•

Benefits and claims. Benefits and claims include incurred claim amounts and changes in future policy benefit reserves. Reinsurance reduces incurred claims in direct proportion to the percentage ~~ceded. Coinsurance also reduces~~ceded and reinsurance cash flows are reflected in the ~~change in future policy benefit~~ceded reserves ~~in direct proportion~~underlying reinsurance recoverables that are an offset to the ~~percentage ceded, while YRT reinsurance does not significantly impact the change in these reserves.~~

•

~~Amortization of DAC.~~ DAC, and therefore amortization of DAC, is reduced on a pro-rata basis for the coinsured business, including the business reinsured with the IPO coinsurers. There is no impact on amortization of DAC associated with our YRT contracts.LFPB.

•

Insurance expenses. Insurance expenses are reduced by the allowances received from coinsurance. There is no impact on insurance expenses associated with our YRT contracts.

We may alter our reinsurance practices at any time due to the unavailability of YRT reinsurance at attractive rates or the availability of alternatives to reduce our risk exposure. We presently intend to continue ceding approximately 90% of our U.S. and Canadian mortality risk on new business.

Expenses. Results are also affected by variances in client acquisition, maintenance and administration expense levels.

Investment and Savings Products Segment. The Investment and Savings Products segment results are primarily driven by sales, the value of assets in client accounts for which we earn ongoing management, marketing and support, and distribution fees, and the number of transfer agent recordkeeping positions and non-bank custodial fee-generating accounts we administer.

Sales. We earn commissions and fees, such as dealer re-allowances and marketing and distribution fees, based on sales of mutual fund products and annuities in the United States and sales of certain mutual fund products in Canada. Sales of investment and savings products are influenced by the overall demand for investment products in the United States and Canada, as well as by the size and productivity of the independent sales force. We generally experience seasonality in the Investment and Savings Products segment results due to our high concentration of sales of retirement account products. These accounts are typically funded in February through April, coincident with our clients’ tax return preparation season. While we believe the size of the independent sales force is a factor in driving sales volume in this segment, there are a number of other variables, such as economic and market conditions, which may have a significantly greater effect on sales volume in any given fiscal period.

Asset values in client accounts. We earn marketing and distribution fees (trail commissions or, with respect to U.S. mutual funds, 12b-1 fees) on mutual fund and annuity assets in the United States and Canada. In the United States, we also earn investment advisory and administrative fees on assets in managed investments. In Canada, we earn marketing, distribution, and shareholder services fees on mutual fund assets for which we serve as the principal distributor and management fees on the segregated funds for which we serve as investment manager. Asset values are influenced by new product sales, ongoing contributions to existing accounts, redemptions and the change in market values in existing accounts. While we offer a wide variety of asset classes and investment styles, our clients’ accounts are primarily invested in equity funds. Volatility in equity markets will impact the value of assets in client accounts and, as a result, the revenue we earn on those assets.

Positions. We earn transfer agent recordkeeping fees for administrative functions we perform on behalf of several of our mutual fund providers. An individual client account may include multiple fund positions for which we earn transfer agent recordkeeping fees. We may also receive fees earned for non-bank custodial services that we provide to clients with retirement plan accounts.

Sales mix. While our investment and savings products all provide similar long-term economic returns to the Company, our results in a given fiscal period will be affected by changes in the overall mix of products within these categories. Examples of changes in the sales mix that influence our results include the following:

•

sales of annuity products in the United States will generate higher revenues in the period such sales occur than sales of other investment products that either generate lower upfront revenues or, in the case of managed investments and segregated funds, no upfront revenues;

•

sales of a higher proportion of managed investments, Canadian mutual funds, and segregated funds products will spread the revenues generated over time because we earn higher revenues based on assets under management for these accounts each period as opposed to earning upfront revenues based on product sales; and

•

sales of a higher proportion of mutual fund products sold will impact the timing and amount of revenue we earn given the distinct transfer agent recordkeeping and non-bank custodial services we provide for certain mutual fund products we distribute.

Senior Health Segment. The Senior Health segment results are primarily driven by approved policies, LTV per approved policy and tail revenue adjustments, CAC per approved policy, and other revenue.

Approved policies. Approved policies represent submitted policies approved by health insurance carriers for the identified product during the indicated period. Not all approved policies will go in force. In general, the relationship between submitted policies and approved policies has been ~~consistent over time.~~seasonally consistent. Therefore, factors impacting the number of submitted policies generally impact the number of approved policies. Revenue is primarily generated from approved policies and LTVs are recorded when the enrollment is approved by the applicable health insurance carrier. Medicare Advantage plans make up the substantial portion of the approved policies we distribute. The number of approved policies are influenced by the following:

•

the size and growth of the population of senior citizens in the United States;

•

the appeal of government-funded Medicare Advantage plans that provide privately administered healthcare coverage with enhanced benefits relative to original Medicare;

•

our ability to generate and obtain leads for our team of e-TeleQuote licensed health insurance agents;

•

our ability to staff and train our team of e-TeleQuote licensed health insurance agents to manage leads and help eligible Medicare participants through the enrollment process;

•

~~our ability to retain Medicare participants in a competitive environment in which participants are actively comparing plans and carriers;~~ and

•

our health insurance carrier relationships that allow us to offer plans that most appropriately meet eligible Medicare participants’ needs.

LTV per approved policy and tail revenue adjustments. When a policy is approved by the health insurance carrier, commission revenue is recognized based on an estimated LTV per approved policy. LTV per approved policy is the cumulative total of commissions estimated to be collected over the expected life of a policy, subject to constraints applied in accordance with our revenue

recognition policy. Specifically, LTV per approved policy is equal to the sum of the initial commissions, less an estimate of chargebacks for paid policies that are disenrolled in the first policy year, plus forecasted renewal commissions. This estimate is driven by a number of factors including, but not limited to, contracted commission rates from carriers, expected policy turnover, emerging chargeback activity and applied constraints. These factors may result in varying values from period to period.

We recognize adjustments to revenue outside of LTV for approved policies from prior periods when our cash collections are, or are expected to be, different from the estimated constrained LTVs, which we refer to as tail revenue adjustments. The recognition of tail revenue adjustments results from a change in the estimate of expected cash collections when actual cash collections or communicated rate increases have indicated a trend that is different from the estimated constrained LTV. Tail revenue adjustments can be positive or negative and we recognize positive adjustments to revenue when we do not believe it is probable that a significant reversal of cumulative revenue will occur.

CAC per approved policy. Results are also driven by the costs of acquisition, which is defined as the total direct costs incurred per approved policy. Our costs of acquisition are primarily comprised of the cost to generate and acquire leads, including fees paid to Primerica Senior Health certified independent sales representatives, and the labor, benefits, bonus compensation, licensing and training costs associated with our team of e-TeleQuote licensed health insurance agents. Other than costs incurred to assist beneficiaries with switching plans within the same carrier, we incur our entire cost of approved policies prior to enrollment and prior to receiving our first commission related payment. Factors that impact our costs of acquisition per approved policy include:

•

the market price of externally-generated leads;

•

our ability to efficiently procure internally-generated leads; and

•

the productivity of our e-TeleQuote licensed health insurance agents in converting procured leads into approved policies.

Other revenue. Other revenue recognized in the Senior Health segment includes marketing development revenues received for providing marketing services to certain health insurance carriers. Marketing development revenue provides additional revenue to deliver approved policies and are based on meeting agreed-upon objectives with certain health insurance carriers. Marketing development revenue serves to offset contract acquisition costs associated with distribution of approved policies. Agreements for marketing development revenue are generally short-term in nature and can vary from period to period.

Corporate and Other Distributed Products Segment. We earn revenues and pay commissions and referral fees within the Corporate and Other Distributed Products segment for mortgage loan originations, prepaid legal services, auto and homeowners’ insurance referrals, and other financial products, all of which are originated by third parties. The Corporate and Other Distributed Products segment also includes in-force policies from several discontinued lines of insurance underwritten by ~~National Benefit Life Insurance Company (“NBLIC”).~~NBLIC.

Corporate and Other Distributed Products segment ~~net investment income reflects actual~~includes net investment income recognized by the Company less the amount allocated to the Term Life Insurance segment based on the assumed net interest accreted to the segment’s U.S. GAAP-measured future policy benefit reserve liability less DAC. Actual netCompany. Net investment income ~~reflected in the Corporate and Other Distributed Products segment~~ is impacted by the size and performance of our invested asset portfolio, which can be influenced by interest rates, credit spreads, and the mix of invested assets.

The Corporate and Other Distributed Products segment also includes corporate income and expenses not allocated to our other segments, general and administrative expenses (other than expenses that are allocated to the Term Life Insurance or Investment and Savings Products segments), interest expense on notes payable, redundant reserve financing transactions and our revolving credit facility (“Revolving Credit ~~Facility,~~Facility”), as well as realized gains and losses on our invested asset portfolio.

Capital Structure. Our financial results are affected by our capital structure, which includes our senior unsecured notes (the “Senior Notes”), redundant reserve financing transactions, our Revolving Credit Facility, and our common stock. See Note 710 (Stockholders’ Equity), Note 1013 (Commitments and Contingent Liabilities), and Note 1215 (Debt) to our unaudited condensed consolidated financial statements included elsewhere in this report for more information on changes in our capital structure.

Foreign Currency. The Canadian dollar is the functional currency for our Canadian subsidiaries and our consolidated financial results, reported in U.S. dollars, are affected by changes in the currency exchange rate. As such, the translated amount of revenues, expenses, assets and liabilities attributable to our Canadian subsidiaries will be higher or lower in periods where the Canadian dollar appreciates or weakens relative to the U.S. dollar, respectively. See Item 7A. Quantitative and Qualitative Disclosures About Market Risk – Canadian Currency Risk included in our ~~2021~~2022 Annual Report and Note 2 (Segment and Geographical Information) to our unaudited condensed consolidated financial statements included elsewhere in this report for more information on our Canadian subsidiaries and the impact of foreign currency on our financial results.

Critical Accounting Estimates

We prepare our financial statements in accordance with U.S. GAAP. These principles are established primarily by the Financial Accounting Standards Board. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions based on currently available information when recording transactions resulting from business operations. Our significant accounting policies are described in Note 1 (Description of Business, Basis of Presentation, and Summary of Significant

Accounting Policies) to our consolidated financial statements included in our ~~2021~~2022 Annual Report. The most significant items on our unaudited condensed consolidated balance sheets are based on fair value determinations, accounting estimates and actuarial determinations, which are susceptible to changes in future periods and could affect our results of operations and financial position.

The estimates that we deem to be most critical to an understanding of our results of operations and financial position are those related to DAC, future policy benefit reserves and corresponding amounts recoverable from reinsurers, income taxes, renewal commissions receivable, goodwill and the valuation of investments. The preparation and evaluation of these critical accounting estimates involve the use of various assumptions developed from management’s analyses and judgments. Subsequent experience or use of other assumptions could produce significantly different results.

Accounting Policy Changes.

During the three ~~and nine~~ months ended ~~September 30, 2022, we made the following updates~~March 31, 2023, there were changes in accounting methodology for ~~items~~Deferred Policy Acquisition Costs and Future Policy Benefit Reserves and Reinsurance that we have identified as critical accounting estimates.

Goodwill represents the excess of the purchase price over the estimated acquired values of identifiable assets and liabilities acquired in a business combination at the acquisition date. In accordance with U.S. GAAP, goodwill is not amortized. The Company tests goodwill for impairment annually on July 1 and whenever events occur or circumstances change that would indicate the carrying value of goodwill may be impaired. All of the Company’s goodwill was obtained from the e-TeleQuote acquisition and the e-TeleQuote business has been designated as a separate operating segment called Senior Health. Therefore, goodwill has been allocated

~~solely to the Senior Health segment and is evaluated for impairment at the Senior Health segment level, which is also defined as the reporting unit.~~

~~During the annual impairment test as of July 1, 2022, the Company performed a quantitative impairment analysis using the incomeapproach~~. We utilized an income approach by preparing a discounted cash flow analysis to determine the reporting unit’s fair value. The discounted cash flow analysis included key assumptions such as the weighted average cost of capital ("WACC"), long-term growth rate and projected operating results such as approved policies, LTVs, contract acquisition costs, operating expenses, collections of renewal commissions receivable, and utilization of net operating losses for income tax purposes. We did not utilize a market approach as part of the quantitative impairment analysis as we believe management’s expectations of the cash flow generated These changes were necessitated by the ~~reporting unit were more relevant~~adoption of LDTI. See Note 1 (Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies), Note 6 (Deferred Policy Acquisition Costs), and Note 9 (Future Policy Benefits) to our condensed consolidated financial statements included elsewhere in determining fair value given inherent limitations in the credibility of available peer company data. The measurement of the reporting unit’s fair value is classified as a Level 3 fair value measurement given the significance of the unobservable inputs such as forecasted operating results and discount rates.

After the fair value of the reporting unit was determined, the Company calculated its carrying value by taking the reporting unit’s assets minus its liabilities. The carrying value of the reporting unit was then compared to its fair value to determine the extent of any goodwill impairment. Based on this analysis, we recognized a non-cash goodwill impairment charge of $60.0 million during the three months ended September 30, 2022, which represents the excess of the Senior Health reporting unit’s carrying value over its estimated fair value at July 1, 2022. The goodwill impairment charge recognized did not impact the Company’s income tax expense as the goodwill acquired from the e-TeleQuote acquisition does not have any tax basis. The decline in the reporting unit's fair value below its carrying value was primarily attributable to an increase in the market-based WACC used to discount the forecasted cash flows. The increase in the WACC was driven by recent increases in the equity market risk premium and higher interest rates. The determination of whether the carrying value of the reporting unit exceeds its fair value involves a high degree of estimation and can be affected by a number of industry and company-specific risk factors that are subject to change over time.

report. For additional information regarding our other critical accounting estimates, see the Critical Accounting Estimates section of MD&A included in our ~~2021~~2022 Annual Report.

Results of Operations

Primerica, Inc. and Subsidiaries Results. Our results of operations were as follows:


	Three months ended September 30,						Change						Nine months ended September 30,						Change						Three months ended March 31,						Change
	2022			2021			$			%			2022			2021			$			%			2023			2022			$			%
	(Dollars in thousands)																								(Dollars in thousands)
Revenues:
Direct premiums	$	810,079		$	785,277		$	24,802			3	%	$	2,417,639		$	2,327,804		$	89,835			4	%	$	817,872		$	798,666		$	19,206			2	%
Ceded premiums		(404,870	)		(401,295	)		3,575			1	%		(1,223,804	)		(1,211,117	)		12,687			1	%		(405,347	)		(399,885	)		5,462			1	%
Net premiums		405,209			383,982			21,227			6	%		1,193,835			1,116,687			77,148			7	%		412,525			398,781			13,744			3	%
Commissions and fees		225,468			269,796			(44,328	)		(16	)%		717,956			754,529			(36,573	)		(5	)%		231,547			251,800			(20,253	)		(8	)%
Investment income net of investment expenses		40,629			35,741			4,888			14	%		112,148			106,970			5,178			5	%		47,500			34,420			13,080			38	%
Interest expense on surplus note		(16,283	)		(15,741	)		542			3	%		(47,613	)		(46,382	)		1,231			3	%		(16,435	)		(15,515	)		920			6	%
Net investment income		24,346			20,000			4,346			22	%		64,535			60,588			3,947			7	%		31,065			18,905			12,160			64	%
Realized investment gains (losses)		292			1,730			(1,438	)	*				924			3,762			(2,838	)	*				(985	)		577			(1,562	)	*
Other investment gains (losses)		(2,991	)		(320	)		(2,671	)	*				(4,765	)		114			(4,879	)	*				(3,623	)		174			(3,797	)	*
Investment gains (loses)		(2,699	)		1,410			(4,109	)	*				(3,841	)		3,876			(7,717	)	*
Investment gains (losses)																										(4,608	)		751			(5,359	)	*
Other, net		20,965			18,051			2,914			16	%		60,709			49,958			10,751			22	%		19,507			20,989			(1,482	)		(7	)%
Total revenues		673,289			693,239			(19,950	)		(3	)%		2,033,194			1,985,638			47,556			2	%		690,036			691,226			(1,190	)	*

Benefits and expenses:
Benefits and claims		171,293			183,425			(12,132	)		(7	)%		511,619			535,561			(23,942	)		(4	)%		168,702			168,288			414		*
Future policy benefits remeasurement (gain) loss																										(508	)		(1,272	)		764			60	%
Amortization of DAC		90,925			62,214			28,711			46	%		262,367			182,604			79,763			44	%		67,358			63,223			4,135			7	%
Sales commissions		105,915			129,268			(23,353	)		(18	)%		359,602			382,465			(22,863	)		(6	)%		110,874			133,924			(23,050	)		(17	)%
Insurance expenses		57,552			51,901			5,651			11	%		176,521			149,246			27,275			18	%		61,125			59,509			1,616			3	%
Insurance commissions		7,666			8,412			(746	)		(9	)%		22,982			25,990			(3,008	)		(12	)%		8,138			7,721			417			5	%
Contract acquisition costs		13,446			23,524			(10,078	)		(43	)%		53,479			23,524			29,955			127	%		14,984			20,649			(5,665	)		(27	)%
Interest expense		6,802			7,529			(727	)		(10	)%		20,469			21,814			(1,345	)		(6	)%		6,690			6,853			(163	)		(2	)%
Goodwill impairment loss		60,000			-			60,000		*				60,000			-			60,000		*
Other operating expenses		73,791			79,864			(6,073	)		(8	)%		239,952			219,559			20,393			9	%		89,536			86,435			3,101			4	%
Total benefits and expenses		587,390			546,137			41,253			8	%		1,706,991			1,540,763			166,228			11	%		526,899			545,330			(18,431	)		(3	)%
Income before income taxes		85,899			147,102			(61,203	)		(42	)%		326,203			444,875			(118,672	)		(27	)%		163,137			145,896			17,241			12	%
Income taxes		34,092			35,663			(1,571	)		(4	)%		90,069			107,403			(17,334	)		(16	)%		38,031			33,512			4,519			13	%
Net income		51,807			111,439			(59,632	)		(54	)%		236,134			337,472			(101,338	)		(30	)%		125,106			112,384			12,722			11	%
Net income attributable to noncontrolling interests		-			(1,017	)		1,017		*				(5,038	)		(1,017	)		(4,021	)	*
Net income (loss) attributable to noncontrolling interests																										-			(2,655	)		2,655		*
Net income attributable to Primerica, Inc.	$	51,807		$	112,456		$	(60,649	)		(54	)%	$	241,172		$	338,489		$	(97,317	)		(29	)%	$	125,106		$	115,039		$	10,067			9	%

* Less than 1% or not meaningful.

Results for the Three Months Ended ~~September 30, 2022~~March 31, 2023

Total revenues. Total revenues were generally flat during the three months ended March 31, 2023 compared to the same period in 2022 as the increases in net premiums earned in our Term Life Insurance segment and net investment income earned in our Corporate and Other Distributed Products segment were offset by lower commissions and fees earned in our Investment and Savings Products segment. These movements are further discussed in detail in the Segment Results section below.

Other, net revenues declined during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 primarily due to a decline in marketing development revenue in our Senior Health segment.

Total benefits and expenses. Total benefits and expenses decreased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the ~~same period in 2021 primarily~~three months ended March 31, 2022 largely due to lower ~~commissions~~commission expenses in our Investment and ~~fees earned~~Savings Products segment as a result of the decrease in sales and client asset values. Also contributing to the decrease were lower CAC in our Senior Health segment as a result of lower sales volumes and lower per unit CAC. Insurance and other operating expenses were higher during 2023 due to higher investments in technology and growth related costs. These movements are discussed in further detail in the Segment Results section below.

Income taxes. Our effective income tax rate for the three months ended March 31, 2023 was 23.3%, which was relatively consistent compared with 23.0% for the three months ended March 31, 2022.

For additional information, see the Segment Results discussions below.

Segment Results

Term Life Insurance Segment Results. Our results for the Term Life Insurance segment were as follows:


	Three months ended March 31,						Change
	2023			2022			$			%
	(Dollars in thousands)
Revenues:
Direct premiums	$	812,880		$	793,254		$	19,626			2	%
Ceded premiums		(404,044	)		(398,446	)		5,598			1	%
Net premiums		408,836			394,808			14,028			4	%
Other, net		12,233			12,175			58		*
Total revenues		421,069			406,983			14,086			3	%
Benefits and expenses:
Benefits and claims		164,375			166,407			(2,032	)		(1	)%
Future policy benefits remeasurement (gain) loss		(31	)		(1,434	)		1,403		*
Amortization of DAC		65,503			61,369			4,134			7	%
Insurance expenses		59,896			58,272			1,624			3	%
Insurance commissions		4,590			3,793			797			21	%
Total benefits and expenses		294,333			288,407			5,926			2	%
Income before income taxes	$	126,736		$	118,576		$	8,160			7	%

* Less than 1% or not meaningful.

Results for the Three Months Ended March 31, 2023

Net premiums. Direct premiums increased during the three months ended ~~September 30, 2022. The decrease in commissions and fees was primarily~~March 31, 2023 compared to the three months ended March 31, 2022 largely due to ~~lower sales-based revenues driven by lower demand for variable annuity and mutual funds investment products. Also contributing~~the layering effect of new policy sales that contributed to growth in the ~~decrease in commissions and fees were lower asset-based revenues driven by unfavorable market performance during 2022.~~in-force book of business. This was partially offset by an increase in ~~Term Life net~~ceded premiums, ~~earned during the three months ended September 30, 2022 compared to the same period~~which includes $16.4 million in ~~2021. The increase in net~~higher non-level YRT reinsurance ceded premiums ~~was driven by incremental premiums on term life insurance policies that are~~as business not subject to the IPO coinsurance transactions ~~as well as~~ages, reduced by $10.8 million in lower coinsurance ceded premiums due to the ~~layering effect~~run-off of ~~life insurance sales.~~business subject to the IPO coinsurance transactions.

Benefits and claims. Benefits and claims decreased slightly during the three months ended March 31, 2023 compared to the three months ended March 31, 2022. Under LDTI, benefits and claims expenses are expected to have low volatility, especially near the Transition Date in the absence of changes to future assumptions, due to the spreading of claims experience variances realized during current periods to future periods by adjusting the net premium ratio used to recognize benefits and claims expenses.

Future policy benefits remeasurement (gain) loss. Future policy benefits remeasurement gain decreased during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 due to smaller experience variances that occurred during the three months ended March 31, 2023.

~~Net investment income~~Amortization of DAC. The amortization of DAC increased slightly during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 primarily due to continued growth in the in-force book of business.

Insurance expenses.Insurance expenses increased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the ~~same period in 2021~~three months ended March 31, 2022 due to ~~$2.4~~ higher investments in technology and growth related costs. These increases were largely offset by lower costs associated with sales force leadership events in the first quarter of 2023.

Insurance commissions. Insurance commissions increased during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 as a result of higher non-deferrable sales force promotional activities that drive growth in the business.

Investment and Savings Products Segment Results.Investment and Savings Products segment results were as follows:


	Three months ended March 31,				Change
	2023		2022		$			%
	(Dollars in thousands)
Revenues:
Commissions and fees:
Sales-based revenues	$	72,388	$	103,242	$	(30,854	)		(30	)%
Asset-based revenues		111,904		113,112		(1,208	)		(1	)%
Account-based revenues		22,790		21,541		1,249			6	%
Other, net		3,120		3,144		(24	)	*
Total revenues		210,202		241,039		(30,837	)		(13	)%
Expenses:
Amortization of DAC		1,493		1,446		47			3	%
Insurance commissions		3,308		3,646		(338	)		(9	)%
Sales commissions:
Sales-based		52,452		74,606		(22,154	)		(30	)%
Asset-based		54,276		53,366		910			2	%
Other operating expenses		42,567		40,936		1,631			4	%
Total expenses		154,096		174,000		(19,904	)		(11	)%
Income before income taxes	$	56,106	$	67,039	$	(10,933	)		(16	)%

* Less than 1% or not meaningful.

Results for the Three Months Ended March 31, 2023

Commissions and fees. Commissions and fees decreased during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 driven by lower sales-based revenues as investor demand for investment and savings products weakened year-over-year. Also contributing to the decrease were lower asset-based revenues which was driven by negative equity market performance. Asset-based revenue declined less in the first quarter of 2023 than average client asset values due to a positive mix shift to asset-based products that earn higher fees including managed accounts and Canadian mutual funds under the new principal distributor model.

Sales commissions. The decrease in sales-based commissions for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 was generally in-line with the decrease in sales-based revenue. Asset-based commissions were up slightly for the three months ended March 31, 2023 and were consistent with the movement in asset-based revenues, excluding Canadian segregated funds revenue. Asset-based expenses for our Canadian segregated funds are reflected within insurance commissions and amortization of DAC.

Other operating expenses. Other operating expenses for the three months ended March 31, 2023 were higher compared to the three months ended March 31, 2022 primarily due to higher investments in technology and growth in managed account expenses. These increases were partially offset by lower costs associated with sales force leadership events in the first quarter of 2023.

Senior Health Segment Results. Senior Health segment results were as follows:


	Three months ended March 31,						Change
	2023			2022			$			%
	(Dollars in thousands)
Revenues:
Commissions and fees (1)	$	15,755		$	1,278		$	14,477		*
Other, net		2,955			4,553			(1,598	)		(35	)%
Total revenues		18,710			5,831			12,879			221	%

Benefits and expenses:
Contract acquisition costs		14,984			20,649			(5,665	)		(27	)%
Other operating expenses		7,488			8,267			(779	)		(9	)%
Total benefits and expenses		22,472			28,916			(6,444	)		(22	)%
Loss before income taxes	$	(3,762	)	$	(23,085	)	$	19,323			84	%

(1)

Includes no tail adjustment for the three months ended March 31, 2023 and a negative tail adjustment of ($19.1) million for the three months ended March 31, 2022.

* Less than 1% or not meaningful.

Results for the Three Months Ended March 31, 2023

Commissions and fees. Excluding the impact of tail revenue adjustments, commissions and fees decreased during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 primarily due to the Company's efforts to control growth in favor of developing more efficient lead procurement and conversion. There was no tail revenue adjustment recorded during the three months ended March 31, 2023 as annual renewals were largely in line with expectations. In comparison, a negative tail

adjustment of $19.1 million was recognized during the three months ended March 31, 2022 as a result of lower than expected renewals for policies approved in prior periods.

Other, net. Other, net decreased during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 primarily due to lower marketing development revenue earned, which was affected by lower approved policy volumes.

Contract acquisition costs. CAC decreased during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 as a result of lower sales volumes and lower per unit costs due to the Company's efforts to control growth in favor of developing more efficient lead procurement and conversion. In addition, a decline in the average number of e-TeleQuote employee agents in the first quarter of 2023 versus the first quarter 2022 contributed to the year-over-year reduction in CAC.

Other operating expenses. Other operating expenses during the three months ended March 31, 2023 did not change significantly as compared to the three months ended March 31, 2022.

Corporate and Other Distributed Products Segment Results. Corporate and Other Distributed Products segment results were as follows:


	Three months ended March 31,						Change
	2023			2022			$			%
	(Dollars in thousands)
Revenues:
Direct premiums	$	4,992		$	5,412		$	(420	)		(8	)%
Ceded premiums		(1,303	)		(1,439	)		(136	)		(9	)%
Net premiums		3,689			3,973			(284	)		(7	)%
Commissions and fees		8,710			12,627			(3,917	)		(31	)%
Investment income net of investment expenses		47,500			34,420			13,080			38	%
Interest expense on surplus note		(16,435	)		(15,515	)		920			6	%
Net investment income		31,065			18,905			12,160			64	%
Realized investment gains (losses)		(985	)		577			(1,562	)	*
Other investment gains (losses)		(3,623	)		174			(3,797	)	*
Investment gains (losses)		(4,608	)		751			(5,359	)	*
Other, net		1,199			1,117			82			7	%
Total revenues		40,055			37,373			2,682			7	%
Benefits and expenses:
Benefits and claims		4,327			1,881			2,446			130	%
Future policy benefits remeasurement (gain) loss		(477	)		162			(639	)	*
Amortization of DAC		362			408			(46	)		(11	)%
Insurance expenses		1,229			1,237			(8	)	*
Insurance commissions		240			282			(42	)		(15	)%
Sales commissions		4,146			5,952			(1,806	)		(30	)%
Interest expense		6,690			6,853			(163	)		(2	)%
Other operating expenses		39,481			37,232			2,249			6	%
Total benefits and expenses		55,998			54,007			1,991			4	%
Loss before income taxes	$	(15,943	)	$	(16,634	)	$	(691	)		(4	)%

* Less than 1% or not meaningful.

Results for the Three Months Ended March 31, 2023

Total revenues. Total revenues increased during the three months ended March 31, 2023 compared to the three months ended March 31, 2022 primarily due to higher net investment income. Net investment income increased $6.3million from higher yields in the invested asset portfolio, a $3.6 million higher return on the deposit asset backing our 10% coinsurance agreement and ~~$1.8~~$2.0 million from a larger invested asset portfolio compared to the same period in the prior ~~year period.~~year. Investment income net of investment expenses includes interest earned on our held-to-maturity asset, which is offset by interest expense on the surplus note (“Surplus ~~Note,~~Note”), thereby eliminating any impact on net investment income. Amounts recognized for each line item will remain offsetting and will fluctuate from period to period along with the principal amounts of the held-to-maturity asset and the Surplus Note based on the balance of reserves being contractually supported under a redundant reserve financing transaction used by Vidalia Re, Inc. (“Vidalia Re”). For more information on the Surplus Note, see Note 3 (Investments) and Note 1215 (Debt) to our unaudited condensed consolidated financial statements included elsewhere in this report.

Investment gains (losses) decreased to a loss during the three months ended ~~September 30, 2022~~March 31, 2023 compared to a gain ~~in the same period in 2021 primarily due to a $2.9 million negative mark-to-market adjustment on equity securities held within our investment~~

~~portfolio~~ during the three months ended ~~September 30,~~March 31, 2022 primarily due to a $2.2 million credit loss recognized for debt securities associated with a specific issuer that we have designated our intent to sell as well as a ~~result of market volatility compared to a $0.4~~$1.5 million negative mark-to-market adjustment on equity securities held within our investment portfolio ~~in the comparable 2021 period.~~

~~Other, net revenues increased~~ during the three months ended ~~September 30, 2022~~March 31, 2023.

Commissions and fees earned from our mortgage distribution business were lower during the three months ended March 31, 2023 compared to the same period in 2021 primarily due to differences in the timing of negotiated marketing development revenue in our Senior Health segment. Also contributing to the increase in Other, net revenues was an increase in fees receivedthree months ended March 31, 2022 as higher mortgage interest rates reduced demand for ~~access to Primerica Online ("POL"), our primary sales force support tool, consistent with subscriber growth.~~mortgage products.

Total benefits and expenses. Total benefits and expenses increased during the three months ended ~~September 30, 2022~~March 31, 2023 compared to the three months ended ~~September 30, 2021 largely~~March 31, 2022 due primarily to ~~a non-cash goodwill impairment charge~~volatility in direct claims and ceded claim reimbursements on closed blocks of ~~$60.0 million, which represents the excess of the Senior Health reporting unit's carrying value over its estimated fair value at July 1, 2022. Also contributing to the~~business in our New York life insurance subsidiary. Partially offsetting this increase ~~in benefits and expenses was growth in amortization of DAC as a result of lower year-over-year persistency in the Term Life Insurance segment’s in-force book of business. These increases~~ were ~~partially offset by~~ lower sales commissions in line with commissions and fees revenue decreases in our Investment and Savings Products segment as discussed above, lower COVID-19 claims experience in the Term Life Insurance segment and lower contract acquisition costs in our Senior Health segment. Other operating expenses were also lower due to non-recurring transaction-related expenses incurred in connection with the acquisition of e-TeleQuote in the 2021 period.

~~Income taxes.~~ ~~Our effective income tax rate~~ for the three months ended September 30, 2022 was 39.7%, compared with 24.2% for the three months ended September 30, 2021. The increase in the effective tax rate in the 2022 period is driven by the non-cash goodwill impairment charge that is not deductible for income tax purposes. Excluding the non-cash goodwill impairment charge, the effective income tax rate for the three months ended September 30, 2022 was 23.4%, which was lower than the 2021 effective rate due to state income tax benefits generated by e-TeleQuote in the current year.

~~Results for the Nine Months Ended September 30, 2022~~

~~Total revenues.~~ Total revenues increased during the nine months ended September 30, 2022 compared to the same period in 2021 primarily driven by growth in net premiums in the Term Life segment. The increase in Term Life net premiums was driven by incremental premiums on term life insurance policies that are not subject to the IPO coinsurance transactions as well as the layering effect of sales of life insurance. Commissions and fees earned during the nine months ended September 30, 2022 compared to the same period in 2021 decreased due to lower sales-based revenues driven by lower demand for variable annuity and mutual funds investment products.

Net investment income increased during the nine months ended September 30, 2022 compared to the same period in 2021 due to $3.5 million from higher yields in the invested asset portfolio and $4.2 million from a larger invested asset portfolio compared to the prior year period. These increases were partially offset by a lower total return on the deposit asset backing the 10% coinsurance agreement that is subject to deposit method accounting. The $3.8 million year-over-year lower total return on this deposit asset was due to a negative mark-to-market adjustment and lower book earnings on the deposit asset during the current year period compared to the prior year period.

Investment gains (losses) decreased to a loss during the nine months ended September 30, 2022 compared to a gain in the same period in 2021 primarily due to a $4.7 million negative mark-to-market adjustment on equity securities held within our investment portfolio during the nine months ended September 30, 2022 as a result of market volatility compared to a $1.1 million positive mark-to-market adjustment on equity securities held within our investment portfolio in the comparable 2021 period.

~~Other, net revenues increased during the nine months ended September 30, 2022 compared to the same period in 2021 primarily due to the same factors as discussed in the three month comparison above.~~

~~Total benefits and expenses.~~ Total benefits and expenses increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 largely due to growth in amortization of DAC as a result of lower year-over-year persistency in the Term Life Insurance segment’s in-force book of business, as well as negative market performance of the funds underlying our Canadian segregated funds product in the Investment and Savings Products segment. Also contributing to the increase was a non-cash goodwill impairment charge of $60.0 million, which represents the excess of the Senior Health reporting unit's carrying value over its estimated fair value at July 1, 2022 and higher contract acquisition costs as a result of the acquisition of e-TeleQuote on July 1, 2021. Insurance and other operating expenses were higher in the nine months ended September 30, 2022 due to growth in the business and higher costs associated with sales force leadership events, which included the biennial convention held in 2022. These increases were partially offset by lower COVID-19 related claims experience in the Term Life Insurance segment and lower sales commissions in line with commissions and fees revenue decreases in our Investment and Savings Products segment as discussed above.

~~Income taxes.~~ Our effective income tax rate for the nine months ended September 30, 2022 was 27.6% compared with 24.1% for the nine months ended September 30, 2021. The higher rate was primarily driven by the same factor discussed above in the three-month comparison. Excluding the non-cash goodwill impairment charge the effective income tax rate for the nine months ended September

~~30, 2022 was 23.3%, which was lower than the 2021 effective rate due to state income tax benefits generated by e-TeleQuote in the current year.~~

~~For additional information, see the Segment Results discussions below.~~

~~Segment Results~~

~~Term Life Insurance Segment Results.~~ ~~Our results for the Term Life Insurance segment were as follows:~~

Three months ended September 30,

Change

Nine months ended September 30,

Change

2022

2021

$

%

2022

2021

$

%

(Dollars in thousands)

Revenues:

Direct premiums

$
804,586

$
779,490

$
25,096

3
%

$
2,401,293

$
2,310,504

$
90,789

4
%
Ceded premiums

(403,416
)

(399,835
)

3,581

1
%

(1,219,268
)

(1,206,413
)

12,855

1
%
Net premiums

401,170

379,655

21,515

6
%

1,182,025

1,104,091

77,934

7
%
Allocated investment income

13,241

9,320

3,921

42
%

36,973

26,324

10,649

40
%
Other, net

13,419

12,476

943

8
%

37,969

36,601

1,368

4
%
Total revenues

427,830

401,451

26,379

7
%

1,256,967

1,167,016

89,951

8
%
Benefits and expenses:

Benefits and claims

167,356

179,696

(12,340
)

(7
)%

499,237

521,148

(21,911
)

(4
)%
Amortization of DAC

88,275

59,287

28,988

49
%

249,826

174,106

75,720

43
%
Insurance expenses

56,471

50,534

5,937

12
%

173,072

145,160

27,912

19
%
Insurance commissions

3,964

4,345

(381
)

(9
)%

11,612

13,999

(2,387
)

(17
)%
Total benefits and expenses

316,066

293,862

22,204

8
%

933,747

854,413

79,334

9
%
Income before income taxes

$
111,764

$
107,589

$
4,175

4
%

$
323,220

$
312,603

$
10,617

3
%

~~Results for the Three Months Ended September 30, 2022~~

~~Net premiums.~~ Direct premiums increased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 largely due to sales of new policies that contributed to growth in the in-force book of business. This was partially offset by an increase in ceded premiums, which includes $14.7 million in higher non-level YRT reinsurance ceded premiums as business not subject to the IPO coinsurance transactions ages, reduced by $11.1 million in lower coinsurance ceded premiums due to the run-off of business subject to the IPO coinsurance transactions.

~~Allocated investment income.~~ Allocated investment income increased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 due to an increase in the assumed net interest accreted to the Term Life Insurance segment’s future policy benefit reserve liability less deferred acquisition costs as the Term Life Insurance segment’s in-force business continues to grow.

~~Benefits and claims.~~ Benefits and claims decreased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 primarily due to lower excess claims experience. Total benefits and claims during the three months ended September 30, 2022 included approximately $2 million of excess claims, net of reinsurance, compared to approximately $14 million of excess claims, net of reinsurance, during the three months ended September 30, 2021 primarily due to fewer COVID-19 related claims.

~~Amortization of DAC.~~ The amortization of DAC increased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 primarily due to changes in policy lapse rates. During the three months ended September 30, 2022, lapses on policies and the resulting amortization of DAC have largely normalized to pre-pandemic levels, other than policies that were issued in the first year of the COVID-19 pandemic, which continue to experience lapse rates that are higher than historical trends.

~~Insurance expenses.~~Insurance expenses increased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 due to higher costs associated with supporting growth in the sales force, growth in the business and higher employee compensation costs from annual merit increases.

~~Results for the Nine Months Ended September 30, 2022~~

~~Net premiums.~~ Direct premiums increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 largely due to sales of new policies that contributed to growth in the in-force book of business. This is partially offset by an increase in ceded premiums, which includes $44.4 million in higher non-level YRT reinsurance ceded premiums as business not subject to the IPO coinsurance transactions ages, reduced by $31.6 million in lower coinsurance ceded premiums due to the run-off of business subject to the IPO coinsurance transactions.

~~Allocated investment income.~~ Allocated investment income increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 due to the same factors as described in the three-month comparison.

~~Benefits and claims.~~ Benefits and claims decreased during the nine months ended September 30, 2022 compared to the same period in 2021 primarily due to lower claims experience. Total benefits and claims during the nine months ended September 30, 2022 includes approximately $14 million of excess claims, net of reinsurance compared to approximately $43 million of excess claims, net of reinsurance, during the nine months ended September 30, 2021 primarily due to fewer COVID-19 related claims.

~~Amortization of DAC.~~ The amortization of DAC increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 due to the same factors as described in the three-month comparison.

~~Insurance expenses.~~ Insurance expenses increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 due to the same factors as discussed in the three month comparison above. Also contributing to the increase were higher costs associated with adding the previously postponed biennial convention to our normal cycle of sales force leadership events.

~~Insurance commissions.~~Insurance commissions decreased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 as a result of higher non-deferrable sales force promotional activities offered in the 2021 period to incentivize the sales force during the 2020 COVID-19 pandemic.

~~Investment and Savings Products Segment Results.Investment and Savings Products segment results were as follows:~~

Three months ended September 30,

Change

Nine months ended September 30,

Change

2022

2021

$

%

2022

2021

$

%

(Dollars in thousands)

Revenues:

Commissions and fees:

Sales-based revenues

$
67,962

$
95,229

$
(27,267
)

(29
)%

$
259,905

$
298,057

$
(38,152
)

(13
)%
Asset-based revenues

107,483

113,558

(6,075
)

(5
)%

328,696

323,288

5,408

2
%
Account-based revenues

22,910

21,456

1,454

7
%

67,043

64,424

2,619

4
%
Other, net

3,342

3,094

248

8
%

9,508

9,001

507

6
%
Total revenues

201,697

233,337

(31,640
)

(14
)%

665,152

694,770

(29,618
)

(4
)%
Expenses:

Amortization of DAC

2,222

2,580

(358
)

(14
)%

11,610

7,641

3,969

52
%
Insurance commissions

3,419

3,747

(328
)

(9
)%

10,514

11,065

(551
)

(5
)%
Sales commissions:

Sales-based

48,775

67,745

(18,970
)

(28
)%

186,784

209,969

(23,185
)

(11
)%
Asset-based

51,549

53,233

(1,684
)

(3
)%

155,791

150,587

5,204

3
%
Other operating expenses

37,355

36,664

691

2
%

118,540

111,623

6,917

6
%
Total expenses

143,320

163,969

(20,649
)

(13
)%

483,239

490,885

(7,646
)

(2
)%
Income before income taxes

$
58,377

$
69,368

$
(10,991
)

(16
)%

$
181,913

$
203,885

$
(21,972
)

(11
)%

~~Results for the Three Months Ended September 30, 2022~~

~~Commissions and fees.~~ Commissions and fees decreased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 driven by lower sales-based revenues as investor demand for mutual fund products and variable annuity products weakened due to continued volatility in capital markets. Also contributing to the decrease were lower asset-based revenues, driven by negative equity market performance, partially offset by positive net flows.

~~Amortization of DAC.~~Amortization of DAC was relatively consistent during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 due to similar market performance of the funds underlying our Canadian segregated funds product during both periods.

~~Sales commissions.~~ The decrease in sales-based commissions for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 was generally in-line with the decrease in sales-based revenue. The decrease in asset-based commissions for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 was consistent with movement in asset-based revenue, excluding Canadian segregated funds revenue. Asset-based expenses for our Canadian segregated funds are reflected within insurance commissions and amortization of DAC.

~~Other operating expenses.~~ ~~Other operating expenses remained relatively consistent during the three months ended September 30, 2022 compared to the three months ended September 30, 2021.~~

~~Results for the Nine Months Ended September 30, 2022~~

~~Commissions and fees.~~ Commissions and fees decreased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 driven by lower sales-based revenues in the 2022 period as investor demand for mutual fund products and variable annuity products weakened due to volatility in capital markets. This decrease was partially offset by higher asset-based revenues largely driven by higher average client asset values on managed accounts.

~~Amortization of DAC.~~ Amortization of DAC increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 due to unfavorable market performance of the funds underlying our Canadian segregated funds product in the first half of 2022 compared to favorable market performance of such funds in the first half of 2021.

~~Sales commissions.~~ The decrease in sales-based commissions for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was generally in-line with the decrease in sales-based revenue. The increase in asset-based commissions for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was consistent with the increase in asset-based revenues, excluding Canadian segregated funds revenue. Asset-based expenses for our Canadian segregated funds are reflected within insurance commissions and amortization of DAC.

~~Other operating expenses.~~ Other operating expenses increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 due to higher costs associated with adding the previously postponed biennial convention to our normal cycle of sales force leadership events.

~~Senior Health Segment Results.~~ ~~Senior Health segment results were as follows:~~

Three months ended September 30,

Change

Nine months ended September 30,

Change

2022

2021

$

%

2022

2021

$

%

(Dollars in thousands)
Revenues:

Commissions and fees (1)

$
14,601

$
21,558

$
(6,957
)

(32
)%

$
25,222

$
21,558

*

*
Other, net

2,583

1,378

1,205

87
%

9,606

1,378

*

*
Total revenues

17,184

22,936

(5,752
)

(25
)%

34,828

22,936

*

*

Benefits and expenses:

Contract acquisition costs

13,446

$
23,524

$
(10,078
)

(43
)%

53,479

$
23,524

*

*
Goodwill impairment loss

60,000

-

60,000

*

60,000

-

*

*
Other operating expenses

7,461

7,902

(441
)

(6
)%

24,308

7,902

*

*
Total benefits and expenses

80,907

31,426

49,481

157
%

137,787

31,426

*

*
Loss before income taxes

$
(63,723
)

$
(8,490
)

$
55,233

651
%

$
(102,959
)

$
(8,490
)

*

*

~~(1)~~

Includes a positive tail revenue adjustment of $1.7 million for the three months ended September 30, 2022 and a net negative tail adjustment of ($22.7) million for the nine months ended September 30, 2022.

* Not meaningful.

~~Results for the Three Months Ended September 30, 2022~~

~~Commissions and fees.~~ Commissions and fees decreased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021. Contributing to the decrease were lower LTVs in 2022 as a result of lower-than-expected persistency and refined renewal estimates. In addition, lower LTVs led us to deliberately limit agent counts at e-TeleQuote in 2022, which resulted in lower sales volumes. Partially offsetting the decrease was the recognition of a $1.7 million positive tail revenue adjustment in 2022 due to renewal rate escalations communicated by health insurance carriers during the quarter. Conversely, no tail adjustment was recognized in 2021.

~~Other, net.~~ Other, net increased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 primarily due to the timing of negotiated marketing development revenue with certain health insurance carriers. The agreements for marketing development revenue are generally short-term in nature and can vary from period to period.

~~Contract acquisition costs.~~ Contract acquisition costs, as well as per policy contract acquisition costs, decreased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 as a result of revised lead sourcing strategies, lessened competition for leads, and lower overall sales volume in the 2022 period.

~~Goodwill impairment loss.~~ Reflects the non-cash goodwill impairment charge recognized during the three months ended September 30, 2022, which represents the excess of the Senior Health reporting unit's carrying value over its estimated fair value as of July 1, 2022. Refer to Note 15 (Goodwill) to our condensed consolidated financial statements included elsewhere in this report for more information.

~~Results for the Nine Months Ended September 30, 2022~~

~~Commissions and fees.~~ Commissions and fees increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the timing of the acquisition of e-TeleQuote on July 1, 2021. The 2022 period includes nine months of operations compared to only three months for the 2021 period. This was largely offset by the recognition of a net $22.7 million of negative tail revenue adjustments during the nine months ended September 30, 2022 as a result of lower-than-expected renewals and refined renewal estimates on policies approved during prior periods. The negative tail adjustment offset commissions and fees revenue of $47.9 million recognized for the lifetime value of commissions for policies approved during the nine months ended September 30, 2022. No tail adjustment was recognized in 2021. The increase in commissions and fees during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was partially offset by the volume and LTV factors described in the three-month comparison above.

~~Other, net.~~ Other, net increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the timing of the acquisition of e-TeleQuote on July 1, 2021. The 2022 period includes nine months of operations compared to only three months for the 2021 period.

~~Contract acquisition costs.~~ Contract acquisition costs increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the timing of the acquisition of e-TeleQuote on July 1, 2021. The 2022 period includes nine months of operations compared to only three months for the 2021 period. This increase was partially offset by the same factors as described in the three-month comparison above.

~~Goodwill impairment loss.~~ ~~Reflects the non-cash goodwill impairment charge recognized during the nine months ended September 30, 2022.~~

~~Other operating expenses.~~ Other operating expenses increased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the timing of the acquisition of e-TeleQuote on July 1, 2021. The 2022 period includes nine months of operations compared to only three months for the 2021 period. Other operating expenses includes $8.2 million and $2.9 million of amortization expense for intangible assets and internally developed software for the nine months ended September 30, 2022 and 2021, respectively.

~~Corporate and Other Distributed Products Segment Results.~~ ~~Corporate and Other Distributed Products segment results were as follows:~~

Three months ended September 30,

Change

Nine months ended September 30,

Change

2022

2021

$

%

2022

2021

$

%

(Dollars in thousands)

Revenues:

Direct premiums

$
5,493

$
5,787

$
(294
)

(5
)%

$
16,346

$
17,300

$
(954
)

(6
)%
Ceded premiums

(1,454
)

(1,460
)

(6
)

*

(4,536
)

(4,704
)

(168
)

(4
)%
Net premiums

4,039

4,327

(288
)

(7
)%

11,810

12,596

(786
)

(6
)%
Commissions and fees

��
12,512

17,995

(5,483
)

(30
)%

37,090

47,202

(10,112
)

(21
)%
Investment income net of investment expenses

27,388

26,421

967

4
%

75,175

80,646

(5,471
)

(7
)%
Interest expense on surplus note

(16,283
)

(15,741
)

542

3
%

(47,613
)

(46,382
)

1,231

3
%
Net investment income

11,105

10,680

425

4
%

27,562

34,264

(6,702
)

(20
)%
Realized investment gains (losses)

292

1,730

(1,438
)

*

924

3,762

(2,838
)

*

Other investment gains (losses)

(2,991
)

(320
)

(2,671
)

*

(4,765
)

114

(4,879
)

*

Investment gains (losses)

(2,699
)

1,410

(4,109
)

*

(3,841
)

3,876

(7,717
)

*

Other, net

1,621

1,103

518

47
%

3,626

2,978

648

22
%
Total revenues

26,578

35,515

(8,937
)

(25
)%

76,247

100,916

(24,669
)

(24
)%
Benefits and expenses:

Benefits and claims

3,937

3,729

208

6
%

12,382

14,413

(2,031
)

(14
)%
Amortization of DAC

428

347

81

23
%

931

857

74

9
%
Insurance expenses

1,081

1,367

(286
)

(21
)%

3,449

4,086

(637
)

(16
)%
Insurance commissions

283

320

(37
)

(12
)%

856

926

(70
)

(8
)%
Sales commissions

5,591

8,290

(2,699
)

(33
)%

17,027

21,909

(4,882
)

(22
)%
Interest expense

6,802

7,529

(727
)

(10
)%

20,469

21,814

(1,345
)

(6
)%
Other operating expenses

28,975

35,298

(6,323
)

(18
)%

97,104

100,034

(2,930
)

(3
)%
Total benefits and expenses

47,097

56,880

(9,783
)

(17
)%

152,218

164,039

(11,821
)

(7
)%
Loss before income taxes

$
(20,519
)

$
(21,365
)

$
(846
)

(4
)%

$
(75,971
)

$
(63,123
)

$
12,848

20
%

* Less than 1% or not meaningful.

~~Results for the Three Months Ended September 30, 2022~~

~~Total revenues.~~ ~~Total revenues decreased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 primarily due to lower commissions and fees from~~ our mortgage distribution business as a result of ~~rising interest rates. Also contributing to the decrease is investment losses, which are discussed in the Primerica, Inc. and Subsidiaries Results of Operations section above.~~

~~Total benefits and expenses.~~ ~~Total benefits and expenses decreased during the three months ended September 30, 2022 compared to the three months ended September 30, 2021 due to~~ lower sales commissions from our mortgage distribution business during the three months ended September 30, 2022. Other operating expenses also decreased due to the 2021 period including approximately $10 million of non-recurring transaction-related expenses incurred in connection with the acquisition of e-TeleQuote, partially offset by higher other operating expenses due to the growth of employee-related expenses.

~~Results for the Nine Months Ended September 30, 2022~~

~~Total revenues.~~ Total revenues decreased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the same factors discussed in the three-month comparison and a decrease in net investment income as more net investment income was allocated to the Term Life Insurance segment.

~~Total benefits and expenses.~~ Total benefits and expenses decreased during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to the same factors discussed in the three-month comparison and lower benefits and claims experienced on closed blocks of non-term life insurance business underwritten by NBLIC.volumes.

Financial Condition

Investments. Our insurance business is primarily focused on selling term life insurance, which does not include an investment component for the policyholder. The invested asset portfolio funded by premiums from ~~the~~our term life insurance business does not involve the substantial asset accumulations and spread requirements that exist with other non-term life insurance products. As a result, the profitability of ~~the~~our term life insurance business is not as sensitive to the impact that interest rates have on our invested asset portfolio and investment income as the profitability of other companies that distribute non-term life insurance products.

We follow a conservative investment strategy designed to emphasize the preservation of our invested assets and provide adequate liquidity for the prompt payment of claims. To meet business needs and mitigate risks, our investment guidelines provide restrictions on our portfolio’s composition, including limits on asset type, per issuer limits, credit quality limits, portfolio duration, limits on the amount of investments in approved countries and permissible security types. We also manage and monitor our allocation of investments to limit the accumulation of any disproportionate concentrations of risk among industry sectors or issuer countries outside of the U.S. and Canada. In addition, as of ~~September 30, 2022,~~March 31, 2023, we did not hold any country of issuer concentrations outside of the U.S. or Canada that represented more than 5% of the fair value of our available-for-sale invested asset portfolio or any industry concentrations of corporate bonds that represented more than 10% of the fair value of our available-for-sale invested asset portfolio.

We invest a portion of our portfolio in assets denominated in Canadian dollars to support our Canadian operations. Additionally, to ensure adequate liquidity for payment of claims, we take into account the maturity and duration of our invested asset portfolio and our general liability profile.

We also hold within our invested asset portfolio a credit enhanced note (“LLC Note”) issued by a limited liability company owned by a third-party service provider which is classified as a held-to-maturity security. The LLC Note, which is scheduled to mature on December 31, 2030, was obtained in exchange for the Surplus Note of equal principal amount issued by Vidalia ~~Re.~~Re, a special purpose financial captive insurance company and wholly owned subsidiary of Primerica Life. For more information on the LLC Note, see Note 3 (Investments) to our unaudited condensed consolidated financial statements included elsewhere in this report.

We have an investment committee composed of members of our senior management team that is responsible for establishing and maintaining our investment guidelines and supervising our investment activity. Our investment committee regularly monitors our overall investment results and our compliance with our investment objectives and guidelines. We use a third-party investment advisor to assist us in the management of our investing activities. Our investment advisor reports to our investment committee.

Our invested asset portfolio is subject to a variety of risks, including risks related to general economic conditions, market volatility, interest rate fluctuations, liquidity risk and credit and default risk. Investment guideline restrictions have been established to minimize the effect of these risks but may not always be effective due to factors beyond our control. Interest rates and credit spreads are highly sensitive to many factors, including governmental monetary policies, domestic and international economic and political conditions and other factors beyond our control. A significant increase in interest rates or credit spreads could result in significant losses in the value of our invested asset portfolio. For example, the significant increase in interest rates during the nine months ended September 30, 2022 resulted in the invested asset portfolio having an unrealized loss of $321.0 million as of September 30, 2022 compared to an unrealized gain of $81.2 million as of December 31, 2021. We believe that fluctuations caused by movement in interest rates and

credit spreads generally have little bearing on the recoverability of our investments as we have the ability to hold these investments until maturity or a market price recovery and we have no present intention to dispose of them.

Details on asset mix (excluding our held-to-maturity security) were as follows:


	September 30, 2022	December 31, 2021	March 31, 2023	December 31, 2022
Average rating of our fixed-maturity portfolio	A	A	A	A
Average duration of our fixed-maturity portfolio	4.8 years	4.8 years	4.8 years	4.7 years
Average book yield of our fixed-maturity portfolio	3.34%	3.12%	3.57%	3.44%

The distribution of fixed-maturity securities in our investment portfolio (excluding our held-to-maturity ~~security)~~security and short-term investments) by rating, including those classified as trading securities, were as follows:

September 30, 2022

December 31, 2021

Amortized cost (1)

%

Amortized cost (1)

%

(Dollars in thousands)

AAA

$
597,966

21
%

$
495,055

19
%
AA

308,333

11
%

312,418

12
%
A

640,533

23
%

644,775

24
%
BBB

1,116,851

40
%

1,079,123

41
%
Below investment grade

76,395

3
%

93,294

4
%
Not rated

42,655

2
%

21,078

*

Total

$
2,782,733

100
%

$
2,645,743

100
%


	March 31, 2023					December 31, 2022
	Amortized cost (1)		%			Amortized cost (1)		%
	(Dollars in thousands)
AAA	$	591,882		21	%	$	606,982		22	%
AA		319,979		11	%		321,450		11	%
A		709,522		25	%		688,936		25	%
BBB		1,151,885		41	%		1,120,096		40	%
Below investment grade		63,351		2	%		67,450		2	%
Not rated		4,874	*				199	*
Total	$	2,841,493		100	%	$	2,805,113		100	%

(1)

Includes trading securities at fair value and available-for-sale securities (excluding short-term investments) at amortized cost.

* Less than 1%.

The ten largest holdings within our fixed-maturity securities invested asset portfolio (excluding our held-to-maturity ~~security)~~security and short-term investments) were as follows:


	September 30, 2022										March 31, 2023
Issuer	Fair value			Amortized cost (1)			Unrealized gain (loss)			Credit rating	Fair value			Amortized cost (1)			Unrealized gain (loss)			Credit rating
	(Dollars in thousands)										(Dollars in thousands)
Government of Canada	$	14,733		$	15,991		$	(1,258	)	AAA	$	20,934		$	22,148		$	(1,214	)	AAA
Province of Ontario Canada												15,066			15,343			(277	)	A+
Province of Quebec Canada		14,271			14,935			(664	)	A+		14,644			14,922			(278	)	AA-
Province of Ontario Canada		13,629			14,274			(645	)	AA
Bank of America Corp												12,985			13,177			(192	)	A-
Ontario Teachers' Pension Plan												12,832			14,333			(1,501	)	AA+
Province of Alberta Canada		10,684			11,729			(1,045	)	BBB+		12,068			12,831			(763	)	A+
Enbridge Inc		10,356			11,320			(964	)	BBB+
Morgan Stanley												11,485			11,807			(322	)	BBB+
Wells Fargo & Co												11,043			11,291			(248	)	BBB+
Manulife Financial Corp		10,274			11,538			(1,264	)	A		10,775			11,600			(825	)	A
Province of British Columbia Canada		9,067			9,513			(446	)	AA+
ConocoPhillips		8,932			10,695			(1,763	)	A
TC Energy Corp		8,869			10,579			(1,710	)	BBB+		10,342			11,644			(1,302	)	BBB+
Ontario Teachers' Pension Plan		8,507			10,205			(1,698	)	AA+
Total – ten largest holdings	$	109,322		$	120,779		$	(11,457	)		$	132,174		$	139,096		$	(6,922	)
Total – fixed-maturity securities	$	2,461,707		$	2,782,733						$	2,577,123		$	2,841,493
Percent of total fixed-maturity securities		4	%		4	%						5	%		5	%

(1)

Includes trading securities at ~~fair~~carrying value and available-for-sale securities (excluding short-term investments) at amortized cost.

For additional information on our invested asset portfolio, see Note 3 (Investments) to our unaudited condensed consolidated financial statements included elsewhere in this report.

Liquidity and Capital Resources

Dividends and other payments to the Parent Company from its subsidiaries are our principal sources of cash. The amount of dividends paid by the subsidiaries is dependent on their capital needs to fund future growth and applicable regulatory restrictions. The primary uses of funds by the Parent Company include the payments of stockholder dividends, interest on notes payable, general operating expenses, and income taxes, as well as repurchases of shares of our common stock outstanding. As of ~~September 30, 2022,~~March 31, 2023, the Parent Company had cash and invested assets of ~~$239.7~~$329.7 million.

The Parent Company’s subsidiaries generate operating cash flows primarily from term life insurance premiums (net of premiums ceded to reinsurers), income from invested assets, commissions and fees collected from the distribution of investment and savings products, Medicare-related insurance plans as well as other financial products. The subsidiaries’ principal operating cash outflows include the payment of insurance claims and benefits (net of ceded claims recovered from reinsurers), commissions to the sales force, contract acquisition costs, insurance and other operating expenses, interest expense for future policy benefit reserves financing transactions, and income taxes.

The distribution and underwriting of term life insurance requires upfront cash outlays at the time the policy is issued as we pay a substantial majority of the sales commission during the first year following the sale of a policy and incur costs for underwriting

activities at the inception of a policy’s term. During the early years of a policy’s term, we generally receive level term premiums in excess of claims paid. We invest the excess cash generated during earlier policy years in fixed-maturity and equity securities held in support of future policy benefit reserves. In later policy years, cash received from the maturity or sale of invested assets is used to pay claims in excess of level term premiums received.

e-TeleQuote is a senior health insurance distributor of Medicare-related insurance plans. ~~e-Tele-Quote~~e-TeleQuote collects cash receipts over a number of years after selling a plan, while the cash outflow for commission expense and other acquisition costs to sell the plans are generally recognized at the time of enrollment. Therefore, in periods of growth, net cash flows at e-TeleQuote are expected to be negative, ~~with~~which may require the Parent Company ~~providing~~to provide working capital to e-TeleQuote.During the ~~first nine~~three months ~~of 2022, as a result of the Company’s efforts to scale back growth in favor of developing more efficient lead procurement and limiting the agent count,~~ended March

31, 2023, the Parent Company did not provide funding to e-TeleQuote as e-TeleQuote generated sufficient cash ~~tax benefits~~to fund its operations from ~~net operating losses were sufficient to cover operating needs.~~the receipt of initial commissions payments for policies approved during AEP period.

Historically, cash flows generated by our businesses, primarily from ~~the~~our existing block of term life policies and our investment and savings products, have provided us with sufficient liquidity to meet our operating requirements. ~~We have maintained strong cash flows despite the COVID-19 pandemic due to strong persistency and reinsurance on ceded mortality claims.~~ We anticipate that cash flows from our businesses will continue to provide sufficient operating liquidity over the next 12 months.

If necessary, we could seek to enhance our liquidity position or capital structure through sales of our available-for-sale investment portfolio, changes in the timing or amount of share repurchases, borrowings against our ~~revolving credit facility, sales of common stock or debt instruments in the capital markets~~Revolving Credit Facility, or some combination of these sources. Additionally, we believe that cash flows from our businesses and potential sources of funding will sufficiently support our long-term liquidity needs.

Cash Flows. The components of the changes in cash and cash equivalents were as follows:


	Nine months ended September 30,						Change			Three months ended March 31,						Change
	2022			2021			$			2023			2022			$
	(In thousands)									(In thousands)
Net cash provided by (used in) operating activities	$	551,278		$	435,121		$	116,157		$	175,946		$	214,299		$	(38,353	)
Net cash provided by (used in) investing activities		(96,791	)		(722,557	)		625,766			(31,186	)		(112,672	)		81,486
Net cash provided by (used in) financing activities		(405,296	)		62,275			(467,571	)		(118,992	)		(134,571	)		15,579
Effect of foreign exchange rate changes on cash		(3,667	)		3,170			(6,837	)		82			222			(140	)
Change in cash and cash equivalents	$	45,524		$	(221,991	)	$	267,515		$	25,850		$	(32,722	)	$	58,572

Operating Activities. ~~Cash~~The largest factor driving the decrease in cash provided by operating activities during the ~~nine~~three months ended ~~September 30, 2022 increased~~March 31, 2023 compared to the ~~nine~~three months ended ~~September 30, 2021. Although net income decreased during the nine months ended September 30,~~March 31, 2022 ~~cash generated from operating activities increased as it excludes non-cash charges such as goodwill impairments, amortization~~was timing differences of ~~deferred policy acquisition costs~~purchases and ~~renewal commission tail adjustments.~~maturities of trading securities. Also contributing to the year-over-year ~~increase~~decrease in cash provided by operating activities were ~~lower deferred acquisition costs due to lower term life insurance policy sales. In addition, cash provided by operating activities was higher~~differences in ~~2022 compared with 2021 due to~~ the timing of ~~purchases~~cash payments for direct claims and ~~maturities~~receipts of ~~trading securities.~~ceded claims from reinsurers.

Investing Activities. Cash used in investing activities during the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 decreased compared to the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 primarily due to ~~funding~~fluctuations in the ~~e-TeleQuote acquisition on July 1, 2021. Also contributing to the decrease was short-term investing activity. During the nine months ended September 30, 2022, short-term investments acquired~~timing of maturities and reinvestments of debt securities held in 2021 matured, which allowed these funds to be deployed for share repurchases. These movements were partially offset by lower sales of fixed-maturity securities during the nine months ended September 30, 2022 as the sharp increase in interest rates provided less attractive selling opportunities. By comparison, during 2021 the Company had higher sales of fixed-maturity securities in anticipation of funding the e-TeleQuote acquisition on July 1, 2021.our available-for-sale investment portfolio.

Financing Activities. Cash flows ~~from~~used in financing activities ~~was a use of cash~~decreased during the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 compared to ~~a source of cash in~~ the ~~nine~~three months ended ~~September 30, 2021. This movement is primarily~~March 31, 2022. In 2022, the Company paid amounts due on a note issued to the sellers of e-TeleQuote, which was the largest driver of the year-over-year decrease in cash used ~~to fund share repurchases during the 2022 period. By comparison, the Company paused share repurchases~~ in ~~2021 to accumulate cash and borrowed $125 million under the Revolving Credit Facility in anticipation of funding the e-TeleQuote acquisition on July 1, 2021.~~financing activities.

Risk-Based Capital (“RBC”). The National Association of Insurance Commissioners (“NAIC”) has established RBC standards for U.S. life insurers, as well as a risk-based capital model act (the “RBC Model Act”) that has been adopted by the insurance regulatory authorities. The RBC Model Act requires that life insurers annually submit a report to state regulators regarding their RBC based upon four categories of risk: asset risk; insurance risk; interest rate risk and business risk. The capital requirement for each is determined by applying factors that vary based upon the degree of risk to various asset, premiums and policy benefit reserve items. The formula is an early warning tool to identify possible weakly capitalized companies for purposes of initiating further regulatory action.

As of ~~September 30, 2022,~~March 31, 2023, our U.S. life insurance subsidiaries maintained statutory capital and surplus substantially in excess of the applicable regulatory requirements and remain well positioned to support existing operations and fund future growth.

In Canada, an insurer’s minimum capital requirement is overseen by the Office of the Superintendent of Financial Institutions (“OSFI”) ~~requires federally-regulated life insurance companies to maintain adequate capital in accordance with regulatory Capital Guidelines. The Capital Guidelines define~~ and ~~establish criteria and limits for determining an insurer’s required capital to support defined risks and~~determined as the ~~amount of qualifying regulatory available capital. In addition, OSFI requires companies to set internal target levels of capital sufficient to provide for all risks~~sum of the ~~insurer, including risks specified~~capital requirements for six categories of risk: asset default risk; mortality/morbidity/lapse/expense risks; changes in ~~OSFI’s Capital Guidelines.~~interest rate environment risk; operational risk; segregated funds risk; and foreign exchange risk. As of ~~September 30, 2022,~~March 31, 2023, Primerica Life ~~Insurance Company of~~ Canada ~~has satisfied its regulatory~~was in compliance with Canada's minimum capital ~~requirements.~~requirements as determined by OSFI.

Redundant Reserve Financings. The Model Regulation entitled Valuation of Life Insurance Policies, commonly known as Regulation XXX, requires insurers to carry statutory policy benefit reserves for term life insurance policies with long-term premium guarantees which are often significantly in excess of the future policy benefit reserves that insurers deem necessary to satisfy claim obligations (“redundant policy benefit reserves”). Accordingly, many insurance companies have sought ways to reduce their capital needs by financing redundant policy benefit reserves through bank financing, reinsurance arrangements and other financing transactions.

We have established Peach Re, Inc. (“Peach Re”) and Vidalia Re as special purpose financial captive insurance companies and wholly owned subsidiaries of Primerica Life. Primerica Life has ceded certain term life policies issued prior to 2011 to Peach Re as part of a Regulation XXX redundant reserve financing transaction ~~(the “Peach Re Redundant Reserve Financing Transaction”)~~ and has ceded certain term life policies issued in 2011 through 2017 to Vidalia Re as part of a Regulation XXX redundant reserve financing transaction (the “Vidalia Re Redundant Reserve Financing Transaction”). These redundant reserve financing transactions allow us to more efficiently manage and deploy our capital.

The NAIC has adopted a model regulation for determining reserves using a principle-based approach (“principle-based reserves” or “PBR”), which is designed to reflect each insurer’s own experience in calculating reserves and move away from a single prescriptive reserving formula. Primerica Life adopted PBR as of January 1, 2018 and ~~National Benefit Life Insurance Company~~NBLIC adopted the New York amended version of PBR effective January 1, 2021. PBR significantly reduced the redundant statutory policy benefit reserve requirements while still ensuring adequate liabilities are held. The regulation only applies for business issued after the effective date. See Note 4 (Investments), Note 10 (Debt) and Note 16 (Commitments and Contingent Liabilities) to our consolidated financial statements within our ~~2021~~2022 Annual Report for more information on these redundant reserve financing transactions.

Notes ~~Payable – Long term.~~Payable. The Company has $600.0 million of publicly-traded Senior Notes outstanding issued at a price of 99.550% with an annual interest rate of 2.80%, payable semi-annually in arrears on May 19 and November 19. The Senior Notes are scheduled to mature on November 19, 2031. We were in compliance with the covenants of the Senior Notes as of ~~September 30, 2022.~~March 31, 2023. No events of default occurred during the three ~~and nine~~ months ended ~~September 30, 2022.~~March 31, 2023.

Rating Agencies. There have been no changes to Primerica, Inc.’s Senior Notes ratings or Primerica Life’s financial strength ratings since December 31, ~~2021.~~2022.

Surplus Note. Vidalia Re issued ~~the~~a Surplus Note in exchange for the LLC Note as a part of the Vidalia Re Redundant Reserve Financing Transaction. The Surplus Note has a principal amount equal to the LLC Note and is scheduled to mature on December 31, 2030. For more information on the Surplus Note, see Note 1215 (Debt) to our unaudited condensed consolidated financial statements included elsewhere in this report.

Off-Balance Sheet Arrangements. We have no transactions, agreements or other contractual arrangements to which an entity unconsolidated with the Company is a party, under which the Company maintains any off-balance sheet obligations or guarantees as of ~~September 30, 2022.~~March 31, 2023.

Credit Facility Agreement. We maintain an unsecured $200.0 million Revolving Credit Facility with a syndicate of commercial banks that has a scheduled termination date of June 22, 2026. Amounts outstanding under the Revolving Credit Facility bear interest at a periodic rate equal to the ~~London Interbank Offered~~Secured Overnight Financing Rate (“~~LIBOR”~~SOFR”) orrate loan ,or the base rate, plus in either case an applicable margin. The Revolving Credit Facility contains language that allows for the Company and the lenders to agree on a comparable or successor reference rate in the event ~~LIBOR~~SOFR is no longer available. The Revolving Credit Facility also permits the issuance of letters of credit. The applicable margins are based on our debt rating with such margins for ~~LIBOR~~SOFR rate loans and letters of credit ranging from 1.000% to 1.625% per annum and for base rate loans ranging from 0.000% to 0.625% per annum. Under the Revolving Credit Facility, we incur a commitment fee that is payable quarterly in arrears and is determined by our debt rating. This commitment fee ranges from 0.100% to 0.225% per annum of the aggregate $200.0 million commitment of the lenders under the Revolving Credit ~~Facility.~~Facility that remains undrawn. During the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, no amounts were ~~drawn~~outstanding under the Revolving Credit Facility and we were in compliance with ~~the~~its covenants. Furthermore, no events of default occurred under the Revolving Credit Facility during the three ~~and nine~~ months ended ~~September 30, 2022.~~March 31, 2023.

Contractual Obligations Update. There have been no material changes in contractual obligations from those disclosed in the ~~2021~~2022 Annual Report.

5049

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

Investors are cautioned that certain statements contained in this report as well as some statements in periodic press releases and some oral statements made by our officials during our presentations are “forward-looking” statements. Forward-looking statements include, without limitation, any statement that may project, indicate or imply future results, events, performance or achievements, and may contain the words “expect”, “intend”, “plan”, “anticipate”, “estimate”, “believe”, “will be”, “will continue”, “will likely result”, and similar expressions, or future conditional verbs such as “may”, “will”, “should”, “would”, and “could”. In addition, any statement concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible actions taken by us or our subsidiaries are also forward-looking statements. These forward-looking statements involve external risks and uncertainties, including, but not limited to, those described under the section entitled “Risk Factors” included herein.

Forward-looking statements are based on current expectations and projections about future events and are inherently subject to a variety of risks and uncertainties, many of which are beyond the control of our management team. All forward-looking statements in this report and subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these risks and uncertainties. These risks and uncertainties include, among others:

Risks Related to Our Distribution Structure

•

Our failure to continue to attract new recruits, retain independent sales representatives or license or maintain the licensing of independent sales representatives would materially adversely affect our ~~business, financial condition and results of operations.~~business.

•

~~There are a number of~~Certain laws and regulations ~~that~~ could apply to our independent contractor distribution model, which could require us to modify our distribution structure.

•

There may be adverse ~~tax, legal or financial~~ consequences if the classification of our independent contractor ~~status of independent~~ sales representatives is ~~overturned.~~changed.

•

~~The Company’s, the independent sales representatives’, or the licensed health insurance agents’ violation~~Violation of, or non-compliance with, laws and regulations and related claims and proceedings could expose us to material liabilities.

•

Any failure to protect the confidentiality of client information could adversely affect our reputation and have a material adverse effect on our business, financial condition and results of operations.

Risks Related to Our Insurance Business and Reinsurance

•

Our life insurance business may face significant losses if our actual experience differs from our expectations regarding mortality or persistency.

•

Our life insurance business is highly regulated, and statutory and regulatory changes may materially adversely affect our ~~business, financial condition and results of operations.~~business.

•

A decline in the regulatory capital ratios of our insurance subsidiaries could result in increased scrutiny by insurance regulators and ratings agencies and have a material adverse effect on our ~~business, financial condition and results of operations.~~business.

•

A significant ratings downgrade by a ratings organization could materially adversely affect our ~~business, financial condition and results of operations.~~business.

•

The failure by any of our reinsurers or reserve financing counterparties to perform its obligations to us could have a material adverse effect on our ~~business, financial condition and results of operations.~~business.

Risks Related to Our Investments and Savings Products Business

•

Our Investment and Savings Products segment is heavily dependent on a limited platform of mutual fund and annuity products offered by a relatively small number of companies and ifmanagers. If these products fail to remain competitive with other investment options, ~~or we lose~~our business could be materially adversely affected.

•

If our relationship with one or more of ~~these companies,~~our funds, annuities or managers is significantly altered or terminated or there is a shift in
the business mix, our business ~~financial condition and results of operations may~~could be materially adversely affected.

•

~~The Company’s or the securities-licensed independent sales representatives’ violations~~Violations of, or non-compliance with, laws and regulations of the securities business could expose us to material liabilities.

•

If heightened standards of conduct or more stringent licensing requirements ~~such~~(such as those adopted by the Securities and Exchange ~~Commission (“SEC”)~~Commission) and ~~those proposed or adopted by~~ the Department of Labor, ~~(“DOL”),~~ state legislatures or regulators or Canadian securities ~~and insurance~~ regulators, are imposed on us or the independent sales representatives, or selling compensation is reduced as a result of new legislation or regulations, it could have a material adverse effect on our ~~business, financial condition and results of operations.~~business.

•

If our suitability policies and procedures, or our policies and procedures for compliance with federal, state or provincial regulations governing standards of care, were deemed inadequate, it could have a material adverse effect on our ~~business, financial condition and results of operations.~~business.

•

Non-compliance with applicable regulations could lead to revocation of our subsidiary's status as a non-bank ~~custodian.~~

~~Risks Related to Our Mortgage Distribution Business~~

•

~~Licensing requirements will impact the size of the mortgage loan sales force.~~

•

Our mortgage distribution business is highly regulated and subject to various federal, state and provincial laws and regulations in the U.S. and Canada. Changes in, non-compliance with, or violations of, such laws and regulationscustodian, which could have a material adverse affect ~~the cost or~~on our ~~ability to distribute our products and could materially adversely affect our business, financial condition and results of operations.~~business.

Risks Related to e-TeleQuote’s Senior Health Insurance Distribution Business

•

Due to our ~~very~~ limited history with e-TeleQuote Insurance, Inc. (“e-TeleQuote”), we ~~cannot~~may not be ~~certain that its~~able to execute an effective business strategy, ~~will be successful or that we will successfully address the risks below or any other risks not now known to us that may become material.~~which could adversely affect our business.

•

e-TeleQuote is highly regulated and subject to compliance requirements of the ~~United States~~U.S. government’s Centers for Medicare and Medicaid Services ~~(“CMS”)~~ and those of its carrier partners. Non-compliance with, or violations of, such requirements may harm its business, which could have a material adverse effect on our ~~business, financial condition and results of operations.~~business.

•

e-TeleQuote ~~receives~~generates leads that are ~~externally acquired from third-party vendors and~~ internally ~~generated~~sourced from marketing initiatives and receives referrals from Primerica
independent sales representatives. It also receives leads externally acquired from third-party vendors. e-TeleQuote’s business may

be harmed if it cannot continue to acquire or generate leads on commercially viable terms, if it is unable to convert leads to sales
at acceptable rates, if Primerica independent sales representatives do not introduce consumers to e-TeleQuote, or if policyholder
retention is lower than assumed, any of which could adversely impact our business.

•

If e-TeleQuote’s ability to enroll individuals during the Medicare annual election period is impeded, its business may be harmed,
which could adversely impact our ~~business, financial condition and results of operations.~~business.

•

e-TeleQuote’s business is dependent on key carrier partners. The loss of a key carrier partner, or the modification of commission
rates or underwriting practices with a key carrier partner, could harm its business which could adversely impact our business.

Risks Related to Our Mortgage Distribution Business

•

Licensing requirements will impact the size of the mortgage loan sales force, which could adversely affect our mortgage
distribution business.

•

Our mortgage distribution business ~~financial condition~~is highly regulated and ~~results~~subject to various laws and regulations in the U.S. and Canada. Changes in, non-compliance with, or violations of, ~~operations.~~such laws and regulations could affect the cost or our ability to distribute our products and could adversely affect our business.

•

In the U.S., we distribute mortgage loans based on contractual agreements with a very limited number of mortgage lenders. A
significant change to or disruption in the mortgage lenders’ mortgage businesses or an inability of the mortgage lenders to satisfy
their contractual obligations to us could adversely affect our business.

Risks Related to Economic Downcycles, Public Health Crises or Catastrophes, and Disaster

•

The effects of economic down cycles, issues affecting the national and/or global economy or global geopolitical event(s) could materially adversely affect our ~~business, financial condition and results of operations.~~business.

•

Major public health pandemics, epidemics or outbreaks ~~such~~(such as the COVID-19 ~~pandemic,~~pandemic) or other catastrophic events, have
impacted and could again materially adversely impact our ~~business, financial condition and results of operations.~~business.

•

In the event of a disaster, our business continuity plan may not be sufficient, which could have a material adverse effect on our ~~business, financial condition and results of operations.~~business.

Risks Related to Information Technology and Cybersecurity

•

If one of our, or a third-party partner’s, significant information technology systems fails, if its security is compromised, or if the Internet becomes disabled or unavailable, our business ~~financial condition and results of operations~~ may be materially adversely affected.

•

The current legislative and regulatory climate with regard to privacy and cybersecurity ~~may~~could adversely affect our ~~business, financial condition,~~business.

•

Any failure to protect the confidentiality of client information could adversely affect our reputation and ~~results of operations.~~have a material adverse
effect on our business.

•

e-TeleQuote’s security measures are designed to protect against breaches of security and other interference with its systems and
networks ~~are not fully mature.~~operate independently from Primerica’s systems. If e-TeleQuote is subject to cyber-attacks or security breaches or is
otherwise unable to safeguard the security and privacy of confidential data ~~including personal health information,~~ e-TeleQuote’s business may be harmed, which could
have a material adverse effect on our ~~business, financial condition and results of operations.~~business.

Financial Risks Affecting Our Business

•

Credit deterioration in, and the effects of interest rate fluctuations on our invested asset portfolio and other assets that are subject to changes in credit quality and interest rates could materially adversely affect our ~~business, financial condition and results of operations.~~business.

•

Valuation of our investments and the determination of expected credit losses when the fair value of our available-for-sale invested assets is below amortized cost are both based on estimates that may prove to be ~~incorrect.~~incorrect, which could adversely affect our
financial condition.

•

Changes in accounting standards can be difficult to predict and could adversely impact how we record and report our financial condition and results of operations.

•

The inability of our subsidiaries to pay dividends or make distributions or other payments to us in sufficient amounts would impede our ability to meet our obligations and return capital to our stockholders.

Risks Related to Legislative and Regulatory Changes

•

We are subject to various federal, state and provincial laws and regulations in the ~~United States~~U.S. and Canada, changes in which may require
us to alter our business practices and could materially adversely affect our ~~business, financial condition and results of operations.~~business.

•

The current legislative and regulatory climate with regard to financial services ~~may~~could adversely affect our ~~business, financial condition, and results of operations.~~business.

•

Medicare Advantage is a product legislated and regulated by the ~~United States~~U.S. government. If the enabling legislation and regulation or
implementing guidance issued by CMS ~~change,~~changes, e-TeleQuote’s business may be harmed, which could have a material adverse
effect on our ~~business, financial condition and results of operations.~~business.

•

The current regulatory climate with regard to climate change may adversely affect our business.

General Risk Factors

•

Litigation and regulatory investigations and actions may result in financial losses and harm our reputation.

•

A significant change in the competitive environment in which we operate could negatively affect our ability to maintain or
increase our market share and profitability.

•

~~The~~Our continued success requires a high-performing and stable team of employees across all levels, and the loss of key employees
could negatively affect our financial results and impair our ability to implement our business strategy.

•

~~Prohibitions on~~We regularly undertake business initiatives to enhance our ~~ability to establish our own COVID-19 protocols~~technology, products, and services. The efficiency and success of these
initiatives may vary significantly and may cause unanticipated costs, errors, or ~~government imposed COVID-19 vaccine mandates~~disruptions which could have a material adverse ~~impact~~
effect on our ~~business and results of operations.~~business.

•

We may be materially adversely affected by currency ~~fluctuations in the United States dollar versus the Canadian dollar.~~fluctuations.

•

Any acquisition of or investment in businesses that we may undertake that does not perform as we expect or that is difficult for us
to integrate could materially adversely impact our ~~business, financial condition and results of operations.~~business.

•

The market price of our common stock may fluctuate.

Developments in any of these areas could cause actual results to differ materially from those anticipated or projected or cause a significant reduction in the market price of our common stock.

The foregoing list of risks and uncertainties may not contain all of the risks and uncertainties that could affect us. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this report may not in fact occur. Accordingly, undue reliance should not be placed on these statements. We undertake no obligation to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise, except as otherwise required by law.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

There have been no material changes in our exposures to market risk since December 31, ~~2021.~~2022. For details on the Company’s interest rate, foreign currency exchange, and credit risks, see “Item 7A. Quantitative and Qualitative Information About Market Risks” in our ~~2021~~2022 Annual Report.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report (the “Evaluation Date”). Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

During the quarter ended ~~September 30, 2022~~March 31, 2023, the Company ~~established~~implemented a new general ledger and financial reporting application. This change was made to utilize advanced technology available in the industry and was not undertaken in response to any actual or perceived deficiencies or to remedy any gaps or weaknesses in the Company's internal ~~controls~~control over financial ~~reporting for e-TeleQuote's processes.~~reporting. In addition, the Company established ~~internal~~ controls over its ~~assessment~~adoption of ~~the initial impact of adopting~~ Accounting Standards Update ~~(“ASU”)~~ 2018-12 Targeted ~~Improvements~~improvements to the Accounting for Long-Duration Insurance Contracts. Otherwise, there have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended ~~September 30, 2022~~March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

We are involved from time to time in legal disputes, regulatory inquiries and arbitration proceedings in the normal course of business. Additional information regarding certain legal proceedings to which we are a party is described under “Contingent Liabilities” in Note 1013 (Commitments and Contingent Liabilities) to our unaudited condensed consolidated financial statements included elsewhere in this report, and such information is incorporated herein by reference. As of the date of this report, we do not believe any pending legal proceeding to which Primerica or any of its subsidiaries is a party is required to be disclosed pursuant to this item.

ITEM 1A. RISK FACTORS.

The ~~following amends the~~ Risk Factors contained in our ~~2021~~2022 Annual Report ~~that~~ are incorporated herein by reference.

If heightened standards of conduct or more stringent licensing requirements, such as those adopted by the SEC and those proposed or adopted by the Department of Labor (“DOL”), state legislatures or regulators or Canadian securities and insurance regulators, are imposed on us or the independent sales representatives, or selling compensation is reduced as a result of new legislation or regulations, it could have a material adverse effect on our business, financial condition and results of operations.

The U.S. independent sales representatives are subject to federal and state regulation as well as state licensing requirements. PFS Investments, Inc., which is regulated as a broker-dealer and registered investment advisor, and U.S. sales representatives are currently subject to general anti-fraud limitations under the Exchange Act and SEC rules and regulations, as well as other conduct standards prescribed by the FINRA. These standards generally require that broker-dealers, investment advisors, and their sales representatives disclose conflicts of interest that might affect the advice or recommendations they provide and require them to make suitable investment recommendations to their customers. On June 5, 2019, the SEC adopted rules and interpretations addressing the standards of conduct applicable to broker-dealers and investment advisers and their associated persons (collectively, the “SEC Rulemaking”). Among other things, the SEC Rulemaking: (i) created a “best interest” standard of conduct for broker-dealers (“Reg BI”), and (ii) imposed disclosure requirements through summary forms intended to clarify relationships among brokers, advisers, and their retail customers (“Form CRS”). On December 15, 2020, the DOL published an interpretation of, and class exemption regarding, the rules governing fiduciary investment advice with respect to IRAs and other retirement accounts (the “DOL Rule”). The effective date of the DOL Rule was February 16, 2021 and the DOL extended its non-enforcement policy through January 31, 2022. The SEC Rulemaking and the DOL Rule in their current forms impose higher standards of care and enhanced obligations that increase regulatory and litigation risk to our business.

In addition to federal regulators, certain states have proposed or passed laws or proposed or issued regulations requiring investment advisers, broker-dealers, and/or insurance agents to meet fiduciary standards or standards of care that their advice be in the customer’s best interest, and to mitigate and disclose conflicts of interest to consumers of investment and insurance products. The severity of the impact that such state laws or regulations could have on our business vary from state to state depending on the content of the legislation or regulation and how it would be applied by state regulators and interpreted by the courts, but such laws or regulations could disrupt our brokerage business in the relevant state. We cannot quantify the financial impact, if any, of any changes to our business that may be necessary in order to comply with such laws or regulations at this time.

The organization of provincial and territorial securities regulators (collectively referred to as the “Canadian Securities Administrators” or “CSA”) published final rule amendments to prohibit upfront sales commissions by fund companies for the sale of mutual funds offered under a prospectus in Canada (“DSC Ban”). The final amendments became effective on June 1, 2022. The DSC Ban has required firms to discontinue the use of the mutual fund deferred sales charge compensation model, which is the primary model for the mutual funds we distribute in Canada. As a result, we have begun offering a broad range of funds under an agreement with two third-party mutual fund companies being sold exclusively by our independent sales representatives (the “Principal Distributor” model). While we received regulatory approval for the Principal Distributor model, the CSA has indicated that it intends to closely examine the model, including potentially through a public consultation on sales practices, and may require undertakings or consider future amendments that would require modifications to the model, including with respect to its advance and chargeback features. Such undertakings or amendments could require us to restructure our Principal Distributor model for sales mutual funds, or discontinue its use, and could have a material adverse effect on our investment and savings products business in Canada.

In an announcement February 10, 2022, and in line with the DSC Ban for the sale of mutual funds, the organization of provincial and territorial insurance regulators (collectively referred to as the “Canadian Council of Insurance Regulators”) urged insurers to refrain from new deferred sale charge sales in segregated fund contracts beginning June 1, 2022, and expect a transition to a cessation of such sales by June 1, 2023. In addition, the Canadian Council of Insurance Regulators announced their intention to issue a joint consultation later this year to consider other changes to upfront compensation, including the agent advance, client chargeback compensation model. The advance/chargeback model is used in our Principal Distributor model, and any changes made by the insurance regulators will likely be adopted by the securities regulators. Such restrictions could require us to restructure our compensation model for sales of segregated funds and for the Principal Distributor model, and could have a material adverse effect on our investment and savings products business in Canada.

In Canada, on October 3, 2019, the CSA published final rule amendments intended to better align the interest of securities dealers and representatives with the interests of their clients, improve outcomes for clients, and make clearer to clients the nature and terms of their relationship with registered firms and their representatives. Collectively these amendments are referred to as the Client Focused Reforms (“CFRs”). The CFRs, among other things, require registered firms to identify and mitigate conflicts of interest between

5452

registered firms and their representatives, on one hand, and clients, on the other, such that recommendations may be made in clients’ best interest. The implementation date to address conflicts and to improve disclosure was June 30, 2021 and the implementation date to enhance overall suitability rules, know your client rules, and know your product requirements was December 31, 2021. CFRs will require changes to our sales process and back-office systems and processes and may necessitate changes in compensation arrangements with the fund companies that offer the mutual fund products we distribute in Canada. The impact of such changes could have a material adverse effect on our investment and savings products business in Canada.

Heightened standards of conduct or restrictions on compensation as a result of any of the above items or other similar proposed rules or regulations could also increase the compliance and regulatory burdens on the sales representatives and could lead to increased litigation and regulatory risks, changes to our business model, a decrease in the number of licensed sales representatives and a reduction in the products we offer to our clients, any of which could have a material adverse effect on our business, financial condition and results of operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the quarter ended ~~September 30, 2022,~~March 31, 2023, we repurchased shares of our common stock as follows:

Period

Total number of shares purchased (1)

Average price paid per share (1)

Total number of shares purchased as part of publicly announced plans or programs

Approximate dollar value of shares that may yet be purchased under the plans or programs (2)

July 1 - 31, 2022

346,388

$
121.04

346,336

$
37,402,550

August 1- 31, 2022

264,260

130.77

263,516

52,945,198

September 1 - 30, 2022

165,959

126.53

165,959

31,946,406

Total

776,607

$
125.52

775,811

$
31,946,406


Period	Total number of shares purchased (1)		Average price paid per share (1)		Total number of shares purchased as part of publicly announced plans or programs (2)		Approximate dollar value of shares that may yet be purchased under the plans or programs (2)
January 1 - 31, 2023		210,653	$	149.53		210,653	$	343,501,568
February 1 - 28, 2023		142,748		166.38		142,748		319,750,822
March 1 - 31, 2023		235,617		174.18		177,322		289,752,859
Total		589,018	$	163.47		530,723	$	289,752,859

(1)

Consists of repurchases of (a) ~~796~~58,295 shares at an average price of ~~$132.88~~$189.42 arising from share-based compensation tax withholdings and (b) open market repurchases of share under the share repurchase program approved by our Board of Directors.

(2)

On November 17, ~~2021,~~2022, our Board of Directors authorized a share ~~repurchasing~~repurchase program ~~which was announced on November 18, 2021, for up to $275.0 million of our outstanding common stock~~ for purchases ~~through December 31, 2022. On February 14, 2022, our Board~~ of Directors authorized an increase of $50.0 million to the share repurchase program authorized on November 17, 2021. On August 11, 2022, our Board authorized an additional increase of $50.0 million to the share repurchase program bringing the authorized share repurchases up to $375.0 million of our outstanding common stock from January 1, 2023 through December 31, ~~2022.~~2023.

For information regarding year-to-date share repurchases, refer to Note 710 (Stockholders’ Equity) to our unaudited condensed consolidated financial statements included elsewhere in this report.

ITEM 5. OTHER INFORMATION.

Procedures for Stockholders to Recommend Director Nominees

Pursuant to the Company’s Second Amended and Restated By-Laws, only persons who are nominated in accordance with the procedures set forth in Section 6 of Article II thereof (“Section 6”) and, if applicable, the “proxy access” provisions set forth in Section 7 of Article II thereof (“Section 7”), shall be eligible for election as directors of the Company.

In connection with the adoption of Rule 14a-19 under the Exchange Act (“Rule 14a-19”), the Company’s Board of Directors (the “Board”) approved and adopted the Company’s Third Amended and Restated By-Laws (the “Third Amended and Restated By-Laws”), effective March 1, 2023.

The Third Amended and Restated By-Laws amend Section 6 to:

•

clarify that any stockholder nominating a person for election to the Board comply with Rule 14a-19;

•

require that any nominating stockholder make a representation whether such stockholder intends to solicit proxies in support of any director nominees other than the Company’s nominees in accordance with Rule 14a-19;

•

provide that, if any stockholder provides notice pursuant to Rule 14a-19(b) with respect to any proposed nominee for election to the Board and subsequently (a) fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) or (b) fails to provide reasonable evidence to the Company, no later than five business days prior to the applicable stockholder meeting, that such stockholder has met the requirements of Rule 14a-19(a)(3), then the nomination of each such proposed nominee will be disregarded;

•

require that, if any stockholder provides notice pursuant to Rule 14a-19(b), such person shall deliver to the Company, no later than five business days prior to the applicable meeting of stockholders, reasonable evidence that such person has met the requirements of Rule 14a-19(a)(3); and

•

require that the notice provided by the nominating stockholder be accompanied by a written consent of each proposed nominee to being named as a nominee, to be included in the proxy materials relating to the applicable meeting of stockholders and to serve as a director if elected.

The Third Amended and Restated By-Laws also amend Section 7 to clarify that, except for a nomination made in compliance with Section 6 and Rule 14a-19, the proxy access provisions set forth in Section 7 shall be the exclusive method for stockholders to include nominees for election to the Board in the Company’s proxy materials.

ITEM 6. EXHIBITS.

The agreements included as exhibits to this report are included to provide you with information regarding the terms of these agreements and are not intended to provide any other factual or disclosure information about the Company or its subsidiaries, our business or the other parties to these agreements. These agreements may contain representations and warranties by each of the parties

to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and:

•

should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

•

have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

•

may apply standards of materiality in a way that is different from what may be viewed as material to our investors; and

•

were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time, and should not be relied upon by investors.


Exhibit Number	Description	Reference
10.1	~~Assignment, Transfer~~Third Amended and ~~Novation Agreement dated as~~Restated By-laws of ~~June 23, 2022 between~~ Primerica, ~~Life Insurance Company, Pecan Re~~ Inc. ~~and Swiss Re Life and Health America Inc.~~, effective March 1, 2023	~~Incorporated by reference to Exhibit 10.1 to Primerica's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (Commission File No. 001-34680).~~
~~10.2~~	~~Second Amended and Restated 80% Coinsurance Agreement dated as of June 23, 2022 between Primerica Life Insurance Company and Swiss Re Life and Health America Inc.~~	~~Incorporated by reference to Exhibit 10.2 to Primerica's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (Commission File No. 001-34680).~~
~~10.3~~	Reinsurance Trust Agreement dated as of June 23, 2022 between Swiss Re Life and Health America Inc., as Grantor, and Primerica Life Insurance Company, as Beneficiary, and The Bank of New York Mellon, as Trustee	~~Incorporated by reference to Exhibit 10.3 to Primerica's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (Commission File No. 001-34680).~~
~~31.1~~	~~Rule 13a-14(a)/15d-14(a) Certification, executed by Glenn J. Williams, Chief Executive Officer.~~	Filed with the Securities and Exchange Commission as part of this Quarterly Report.
10.2	First Amendment to Amended and Restated Credit Agreement, dated as of April 5, 2023 between the Registrant, the Lenders referred to therein, and Wells Fargo Bank, National Association	Filed with the Securities and Exchange Commission as part of this Quarterly Report.
31.1	Rule 13a-14(a)/15d-14(a) Certification, executed by Glenn J. Williams, Chief Executive Officer.	Filed with the Securities and Exchange Commission as part of this Quarterly Report.
31.1
31.2	Rule 13a-14(a)/15d-14(a) Certification, executed by Alison S. Rand, Executive Vice President and Chief Financial Officer.	Filed with the Securities and Exchange Commission as part of this Quarterly Report.
31.2
32.1	Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350), executed by Glenn J. Williams, Chief Executive Officer, and Alison S. Rand, Executive Vice President and Chief Financial Officer.	Filed with the Securities and Exchange Commission as part of this Quarterly Report.
32.1
101.INS	Inline XBRL Instance Document.	The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase.
104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Primerica, Inc.

~~November~~May 9, ~~2022~~2023	/s/ Alison S. Rand
	Alison S. Rand
	Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

5755


	Three months ended September 30,						Nine months ended September 30, (1)
	2022			2021			2022			2021
	(In thousands)
Level 3 assets, beginning of period	$	1,634		$	3,336		$	3,596		$	2,047
Net unrealized gains (losses) included in other comprehensive income		(8	)		1			99			1
Realized gains (losses) and accretion (amortization) recognized in earnings		(127	)		(125	)		(328	)		(359	)
Purchases		6,170			2,068			13,661			3,067
Sales		-			-			-			-
Settlements		15			(1	)		(1,385	)		(2,191	)
Transfers into Level 3		-			-			1,399			2,714
Transfers out of Level 3		-			(1,501	)		(9,358	)		(1,501	)
Level 3 assets, end of period	$	7,684		$	3,778		$	7,684		$	3,778


	Preliminary Purchase Price Adjustment		2021 Measurement Period Adjustments				2022 Measurement Period Adjustments			Final Acquisition Date Purchase Price Allocation
	(In thousands)
Assets:
Cash and cash equivalent		1,080		-				-			1,080
Accounts receivables		692		(389	)			-			303
Renewal commissions receivable		199,575		(46,128	)			(11,863	)		141,584
Other assets		15,705		-				-			15,705
Intangible assets		162,000		(6,000	)			-			156,000
Goodwill		224,180		30,973				8,553			263,706
Total assets		603,232		(21,544	)			(3,310	)		578,378

Liabilities:
Accounts payable and accrued expenses		8,785		(4,195	)	(1)		-			4,590
Deferred tax liability		65,425		(13,482	)			(3,310	)		48,633
Other liabilities		10,046		-				-			10,046
Total liabilities		84,256		(17,677	)			(3,310	)		63,269
Net assets acquired		518,976		(3,867	)			-			515,109

Temporary Stockholders' Equity:
Redeemable noncontrolling interests		8,437		-				-			8,437
Total temporary stockholders' equity		8,437									8,437


	September 30, 2022		September 30, 2021
Life-licensed independent sales representatives		134,313		130,023